

	<b>BNF Chapter</b>
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous
Section 18:	Emergency Treatment of Poisoning

**Version 10.16 (April 2026)**

**NICE** National Institute for  
Health and Care Excellence

Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

## Formulary status definitions

**Formulary** (OK to be prescribed - but after any 1<sup>st</sup> or 2<sup>nd</sup> line options)

1<sup>st</sup> line formulary (when there are few formulary options, this is the 1<sup>st</sup> choice)

2<sup>nd</sup> line formulary (when there are few formulary options, this is the 2<sup>nd</sup> choice)

Where there is no preferred 1<sup>st</sup> line agent provided, the drug choice appears in alphabetical order.

1<sup>st</sup> line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



## GMMMGM Red/Amber/Green classifications



### RED

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

### AMBER

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMGM shared care protocol (SCP).

[See here for a list of GMMMGM approved SCPs.](#)

### GREEN

Drugs that are suitable for initiation and ongoing prescribing within primary care.

#### SA

Green following specialist advice. Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

#### SI

Green following specialist initiation. Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

### (DNP)

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

**Criteria for inclusion on DNP/grey lists:**

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns.

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

### GREY

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

**Criteria for inclusion on DNP/grey lists:**

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns.

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.













### OTC

In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care.



Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be annotated as follows: *drug name*

## Formulary symbols

	Medicines Management Committee decisions
	Electronic medicines compendium (SmPC & PIL)
	British National Formulary (BNF)
	British National Formulary for Children (BNFC)
	NICE guidance
	NHS Payment Scheme (NHSPS) excluded medicine (previously known as PbR excluded)
	Controlled Drug
	Unlicensed medicine
	High cost medicine
	Blueteq enabled forms
	MedTeq Enabled Forms
	Not routinely stocked, can be ordered if existing patient supply is exhausted

## PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY   
GMMMG Adult Red/Amber/Green; DNP and Grey Drug List  
GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List  
GMMMG Approved Shared Care Protocols

## Useful Links

All Wales Medicines Strategy Group  
British HIV Association (BHIVA)  
British National Formulary (No password required)  
British National Formulary for Children (No password required)  
Commission on Human Medicines (CHM)  
electronic Medicines Compendium (eMC)  
General Pharmaceutical Council (GPhC)  
Greater Manchester Medicines Management Group (GMMMG)  
Medicines and Healthcare products Regulatory Agency (MHRA)  
Midlands Therapeutics Review and Advisory Committee (MTRAC)  
National Institute for Health and Clinical Excellence (NICE)  
Scottish Medicines Consortium (SMC)  
Specialist Pharmacist Service (SPS)

# Section 1: Gastro-Intestinal system

Supported by the  
formulary (click here)



## 1.1 Dyspepsia & gastro-oesophageal reflux disease

1.1.1 Antacids & Simeticone

1.1.2 Compound Alginates & Proprietary Indigestion Preparations

## 1.2 Anti-spasmodics & other drugs altering gut motility

Antimuscarinics

Other Antispasmodics

Motility Stimulants

## 1.3 Antisecretory drugs & mucosal protectants

1.3.1 H<sub>2</sub>-Receptor Antagonists

1.3.3 Chelates & Complexes

1.3.5 Proton Pump Inhibitors

## 1.4 Acute diarrhoea

1.4.2 Antimotility Drugs

## 1.5 Chronic bowel disorders

1.5.1 Aminosalicylates

1.5.2 Corticosteroids & Enemas

1.5.3 Drugs Affecting the Immune Response

Advanced therapies (biologic and targeted synthetic treatments)

## 1.6 Laxatives

1.6.1 Bulk-forming Laxatives

1.6.2 Stimulant Laxatives

1.6.3 Faecal Softeners

1.6.4 Osmotic Laxatives

1.6.5 Bowel Cleansing Preparation

1.6.6 Peripheral opioid-receptor antagonists

1.6.7 Other drugs used in constipation

## 1.7 Local preparations for anal & rectal disorders

1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids

1.7.4 Management of anal fissures

## 1.9 Drugs affecting intestinal secretions

1.9.1 Drugs affecting biliary composition & flow

1.9.2 Bile acid sequestrants

1.9.4 Pancreatin

## 1.10 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines

**GASTRO / ENDOSCOPY** - medicine & prescribing policies / guidelines (MFT Policy Hub)

**ADULT** - medicine & prescribing policies / guidelines (MFT Policy Hub)

**PAEDIATRIC** - medicine & prescribing policies / guidelines (MFT Policy Hub)

**NEONATAL** - medicine & prescribing policies / guidelines (MFT Policy Hub)

[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)

Faecal Incontinence (CG49)

Irritable Bowel Syndrome (CG61)

Diarrhoea and vomiting in children under 5 (CG84)

Constipation in children and young people (CG99)

Acute upper GI bleeding (CG141)

Dyspepsia and gastro-oesophageal reflux disease (CG184)

Coeliac disease: recognition, assessment and management (NG20)

Crohn's disease: management (NG129)

Ulcerative colitis: management (NG130)

Ulcerative colitis (acute exacerbations) - infliximab (TA163)

Crohn's disease - infliximab & adalimumab (TA187)

Constipation (women) - prucalopride (TA211)

Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)

Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

Naloxegol for treating opioid induced constipation (TA345)

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

Obeticholic acid for treating primary biliary cholangitis (TA443)

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

Naldemedine for treating opioid-induced constipation (TA651)

Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)

Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

Teduglutide for treating short bowel syndrome (TA804)

Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

Elafibranor for previously treated primary biliary cholangitis (TA1016)

Mirikizumab for treating moderately to severely active Crohn's disease (TA1080)

Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

Targeted-release budesonide for treating primary IgA nephropathy (updates & replaces TA937) (TA1128)

## GMMMG Formulary

Formulary Homepage

Chapter 1: Gastro-Intestinal system

GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List

GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

# 1.1 Dyspepsia & gastro-oesophageal reflux disease



## 1.1.1 Antacids & Simeticone

### Aluminium & Magnesium Containing Antacids

**Co-magaldrox**

GREEN

195/220 suspension<sup>SF</sup>



1<sup>st</sup> line use

**Magnesium trisilicate**

suspension



### Simeticone alone (activated dimeticone)

**Simeticone**

(DNP)

Infacol® 40mg/mL liquid



### 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

**Alginate raft-forming oral suspensions<sup>SF</sup>**

GREEN

suspension



## 1.2 Anti-spasmodics & other drugs altering gut motility



### Antimuscarinics

#### Hyoscine butylbromide

GREEN

tablets; injection



MHRA Drug Safety Update (Feb-17): Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease

#### Glycopyrronium bromide (Glycopyrrolate)

SI

(Robinul®, Sialanar®) tablets; injection; oral solution; cream



### Other Antispasmodics

#### Mebeverine hydrochloride

GREEN

135mg tablets

1<sup>st</sup> line use

#### Peppermint oil

GREEN

capsules



#### Alverine citrate with simeticone

GREEN

SimAlvia® 60mg/300mg capsules



### Motility Stimulants

#### Metoclopramide

GREEN

10mg tablets (see also section 4.6)

1<sup>st</sup> line use

MHRA (Aug-13): Metoclopramide: risk of neurological adverse effects

#### Domperidone

GREEN

AMBER

RED

10mg tablets (see also section 4.6)

Use where 1<sup>st</sup> line unsuitable

MHRA Drug Safety Update (Dec19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects

MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects

# 1.3 Antisecretory drugs & mucosal protectants



## 1.3.1 H<sub>2</sub>-receptor antagonists

**Famotidine**

GREEN

20mg; 40mg tablets

MMC BNF emc

## 1.3.3 Chelates & Complexes

**Sucralfate**

SI

1g tablets; oral suspension

MMC BNF emc

**Bismuth subsalicylate (Pepto-Bismol®)**

262.5mg chewable tablets

MMC BNF emc

**RESTRICTED**  
Adults, H. Pylori eradication regime

## 1.3.5 Proton Pump Inhibitors

**Omeprazole**

GREEN

10mg; 20mg; 40mg capsules; 40mg infusion

NICE BNF emc

**Lansoprazole**

GREEN

15mg & 30mg capsules; 15mg & 30mg orodispersible tablets

NICE MMC BNF emc

**RESTRICTED**  
tablets - enteral feeding tubes /  
dysphagia

**Esomeprazole**

40mg infusion; granules

MMC BNF emc

**RESTRICTED**  
PPI indicated / enteral route not  
available/appropriate

MHRA (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice

MHRA Drug Safety Update (Sep-15): Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus

**Other PPIs are not available at this Trust**

# 1.4 Acute diarrhoea

(DNP)



## 1.4.2 Antimotility Drugs

### Loperamide hydrochloride

GREEN

2mg capsules; 1mg/5mL syrup<sup>SF</sup>

NICE BNF emc

1<sup>st</sup> line use

### Codeine phosphate

GREEN

15mg; 30mg & 60mg tablets

NICE BNF emc

**RESTRICTED**  
Adults - high output stomas

### Teduglutide

RED EF

Revestive® injection

PbRx NICE MMC BNF emc blueiq

**RESTRICTED** Gastro. Consultants  
only in line with NICE TA804

# 1.5 Chronic bowel disorders



## 1.5.1 Aminosaliculates

### Mesalazine

SA

tablets; M/R tablets; M/R granules; enema; foam enema; suppositories

PbR X

BNF emc

**PRESCRIBE BY BRAND NAME**

MHRA Drug Safety Update (Dec-25): Mesalazine and idiopathic intracranial hypertension

### Balsalazide sodium

750mg capsules

MMC BNF emc

## 1.5.2 Corticosteroids & Enemas

### Prednisolone

GREEN

5mg tablets

BNF emc

**1<sup>st</sup> line use**

### Budesonide

SA

Budenofalk® 3mg capsules; 2mg rectal foam; 4mg suppositories

MMC BNF emc

**RESTRICTED**  
eosinophilic esophagitis

### Budesonide

SI

Jorveza® 1mg orodispersible tablets

NICE MMC BNF emc

**RESTRICTED**  
Adults - Gastro. Consultants only

### Budesonide

SA

3mg CR capsules

MMC BNF emc

**RESTRICTED** Consultants for  
primary IgA nephropathy as per NICE

### Budesonide

RED

Kinpeygo® 4mg M/R hard capsules

NICE MMC BNF emc

### Hydrocortisone

foam enema

BNF emc

## 1.5.3 Drugs Affecting the Immune Response

### Azathioprine

AMBER

tablets; oral solution (see also sections 8.2.1; 10.1.3 & 13.5.3)

PbR X

BNF emc

**1<sup>st</sup> line use**

MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy

### Ciclosporin (oral and I.V. preparations)

AMBER

capsules; infusion; oral solution (see also section 8.2.2)

MMC BNF emc

### Mercaptopurine

AMBER

tablets; oral suspension (see also section 8.1.3)

PbR X

BNF emc

MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy

### Methotrexate (s/c and oral preparations)

RED AMBER

tablets; injection; oral solution (see also section 10.1.3)

MMC BNF emc

MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions

MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing

### Tacrolimus (suppositories) U

suppository

MMC

**RESTRICTED**  
Gastro. Consultants - proctitis

## Advanced therapies (biologic and targeted synthetic treatments)

### Adalimumab

RED ££

injection (see also sections 10.1.3, 11.4.2 & 13.5.3)

PbR X

NICE MMC BNF emc

**RESTRICTED** Gastro. Consultants for  
IBD as per NICE

MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely

### Infliximab

RED ££

infusion (see also sections 10.1.3 & 13.5.3)

PbR X

NICE MMC BNF emc

**RESTRICTED** Gastro. Consultants for  
IBD as per NICE

MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely

### Etrasimod

RED ££

Velsipity® tablets

PbR X

NICE MMC BNF emc

**RESTRICTED** Gastro. Consultants in  
line with NICE TA956

### Filgotinib

RED ££

Jyseleca® 100mg; 200mg tablets (see also section 10.1.3)

PbR X

NICE MMC BNF emc

**RESTRICTED** Gastro. Consultants for  
Ulcerative colitis as per NICE

MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality

### Golimumab

RED ££















































































injection (see also section 10.1.3)

PbR X

NICE MMC BNF emc

**RESTRICTED** Gastro. Consultants for  
IBD as per NICE

MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely

<b>Guselkumab</b>   100mg/mL injection (see also sections 10.1.3 and 13.5.3)     	<b>RESTRICTED</b> in line with NICE
<b>Mirikizumab</b>   Omvoh® injection; infusion      	<b>RESTRICTED</b> Gastro. Consultants in line with NICE TA925
<b>Ozanimod</b>   Zeposia® capsules      	<b>RESTRICTED</b> Gastro. Consultants in line with NICE TA828
<b>Risankizumab</b>   Skyrizi® 75mg; 150mg injection (see also section 13.5.3)      	<b>RESTRICTED</b> Specialist use only in line with NICE TA888 / TA998
<b>Tofacitinib</b>   tablets (see also section 10.1.3)       MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of VTE and of serious and fatal infections MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing	<b>RESTRICTED</b> Consultants only in line with NICE
<b>Upadacitinib</b>   MR tablet (see also sections 10.1.3 and 13.5.3)      	<b>RESTRICTED</b> Consultants only in line with NICE TA856 / TA905
<b>Ustekinumab</b>   Stelara® injection (see also sections 10.1.3 & 13.5.3)      	<b>RESTRICTED</b> Gastro. Consultants as per NICE
<b>Ustekinumab</b>   Wezenla® injection (see also sections 10.1.3 & 13.5.3)      	<b>RESTRICTED</b> Gastro. Consultants as per NICE / NOT ulcerative colitis
<b>Vedolizumab</b>   infusion      	<b>RESTRICTED</b> Gastro. Consultants for IBD as per NICE
<b>ICAM-1 Inhibitor</b>	
<b>Alicaforsen</b>   enema     	<b>RESTRICTED</b> Gastro. Consultants only - pouchitis

# 1.6 Laxatives



## 1.6.1 Bulk-forming Laxatives

### Ispaghula husk

GREEN

3.5g sachets

1<sup>st</sup> line use

## 1.6.2 Stimulant Laxatives

### Docusate sodium

GREEN

capsules; oral solution

1<sup>st</sup> line use

### Senna

GREEN

tablets; oral solution

1<sup>st</sup> line use

MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use

### Bisacodyl

GREEN

tablets; suppositories



MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use

### Glycerol

GREEN

suppositories



### Sodium picosulfate

oral solution



MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use

### Co-danthramer

GREEN

oral suspension



**RESTRICTED**  
Adults, Palliative Care only

### Co-danthrusate

GREEN

oral suspension



**RESTRICTED**  
Adults, Palliative Care only

## 1.6.3 Faecal Softeners

### Arachis oil

enema



## 1.6.4 Osmotic Laxatives

### Lactulose

GREEN OTC

oral solution

1<sup>st</sup> line use

### Macrogols (Polyethylene glycols)

GREEN OTC

sachets



2<sup>nd</sup> / 3<sup>rd</sup> line use Rehab patients /  
paediatrics

### Phosphates (Rectal)

GREEN

128mL enema



### Sodium citrate (Rectal)

GREEN

450mg micro-enema



## 1.6.5 Bowel Cleansing Preparations

NPSA RRR (Feb-09): Reducing risk of harm from oral bowel cleansing solutions

### Sodium picosulfate with magnesium citrate

RED

Picolax® oral powder

1<sup>st</sup> line use

### Macrogol 3350

RED

Plenvu® powder for oral solution (see also section 18.1.2)



1<sup>st</sup> line use  
oral bowel preparation

### Macrogol 3350

RED

Moviprep® powder for oral solution



**RESTRICTED**  
patients intolerant or allergic to Plenvu®

### Sodium dihydrogen phosphate dihydrate with disodium phosphate dodecahydrate






















RED

Phospho-soda® 24.4g/10.8g oral solution



**RESTRICTED**  
Colon Capsule Endoscopy (CCE)

**1.6.6 Peripheral opioid-receptor antagonists**

<b>Methylnaltrexone bromide</b> injection  	<b>RESTRICTED</b> Adults, Palliative Care only
<b>Naldemedine</b>  200 microgram tablets    	<b>RESTRICTED</b> Adults only in line with TA651
<b>Naloxegol</b>  12.5mg; 25mg tablets    	<b>RESTRICTED</b> Adults only in line with TA345
<b>1.6.7 Other drugs used in constipation</b>	
<b>Prucalopride</b>  1mg; 2mg tablets    	<b>RESTRICTED - Adult women, Gastro. Consultants only</b>
<b>Linaclootide</b>  290 micrograms capsules   	<b>RESTRICTED - 3<sup>rd</sup> line use Adults Gastro. Consultants only</b>

# 1.7 Local preparations for anal & rectal disorders



## 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids

**Anusol®**

GREEN OTC

ointment

BNF emc

**Proctosedyl®**

GREEN

ointment

BNF emc

**Scheriproct®**

GREEN

ointment; suppositories

BNF emc

## 1.7.4 Management of anal fissures

**Glyceryl trinitrate**

GREEN

1<sup>st</sup> line for anal fissure

*Rectogesic*® 0.4% ointment

MMC BNF emc

**Diltiazem hydrochloride** Ⓢ

SI

2% cream; ointment

BNF emc

# 1.9 Drugs affecting intestinal secretions



## 1.9.1 Drugs affecting biliary composition & flow

### Ursodeoxycholic acid

SA

150mg tablets

MMC BNF emc

1<sup>st</sup> line use

### Obeticholic acid

RED Ef

Ocaliva® 5mg; 10mg tablets

PbR X NICE MMC BNF emc blueiq

**RESTRICTED** Hepatology  
Consultants only 2<sup>nd</sup> line per TA443

### Elafibranor

RED Ef

Iqirvo® 80mg tablets

PbR X NICE MMC BNF emc blueiq

**RESTRICTED** Hepatology  
Consultants only as per TA1016

## 1.9.2 Bile acid sequestrants

### Colestyramine

SA

powder 4g sachet (see also section 2.12)

BNF emc

1<sup>st</sup> line use

### Colesevelam hydrochloride

SA

625mg tablets (see also section 2.12)

MMC BNF emc

**RESTRICTED** adults. Gastro & Lipid  
Clinic Consultants only

## 1.9.4 Pancreatin

### Pancreatin

SI

capsules

BNF emc

**NOT  
STOCKED**

# 1.10 Miscellaneous preparations



## Glucarpidase



Voraxaze® 1,000 unit injection ([see also sections 8.4, 10.4, 13.14 & 18.1.2](#))



**RESTRICTED**  
2<sup>nd</sup> line rescue therapy



# Non-Formulary Items



<b>Darvadstrocel</b> (DNP) <i>Alofisel</i> ® 5 million cells/mL injection NICE MMC emc	<b>REJECTED in line with NICE TA556 Criterion 1</b>
<b>Diarrhoea (adults)</b> (DNP)	<b>in line with GMMMG / NHSE</b>
<b>Dicycloverine hydrochloride</b> (DNP) BNF emc	<b>in line with GMMMG Criterion 2</b>
<b>Haemorrhoids</b> (DNP)	<b>in line with GMMMG / NHSE</b>
<b>Indigestion and heartburn</b> (DNP)	<b>in line with GMMMG / NHSE</b>
<b>Infant colic</b> (DNP)	<b>in line with GMMMG / NHSE</b>
<b>Infrequent constipation (duration less than 2 weeks)</b> (DNP)	<b>in line with GMMMG / NHSE</b>
<b>IQoro</b> (DNP) Neuromuscular training device	<b>in line with GMMMG Criterion 1</b>
<b>Lactase drops</b> (DNP) e.g. <i>Colief</i> ®	<b>in line with GMMMG Criterion 1</b>
<b>Lubiprostone</b> capsules NICE MMC emc	<b>Discontinued Jan-19</b>
<b>Macrogols</b> <i>Klean-Prep</i> ® oral powder MMC BNF emc	<b>Discontinued Apr-24</b>
<b>OTC haemorrhoid preparations</b> (DNP) NICE BNF emc	<b>in line with GMMMG</b>
<b>Racecadotril</b> (DNP) capsules; granules for oral suspension; tablets emc	<b>in line with GMMMG Criterion 1</b>
<b>Ranitidine</b> 150mg; 150mg effervescent tablets; 300mg tablets BNF emc	<b>Discontinued Nov-19</b> 
<b>Rifaximin</b> (DNP) 200mg tablets (see also section 5.1.7) NICE MMC BNF emc	<b>in line with GMMMG for Traveller's diarrhoea</b>
<b>Short chain fatty acid (SCFA) enema</b> Ⓢ <i>Nutricol</i> ® / <i>Prulab Pharma</i> enema MMC	<b>REMOVED</b>
<b>Stoma deodorant sprays</b> (DNP)	<b>in line with GMMMG Criterion 3</b>
<b>VSL#3® / Vivomixx® food supplement</b> (DNP)	<b>in line with GMMMG Criterion 1</b>

## Section 2: Cardiovascular system

Supported by the  
formulary ([click here](#))



### 2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

### 2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

### 2.3 Anti-arrhythmic drugs

- 2.3.2 Drugs for Arrhythmias

### 2.4 Beta-adrenoceptor blocking drugs

### 2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
  - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
  - 2.5.5.2 Angiotensin-II Receptor Antagonists
  - 2.5.5.3 Renin Inhibitors
  - 2.5.5.4 Heart Failure

### 2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

### 2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

### 2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

### 2.9 Antiplatelet drugs

### 2.10 Stable angina, acute coronary syndromes & fibrinolysis

- 2.10.2 Fibrinolytic Drugs

### 2.11 Antifibrinolytic drugs & haemostatics

### 2.12 Lipid-regulating drugs

### 2.13 Local sclerosants

### 2.14 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines

CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Prophylaxis against infective endocarditis (CG64)  
 Familial hypercholesterolaemia (CG71)  
 Chest pain of recent onset (CG95)  
 Stable angina (CG126)  
 Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)  
 Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)  
 Chronic heart failure in adults: diagnosis and management (NG106)  
 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)  
 Hypertension in pregnancy: diagnosis and management (NG133)  
 Hypertension in adults: diagnosis and management (NG136)  
 Acute coronary syndromes (NG185)  
 Atrial fibrillation: diagnosis and management (NG196)  
 Volanesorsen for treating familial chylomicronaemia syndrome (HST13)  
 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47)  
 Myocardial infarction - thrombolysis (TA52)  
 Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)  
 Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated by TA95 & TA126)  
 Hypercholesterolaemia - Ezetimibe (TA132)  
 Coronary artery disease - drug eluting stents (TA152)  
 Venous thromboembolism - dabigatran (TA157)  
 Rivaroxaban for the prevention of VTE (TA170)  
 Atrial Fibrillation - dronedarone (TA197)  
 Vascular disease - clopidogrel and dipyridamole (TA210)  
 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)  
 Acute coronary syndromes - ticagrelor (TA236)  
 Venous thromboembolism - apixaban (hip and knee surgery) (TA245)  
 Atrial fibrillation - dabigatran etexilate (TA249)  
 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)  
 Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)  
 Stroke (acute, ischaemic) - alteplase (TA264)  
 Chronic heart failure - ivabradine (TA267)  
 Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)  
 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)  
 Prasugrel with PCI for treating ACS (review of TA182) (TA317)  
 Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)  
 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)  
 Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)  
 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)  
 Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)  
 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)  
 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)  
 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)  
 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)  
 Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)  
 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)  
 Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)  
 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)  
 andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)  
 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)  
 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)  
 Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)  
 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)  
 Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)  
 Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)  
 Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)  
 Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)  
 Tenecteplase for treating acute ischaemic stroke (TA990)  
 Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)  
 Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)  
 Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)

## GMMMG Formulary

Formulary Homepage  
 Chapter 2: Cardiovascular system  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## 2.1 Positive inotropic drugs



### 2.1.1 Cardiac Glycosides

#### Digoxin

GREEN

tablets; elixir; injection



1<sup>st</sup> line use

#### Digoxin-specific antibody fragments

RED

infusion (see also section 18.1.2)



### 2.1.2 Phosphodiesterase Inhibitors

#### Enoximone

RED

Perfan® 5mg/1mL injection



#### Milrinone

RED

Primacor® 10mg/10mL injection



1<sup>st</sup> line use Paediatrics

#### Levosimendan

RED

Simdax® 12.5mg/5mL Injection



**RESTRICTED** adults.  
Cardiology ITU Consultant only

## 2.2 Diuretics



### 2.2.1 Thiazides & Related Diuretics

#### Bendroflumethiazide

GREEN

tablets



1<sup>st</sup> line use

#### Chlortalidone

tablets



#### Metolazone

SI

tablets



2<sup>nd</sup> line use with loop diuretic

MHRA Drug Safety Update (Jan-23): Xaquia (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations

### 2.2.2 Loop Diuretics

#### Furosemide

GREEN

tablets; liquid; injection



1<sup>st</sup> line use

#### Bumetanide

GREEN

tablets; oral solution



2<sup>nd</sup> line use

### 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists

#### Amiloride hydrochloride

GREEN

tablets; oral solution



1<sup>st</sup> line use

#### Spironolactone

GREEN

tablets



1<sup>st</sup> line use

MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

#### Eplerenone

SI

tablets



#### Finerenone

SA

Kerendia® tablets



**RESTRICTED adults.**  
Diabetes / Renal Consultant only

### 2.2.4 Potassium-sparing Diuretics with other Diuretics

#### Co-amilofruse

GREEN

tablets



1<sup>st</sup> line use

### 2.2.5 Osmotic Diuretics

#### Mannitol

infusion



## 2.3 Anti-arrhythmic drugs



### 2.3.2 Drugs for Arrhythmias

<b>Adenosine</b>		
injection		
<b>Amiodarone hydrochloride</b>		
<b>AMBER</b>		
tablets; injection		
MHRA Drug Safety Update (Mar-22): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision		
<b>Disopyramide</b>		
capsules; tablets		
<b>Flecainide acetate</b>		
<b>SL</b> Paeds <b>RED</b> then <b>GREEN</b>		
tablets; injection		
<b>Lidocaine (lignocaine) hydrochloride</b>		
injection (see also section 15.2)		
<b>Mexiletine</b>		<b>RESTRICTED</b> Neurology only
<b>RED</b>		
NaMuscla® 167mg capsules		
<b>Mexiletine hydrochloride</b> Ⓢ		<b>RESTRICTED</b> Cardiology / Neurology only
<b>RED</b>		
Mexitil® 50mg; 100mg; 200mg capsules		
<b>Propafenone hydrochloride</b>		
tablets		
<b>Dronedarone</b>		<b>RESTRICTED</b> adults. Cardiology Consultant only, in line with TA197
<b>AMBER</b>		
tablets		
MHRA Drug Safety Update (Oct-11): Dronedarone (Multaq▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements		

## 2.4 Beta-adrenoceptor blocking drugs



		NICE NG106
		NICE NG136
2.4 Beta-Adrenoceptor Blocking Drugs		NICE NG196
<b>Atenolol</b> <b>GREEN</b> tablets; liquid; injection		
<b>Bisoprolol fumarate</b> <b>GREEN</b> tablets	<b>MMC</b>	<b>RESTRICTED</b> adults. Cardiology Consultant only
<b>Carvedilol</b> <b>GREEN</b> tablets	<b>MMC</b>	<b>RESTRICTED</b> adults. Cardiology Consultant only <b>ALSO 2ND LINE FOR VARICEAL BLEED</b>
<b>Esmolol hydrochloride</b> injection		<b>RESTRICTED</b> <i>I.V.</i> only
<b>Etilefrine hydrochloride</b> Ⓢ tablets	<b>MMC</b>	<b>RESTRICTED</b> Haematology Consultants - SCD
<b>Labetalol hydrochloride</b> <b>GREEN</b> tablets; injection		<b>RESTRICTED</b> oral preps in pregnancy
<b>Metoprolol tartrate</b> tablets; injection		
<b>Nadolol</b> tablets	<b>MMC</b>	<b>RESTRICTED</b> paed. ventricular arrhythmias in long QT syndrome
<b>Nebivolol</b> tablets		
<b>Propranolol hydrochloride</b> <b>GREEN</b> tablets; capsules; oral solution; injection	<b>MMC</b>	<b>RESTRICTED</b> not in Cardiology
<b>Sotalol hydrochloride</b> tablets		

## 2.5 Hypertension & heart failure



		NICE NG106
		NICE NG136
		NICE NG196
<b>2.5.1 Vasodilator Antihypertensive Drugs</b>		<b>NHSE PAH</b>
<b>Hydralazine hydrochloride</b> SA tablets; injection		<b>1<sup>st</sup> line use</b>
<b>Minoxidil</b> RED tablets		
<b>Ambrisentan</b> RED ££ tablets		<b>RESTRICTED PAH in line with NHSE</b>
<b>Bosentan</b> RED ££ tablets		<b>RESTRICTED PAH in line with NHSE</b>
<b>Sildenafil</b> RED ££ Revatio® tablets; injection (see also section 7.4.5)		<b>RESTRICTED PAH in line with NHSE</b>
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio and Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
<b>Macitentan</b> RED ££ Opsumit® tablets		<b>RESTRICTED PAH in line with NHSE</b>
<b>Tadalafil</b> RED ££ Adcirca® tablets (see also section 7.4.5)		<b>RESTRICTED PAH in line with NHSE</b>
<b>2.5.2 Centrally Acting Antihypertensive Drugs</b>		
<b>Clonidine hydrochloride</b> tablets; oral solution; injection; patches		
<b>Methyldopa</b> SA tablets		
<b>Moxonidine</b> SI tablets		<b>RESTRICTED 3<sup>rd</sup> line use after other treatments fail</b>
<b>2.5.4 Alpha-Adrenoceptor Blocking Drugs</b>		
<b>Doxazosin</b> GREEN 1mg; 2mg & 4mg tablets		<b>1<sup>st</sup> line use</b>
<b>Phenoxybenzamine hydrochloride</b> RED 10mg capsules		<b>RESTRICTED adults. Specialist initiation only</b>
<b>Phentolamine mesilate</b> Ⓢ RED injection		<b>RESTRICTED adults. Specialist use, theatres only</b>
<b>2.5.5 Drugs Affecting the Renin-Angiotensin System</b>		
<b>Sparsentan</b> RED Filspari® tablets		<b>RESTRICTED adults. Specialist use only IgA nephropathy</b>

**2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors**

MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

<b>Ramipril</b> GREEN		
1.25mg; 2.5mg; 5mg & 10mg capsules	BNF emc	
<b>Captopril</b>		<b>RESTRICTED</b> Paediatrics only
12.5mg; 25mg & 50mg tablets	BNF emc	
<b>Enalapril maleate</b> RED		<b>RESTRICTED</b> Paediatric cardiology only
Aqumeldi® 0.25mg; 1mg orodispersible tablets	MMC BNF emc	
<b>Lisinopril</b> GREEN		<b>1<sup>st</sup> line use</b>
2.5mg; 5mg; 10mg & 20mg tablets	MMC BNF emc	GMMMG
<b>Perindopril erbumine</b> (DNP)		
2mg; 4mg & 8mg tablets	MMC BNF emc	

**2.5.5.2 Angiotensin-II Receptor Antagonists**

MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia

<b>Candesartan cilexetil</b> GREEN		<b>1<sup>st</sup> line use</b> hypertension
2mg; 4mg; 8mg; 16mg & 32mg tablets	MMC BNF emc	GMMMG
<b>Losartan potassium</b> GREEN		<b>2<sup>nd</sup> line use</b> hypertension
12.5mg; 25mg; 50mg & 100mg tablets	BNF emc	
<b>Irbesartan</b> GREEN		<b>2<sup>nd</sup> line use</b> hypertension
75mg; 150mg & 300mg tablets	MMC BNF emc	
<b>Valsartan</b> GREEN		<b>2<sup>nd</sup> line use</b> hypertension
40mg; 80mg & 160mg capsules	MMC BNF emc	
<b>Sacubitril / valsartan</b> SI		<b>RESTRICTED</b> use in line with NICE TA388 / NG106 HF team recommendation
Entresto® 24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets	NICE MMC BNF emc	

**2.5.5.3 Renin inhibitors**

<b>Aliskiren</b> (DNP)		<b>RESTRICTED</b> adults. Specialist initiation only
150mg; 300mg tablets	MMC BNF emc	

MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardiovascular and renal adverse reactions

**2.5.5.4 Heart Failure** NICE

<b>Dapagliflozin</b> SA		<b>RESTRICTED</b> in line with NICE TA679 / TA902 / NG106
Forxiga® tablets	NICE MMC BNF emc	
MHRA Drug Safety Update (Dec-21): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus		
<b>Empagliflozin</b> SA		<b>RESTRICTED</b> in line with NICE TA773 / TA929 / NG106
Jardiance® tablets	NICE MMC BNF emc	

## 2.6 Nitrates, calcium-channel blockers & other antianginals



### 2.6.1 Nitrates

**Glyceryl trinitrate**

GREEN

S/L tablets; S/L spray; patches; injection; ointment (see also section 18.1.1)



**Isosorbide mononitrate**

GREEN

tablets; capsules



### 2.6.2 Calcium-channel Blockers

**Amlodipine**

GREEN

tablets; oral solution



1<sup>st</sup> choice dihydropyridine



**Diltiazem hydrochloride**

GREEN

tablets; capsules; ointment



1<sup>st</sup> choice  
non-dihydropyridine  
**PRESCRIBE BY BRAND NAME**

**Nifedipine**

tablets; capsules; oral drops



2<sup>nd</sup> choice  
dihydropyridine  
**PRESCRIBE BY BRAND NAME**

**Verapamil hydrochloride**

GREEN

tablets; injection; oral solution



2<sup>nd</sup> choice  
non-dihydropyridine

**Nimodipine**

tablets; infusion



**RESTRICTED** subarachnoid  
haemorrhage / I.V. then oral

### 2.6.3 Other Antianginal Drugs

**Nicorandil**

GREEN

tablets



1<sup>st</sup> line use

MHRA Drug Safety Update (Jan-16): Nicorandil (Ikorel): now 2nd-line treatment for angina - risk of ulcer complications

**Ivabradine**

SL

tablets



**RESTRICTED** 2<sup>nd</sup> line  
Cardiology Consultant only

MHRA Drug Safety Update (Dec-14): Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects

**Ranolazine**

SA

M/R tablets



**RESTRICTED** adults 3<sup>rd</sup> line angina  
patients not suitable for surgery

### 2.6.4 Peripheral Vasodilators & Related Drugs

**Naftidrofuryl oxalate**

SA

capsules



**Defibrotide**

RED

infusion



**RESTRICTED** Specialist use only in  
line with NHSE



## 2.7 Sympathomimetics



### 2.7.1 Inotropic Sympathomimetics

#### Dobutamine

infusion (see also section 18.1.1)



**RESTRICTED / V.**  
Specialist use only

#### Dopamine hydrochloride

infusion (see also section 18.1.1)



**RESTRICTED / V.**  
Specialist use only

#### Dopexamine

infusion



**RESTRICTED / V.**  
Specialist use only

#### Isoprenaline hydrochloride

injection (see also section 18.1.1)



**RESTRICTED / V.**  
Specialist use only

### 2.7.2 Vasoconstrictor Sympathomimetics

#### Adrenaline acid tartrate

1 in 1000 (0.1%w/v) cutaneous solution)



**Specialist use endoscopic sinus surgery**

#### Ephedrine hydrochloride

injection



**RESTRICTED / V.**  
Specialist use only

#### Metaraminol

injection



#### Midodrine

**SI**

tablets



**Specialist use Cardiology /  
Healthcare of the elderly**

#### Noradrenaline acid tartrate

infusion



**RESTRICTED / V.**  
Specialist use only

#### Phenylephrine hydrochloride

injection



**RESTRICTED / V.**  
Specialist use only

### 2.7.3 Cardiopulmonary Resuscitation

#### Adrenaline / Epinephrine

**GREEN**

injection



## 2.8 Anticoagulants & protamine



### 2.8.1 Parenteral Anticoagulants

**NICE NG89**

#### ACD-A Anticoagulant Citrate Dextrose

 solution MMC **BNF** emc

#### Dalteparin sodium

SA SI RED

 injection MMC **BNF** emc

#### Epoprostenol

RED

 infusion PbR X **BNF** emc

MHRA Drug Safety Update (Dec-14): Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices

#### Heparin

RED

 injection; infusion **BNF** emc

#### Bivalirudin

RED

 infusion NICE MMC **BNF** emc

#### Fondaparinux sodium

SA SI RED

 injection MMC **BNF** emc

#### Tinzaparin sodium

SA SI RED

 injection MMC **BNF** emc

#### Enoxaparin sodium

SA SI RED

 injection MMC **BNF** emc

#### Argatroban monohydrate

RED

 infusion MMC **BNF** emc

### 2.8.2 Oral Anticoagulants

#### Acenocoumarol

GREEN

 tablets **BNF** emc

#### Phenindione

 tablets **BNF** emc

#### Warfarin sodium

GREEN

 tablets PbR X **BNF** emc

MHRA Drug Safety Update (Jun-24): Warfarin: be alert to the risk of drug interactions with tramadol

MHRA Drug Safety Update (Oct-20): Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic

MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR

MHRA Drug Safety Update (Jul-16): Warfarin: reports of calciphylaxis

#### Apixaban

GREEN

 tablets PbR X NICE MMC **BNF** emc

MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment

#### Dabigatran etexilate

GREEN

 capsules PbR X NICE MMC **BNF** emc

MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment

MHRA Drug Safety Update (Jul-12): Dabigatran (Pradaxa ▼): risk of serious haemorrhage

#### Edoxaban

GREEN

 tablets PbR X NICE MMC **BNF** emc

MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment

#### Rivaroxaban















SA GREEN

 tablets PbR X NICE MMC **BNF** emc

MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment

MHRA Drug Safety Update (Jul-19): Rivaroxaban (Xarelto ▼): reminder that 15 mg and 20 mg tablets should be taken with food





























MHRA Drug Safety Update (Oct-18): Rivaroxaban (Xarelto ▼) after TAVR: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial

<b>Antidotes</b>		
<p><b>Andexanet alfa</b>   </p> <p><i>Ondexxya</i>® infusion (see also section 18.1.2)</p>	   	<p><b>RESTRICTED</b> in line with NICE</p>
<p><b>Idarucizumab</b>   </p> <p><i>Praxbind</i>® infusion (see also section 18.1.2)</p>	  	<p><b>RESTRICTED</b> reversal of dabigatran in emergency surgery</p>
<b>2.8.3 Protamine Sulfate</b>		
<p><b>Protamine sulfate</b>  </p> <p>injection (see also section 18.1.2)</p>	 	

## 2.9 Antiplatelet drugs



NICE NG185

<b>Aspirin</b> <b>GREEN</b> tablets (dispersible & E/C); suppositories  	
<b>Clopidogrel</b> <b>GREEN</b> 75mg tablets MHRA Drug Safety Update (Dec-13): Clopidogrel: risk of acquired haemophilia MHRA Drug Safety Update (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice     	
<b>Ticagrelor</b> <b>SI</b> 60mg; 90mg tablets; orodispersible tablets    	
<b>Prasugrel</b> <b>SI</b> 5mg; 10mg tablets MHRA Drug Safety Update (Jan-14): Prasugrel (Efient): increased risk of bleeding MHRA Drug Safety Update (May-11): Prasugrel (Efient ▼): rare but serious hypersensitivity reactions     	<b>RESTRICTED adults. Cardiac Catheter Lab as per NICE</b>
<b>Dipyridamole</b> <b>GREEN</b> M/R capsules; oral suspension; tablets; injection    	2 <sup>RY</sup> prevention of stroke in patients already on aspirin
<b>Tirofiban</b> <b>RED</b> infusion    	<b>RESTRICTED adults. Cardiac Catheter Lab only (1<sup>st</sup> line)</b>
<b>Eptifibatide</b> <b>RED</b> injection; infusion    	<b>RESTRICTED adult patients admitted on this or tirofiban</b>

## 2.10 Stable angina, ACS & fibrinolysis



- Stable angina (BNF treatment summary)
- Acute coronary syndromes (BNF treatment summary)
- Fibrinolytic Drugs (BNF treatment summary)

### 2.10.2 Fibrinolytic Drugs

NICE CG126

NICE NG128

#### Tenecteplase

RED

injection

NICE MMC BNF emc

#### Streptokinase

RED

infusion

NICE BNF emc

#### Urokinase

RED

injection

MMC BNF emc

#### Alteplase

RED

injection; infusion

NICE MMC BNF emc

RESTRICTED

## 2.11 Antifibrinolytic drugs & haemostatics



### Antifibrinolytic Drugs & Haemostatics

<b>Etamsylate</b>		
tablets		
<b>Tranexamic acid</b> 		
injection; tablets		
<b>Aprotinin</b> 		<b>RESTRICTED</b>
infusion		
<b>Aminocaproic acid</b> 		<b>RESTRICTED</b>
sachets		
<b>Efanesoctocog alfa</b> 		<b>RESTRICTED</b> Haematology as per NICE TA1051
<i>Altuvoct</i> ® injection		
<b>Emicizumab</b> 		<b>RESTRICTED</b> Haematology as per NHSE
<i>Hemlibra</i> ® injection		
<b>Marstacimab</b> 		<b>RESTRICTED</b> Haematology as per NICE TA1073
<i>Altuvoct</i> ® injection		
<b>Vonicog alfa</b> 		<b>RESTRICTED</b> Haematology as per NHSE
<i>Veyvondi</i> ® injection		

## 2.12 Lipid-regulating drugs



<b>Statins</b>	
<p><b>Simvastatin</b> GREEN</p> <p>tablets</p> <p>PbR X NICE MMC BNF emc</p> <p>MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis</p>	
<p><b>Atorvastatin</b> (DNP)</p> <p>10mg; 20mg; 40mg &amp; 80mg tablets (30mg &amp; 60mg tablets) (DNP)</p> <p>PbR X NICE BNF emc</p> <p>MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis</p>	<b>1<sup>st</sup> line use</b>
<p><b>Rosuvastatin</b> GREEN</p> <p>tablets</p> <p>PbR X NICE MMC BNF emc</p> <p>MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis</p>	<b>RESTRICTED</b> Not stocked
<p><b>Pravastatin sodium</b> GREEN</p> <p>tablets</p> <p>PbR X NICE BNF emc</p> <p>MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis</p>	<b>RESTRICTED MCSH</b> for cases with potential drug interactions
<b>Bile Acid Sequestrants</b>	
<p><b>Colestyramine</b> GREY SA</p> <p>sachets (see also section 1.9.2)</p> <p>BNF emc</p>	
<p><b>Colesevelam hydrochloride</b> GREY SA</p> <p>tablets (see also section 1.9.2)</p> <p>MMC BNF emc</p>	<b>RESTRICTED</b> adults. Gastro & Lipid Clinic Consultants only
<b>Fibrates</b>	
<p><b>Bezafibrate</b></p> <p>M/R tablets; tablets</p> <p>BNF emc</p>	<b>1<sup>st</sup> line use</b>
<p><b>Fenofibrate</b> SA</p> <p>67mg / 200mg / 267mg capsules; 160mg tablets</p> <p>MMC BNF emc</p>	<b>2<sup>nd</sup> line use</b>
<b>Omega-3 fatty acid compounds</b>	
<p><b>Omega-3-acid ethyl esters</b> GREY SI</p> <p>capsules</p> <p>PbR X MMC BNF emc</p> <p>MHRA Drug Safety Update (Jan-24): Omega-3-acid ethyl ester (1000mg caps): dose-dependent increased risk of AF in patients with established CV diseases or CV risk factors</p>	<b>RESTRICTED</b> Lipid Clinic Hypertriglyceridaemia
<p><b>Omegaven</b>® RED EE</p> <p>10% emulsion for infusion</p> <p>MMC emc</p>	<b>RESTRICTED</b> Gastro. parenteral nutrition-associated cholestasis (PNAC) in infants
<p><b>Ezetimibe</b> GREEN</p> <p>10mg tablets</p> <p>NICE MMC BNF emc</p>	<b>RESTRICTED</b> adults. Lipid Clinic Consultants only

Lipid-regulating drugs		
<b>Alirocumab</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with TA393
<i>Praluent</i> ® injection	PbR X NICE MMC BNF emc	
<b>Bempedoic acid</b> (see also <i>Nustendi</i> ®) <span style="background-color: green; color: white; padding: 2px;">GREEN</span>		<b>RESTRICTED</b> adults. Consultants in line with TA694
<i>Nilemdo</i> ® tablets	PbR X NICE MMC BNF emc	
<b>Bempedoic acid with ezetimibe</b> (see also <i>Nilemdo</i> ®) <span style="background-color: green; color: white; padding: 2px;">GREEN</span>		<b>RESTRICTED</b> adults. Consultants in line with TA694
<i>Nustendi</i> ® tablets	PbR X NICE MMC BNF emc	
<b>Evinacumab</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>RESTRICTED</b> adults. Consultants in line with TA1002
<i>Repatha</i> ® injection	PbR X NICE MMC BNF emc	
<b>Evolocumab</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>RESTRICTED.</b> Lipid Clinic Consultants only for HoFH / & NICE TA394
<i>Repatha</i> ® injection	PbR X NICE MMC BNF emc	
<b>Icosapent ethyl</b> <span style="background-color: green; color: white; padding: 2px;">SA</span>		<b>RESTRICTED</b> adults in line with NICE TA805
<i>Vazkepa</i> ® capsules	PbR X NICE MMC BNF emc	
<b>Inclisiran</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span>		<b>RESTRICTED</b> adults. Consultants in line with TA733 for Primary Care Referral
<i>Leqvio</i> ® injection	PbR X NICE MMC BNF emc	
<b>Lomitapide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span>		<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with NHSE
<i>Lojuxta</i> ® capsules	PbR X MMC BNF emc	
<b>Volanesorsen</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span>		<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with HST13
<i>Waylivra</i> ® injection	PbR X NICE MMC BNF emc	

## 2.13 Local sclerosants



### Local Sclerosants

**Ethanolamine oleate**

RED

injection

**Sodium tetradecyl sulfate**







RED

injection



## 2.14 Miscellaneous preparations



<p><b>Ajmaline</b>     <i>Gilurytmal</i>® 50mg/10mL injection</p>	<p><b>RESTRICTED</b> adults.                  Cardiology Consultant only</p>
<p><b>Mavacamten</b>     <i>Camzyos</i>® capsules</p>	<p><b>RESTRICTED specialist use</b>                  in line with NICE TA913</p>
<p><b>Regadenoson</b>     <i>Rapiscan</i>® 400micrograms/5mL injection</p>	<p><b>RESTRICTED</b> adults.                  Myocardial perfusion scans</p>

Non-Formulary Items		GMMMG
<b>Atorvastatin</b> (DNP) 30mg; 60mg tablets Pbr X NICE BNF emc		<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Cilostazol</b> (DNP) Pletal® 50mg; 100mg tablets NICE MMC BNF emc		<b>REJECTED in line with NICE TA223</b> <b>GMMMG Criterion 2</b>
<b>Diuretics with potassium</b> (DNP)		<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Doxazosin</b> (DNP) M/R tablets / 8mg immediate release tablets MMC BNF emc		<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Inositol nicotinate</b> (DNP) Hexopal® tablets NICE MMC BNF emc		<b>REJECTED in line with NICE TA223</b> <b>GMMMG Criterion 2</b>
<b>Moxisylyte</b> (DNP)		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Pentoxifylline</b> (DNP) Trental® tablets NICE MMC BNF emc		<b>REJECTED in line with NICE TA223</b> <b>GMMMG Criterion 2</b>
<b>Perindopril arginine</b> (DNP) 2.5mg; 5mg & 10mg tablets NICE BNF emc		<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>RESPeRATE</b> (DNP)		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Simvastatin with ezetimibe</b> (DNP) Inegy® 10mg/20mg; 10mg/40mg & 10mg/80mg tablets NICE MMC BNF emc		<b>in line with GMMMG</b> <b>Criterion 2</b>

## Section 3: Respiratory system

Supported by the  
formulary (click here)



### 3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers
  - Inhaler Devices
  - Nebuliser Diluent

### 3.2 Corticosteroids

- Compound preparations

### 3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

### 3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

### 3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants

### 3.6 Oxygen (refer to oxygen guidelines)

### 3.7 Mucolytics

### 3.8 Aromatic inhalations

### 3.9 Cough preparations

- 3.9.1 Cough Suppressants
  - Cough Suppressants (Palliative Care ONLY)
- 3.9.2 Demulcent & expectorant cough preparations

### 3.10 Systemic Nasal Decongestants

### 3.11 Antifibrotics

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Idiopathic pulmonary fibrosis (CG163)  
 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)  
 Asthma pathway (BTS, NICE, SIGN) (NG244)  
 Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)  
 Venom anaphylaxis - immunotherapy pharmlagen (TA246)  
 Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)  
 Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)  
 Omalizumab for previously treated chronic spontaneous urticaria (TA339)  
 Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)  
 Reslizumab for treating severe eosinophilic asthma (TA479)  
 Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)  
 Benralizumab for treating severe eosinophilic asthma (TA565)  
 Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)  
 Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)  
 Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)  
 Dupilumab for treating severe asthma with type 2 inflammation (TA751)  
 Palforzia for treating peanut allergy in children and young people (TA769)  
 Tezepelumab for treating severe asthma (TA880)  
 Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)  
 Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis in people 6yr & over (TA1085)  
 Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)  
 Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)  
 Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)  
 Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134)

## GMMMG Formulary

Formulary Homepage  
 Chapter 3: Respiratory system  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## 3.1 Bronchodilators



<i>Asthma (chronic)</i>	<i>Asthma (acute)</i>	
<b>Methacholine chloride</b>		<b>RESTRICTED detection test for bronchial airway hyperreactivity</b>
<i>Provocholine</i> ® nebuliser solution		MMC
<b>3.1.1 Adrenoceptor agonists</b>		
<b>3.1.1.1 Selective beta<sub>2</sub> agonists</b>		
<b>Salbutamol</b> (Dry Powder Inhaler (DPI) devices) 		
100micrograms/dose; 200micrograms/dose		
MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma		
<b>Salbutamol</b> (nebuliser solution) 		
2.5mg/2.5mL; 5mg/2.5mL nebuliser liquid unit dose ampoules		MMC
MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma		
<b>Salbutamol</b> (injection) 		
500 micrograms/1mL solution for injection ampoules; 5mg/5mL solution for intravenous infusion. (see also section 7.1.3)		MMC
MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma		
<b>Terbutaline sulfate</b> (Dry Powder Inhaler (DPI) devices) 		
500micrograms/dose		
MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma		
<b>Terbutaline sulfate</b> (nebuliser solution) 		
5mg/2mL nebuliser liquid unit dose vials		
MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma		
<b>Terbutaline sulfate</b> (injection) 		
500 micrograms/mL; 2.5mg/5mL solution for injection ampoules. (see also section 7.1.3)		
MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma		
<b>Salmeterol</b>		
<b>Formoterol fumarate</b> 		
		MMC
<b>3.1.1.2 Other Adrenoceptor Agonists</b>		
<b>Ephedrine hydrochloride</b>		
<b>3.1.2 Antimuscarinic Bronchodilators</b>		
<b>Ipratropium bromide</b> 		
<b>1<sup>st</sup> line use</b>		
<b>Tiotropium</b> 		
		MMC
<b>2<sup>nd</sup> line use COPD maintenance</b>		
MHRA Drug Safety Update (Feb-15): Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial		
<b>Acclidinium bromide</b> 		
		MMC
<b>2<sup>nd</sup> line use COPD maintenance</b>		
<i>Eklira Genuair</i> ®		
		MMC
<b>Glycopyrronium bromide</b> 		
<b>2<sup>nd</sup> line use COPD maintenance</b>		
<i>Seebri Breezhaler</i> ®		
		MMC
<b>Umeclidinium bromide</b> 		
<b>2<sup>nd</sup> line use COPD maintenance</b>		
<i>Incruse Ellipta</i> ®		
		MMC
<b>3.1.3 Theophylline</b>		
<b>Theophylline</b> 		
M/R tablets; M/R capsules		
<b>1<sup>st</sup> line use PRESCRIBE BY BRAND NAME</b>		
<b>Aminophylline</b> 		
M/R tablets; injection		
<b>PRESCRIBE BY BRAND NAME</b>		

3.1.4 Compound Bronchodilator Preparations		GMMMG
<b>Acclidinium bromide with formoterol fumarate dihydrate</b> GREEN Duaklir Genuair®	MMC BNF emc	3 <sup>rd</sup> line use COPD maintenance
<b>Glycopyrronium bromide with formoterol fumarate</b> GREEN Bevespi Aerosphere®	MMC BNF emc	3 <sup>rd</sup> line use COPD maintenance
<b>Glycopyrronium bromide with indacaterol maleate</b> GREEN Ultibro®	MMC BNF emc	3 <sup>rd</sup> line use COPD maintenance
<b>Ipratropium bromide with salbutamol</b> Combivent®	BNF emc	
<b>Tiotropium bromide monohydrate with olodaterol hydrochloride</b> GREEN Spiolto Respimat®	MMC BNF emc	3 <sup>rd</sup> line use COPD maintenance
<b>Umeclidinium bromide with vilanterol trifenate</b> GREEN Anoro Ellipta®	MMC BNF emc	3 <sup>rd</sup> line use COPD maintenance
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers		GMMMG GMMMG GMMMG
Inhaler Devices		
<b>Volumatic® (spacer inhaler)</b> GREEN Large volume device with mouthpiece	NICE BNF emc	
<b>Aerochamber® Plus (spacer device)</b> GREEN Standard device with mouthpiece; Standard device with adult face mask	NICE BNF	
<b>Able Spacer® (spacer device)</b> GREEN	NICE MMC BNF	
Nebuliser Diluent		
<b>Sodium chloride</b> GREEN 0.9% nebuliser diluent	BNF emc	

## 3.2 Corticosteroids



Corticosteroids		NICE	GMMMG	
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects				
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration				
<b>Beclometasone dipropionate</b>				
GREEN				
MDI ( <i>Clenil Modulite</i> ® 50, 100, 200, 250)		MMC	BNF	emc
<b>Beclometasone dipropionate (CFC-free)</b>				
GREEN				
MDI ( <i>Qvar Easi-Breathe</i> ® or <i>Qvar Autohaler</i> ® 50, 100)		MMC	BNF	emc
				<b>PRESCRIBE BY BRAND NAME</b>
<b>Budesonide</b>				
GREEN				
DPI ( <i>Easyhaler</i> ®; <i>Pulmicort</i> ® <i>Turbohaler</i> ® 100, 200, 400) 500micrograms/2mL & 1mg/2mL nebuliser liquid		MMC	BNF	emc
<b>Fluticasone propionate</b>				
MDI ( <i>FlixotideEvohaler</i> ®) 50, 125, 250; DPI ( <i>FlixotideAccuhaler</i> ® 50,100, 250, 500)			BNF	emc
<b>Compound preparations</b>		NICE		
<b>Budesonide with formoterol fumarate</b>				
GREEN				
DPI ( <i>Fobumix Easyhaler</i> ® 80/4.5, 160/4.5, 320/9); DPI ( <i>Symbicort Turbohaler</i> ® 100/6, 200/6, 400/12); DPI ( <i>Duoresp Spiromax</i> ® 160/4.5, 320/9); DPI ( <i>WockAIR</i> ® 160/4.5, 320/9)		MMC	BNF	emc
				Asthma BTS step 3 management
				GMMMG
				GMMMG
<b>Beclometasone dipropionate with formoterol fumarate</b>				
GREEN				
MDI ( <i>Luforbec</i> ®; <i>Fostair</i> ®; 100/6, 200/6); DPI ( <i>Fostair NEXThaler</i> ® 100/6, 200/6)		MMC	BNF	emc
				Asthma BTS step 3 management
<b>Fluticasone furoate with vilanterol trifenate</b>				
GREEN				
DPI ( <i>Relvar Ellipta</i> ® 92/22 asthma or COPD; 184/22 asthma)		MMC	BNF	emc
				Asthma BTS step 3 management
<b>Fluticasone propionate with salmeterol</b>				
MDI ( <i>Sirdupla</i> ® 125, 250)		MMC	BNF	emc
				Asthma BTS step 3 management
<b>Fluticasone propionate with salmeterol</b>				
MDI ( <i>SeretideEvohaler</i> ® 50, 125, 250)				Asthma BTS step 3 management
<b>Fluticasone propionate with formoterol fumarate</b>				
MDI ( <i>Flutiform</i> ® 50/5, 125/5, 250/10)		MMC	BNF	emc
				Asthma BTS step 3 management
<b>Beclometasone dipropionate with formoterol fumarate &amp; glycopyrronium bromide</b>				
GREEN				
MDI ( <i>Trimbow</i> 87/5/9® & 172/5/9®) DPI ( <i>Trimbow NEXThaler</i> 88/5/9®)		MMC	BNF	emc
				<b>RESTRICTED - COPD patients who require triple therapy</b>
				GMMMG
				GMMMG
<b>Fluticasone furoate with umeclidinium bromide &amp; vilanterol trifenate</b>				
GREEN				
DPI ( <i>Trelegy Ellipta</i> ® 92/55/22 micrograms)		MMC	BNF	emc
				<b>RESTRICTED - COPD patients who require triple therapy</b>
				GMMMG
				GMMMG
<b>Formoterol fumarate with glycopyrronium bromide &amp; budesonide</b>				
GREEN				
DPI ( <i>Trixeo Aerosphere</i> ® 5/7.2/160 micrograms)		MMC	BNF	emc
				<b>RESTRICTED - COPD patients who require triple therapy</b>
				GMMMG
				GMMMG
<b>Indacaterol with mometasone furoate</b>				
GREEN				
DPI ( <i>Ateectura</i> ® <i>Breezhaler</i> ®)		MMC	BNF	emc
				GMMMG
				GMMMG
<b>Mometasone furoate with glycopyrronium bromide &amp; indacaterol</b>				
GREEN				
DPI ( <i>Enerzair</i> ® <i>Breezhaler</i> ®)		MMC	BNF	emc
				GMMMG
				GMMMG
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects				
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration				

## 3.3 Cromoglicic acid & related therapy & leukotriene receptor antagonists



### 3.3.1 Cromoglicic acid & Related Therapy

Sodium cromoglicic acid



### 3.3.2 Leukotriene Receptor Antagonists

Montelukast

GREEN

tablets; chewable tablets; sachets



BTS step 2 or 3 in paediatrics

MHRA Drug Safety Update (Apr-24): Montelukast: reminder of the risk of neuropsychiatric reactions

MHRA Drug Safety Update (Sep-19): Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions

### 3.3.3 Phosphodiesterase type-4 inhibitors

Roflumilast

SI

tablets



**RESTRICTED**  
as per NICE TA461

### 3.4 Antihistamines, hyposensitisation & allergic emergencies



#### 3.4.1 Antihistamines

##### Non-sedating antihistamines

###### Cetirizine hydrochloride

GREEN OTC

tablets; oral solution

BNF emc

###### Loratadine

GREEN OTC

tablets; oral solution

BNF emc

###### Desloratadine

tablets; oral solution

MMC BNF emc

**RESTRICTED**  
children 1-2 years old

###### Fexofenadine hydrochloride

OTC

tablets

MMC BNF emc

##### Sedating antihistamines

###### Chlorphenamine maleate

GREEN OTC

tablets; oral solution; injection

MMC BNF emc

###### Cyprohepatadine hydrochloride

4mg tablets

MMC BNF emc

###### Hydroxyzine hydrochloride

GREEN

tablets; oral solution

BNF emc

MHRA Drug Safety Update (Apr-15): Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes

###### Promethazine hydrochloride

tablets; oral solution

MMC BNF emc

###### Alimemazine tartrate

(DNP)

tablets; oral solution

MMC BNF emc

#### 3.4.2 Allergen Immunotherapy

###### Acarovac Plus®

3,000 units/mL injection

MMC

**RESTRICTED**  
Immunology Consultants only

###### Acaroid®

injection

MMC

**RESTRICTED**  
Immunology Consultants only

###### Allergoid immunotherapy tablets

Lofarma Lais®

MMC BNF emc

**RESTRICTED**  
Immunology Consultants only

###### Bee venom extract

RED

injection

NICE BNF emc

**RESTRICTED**  
Immunology Consultants only

###### Grass & Rye or tree pollen extract

GREY RED

Pollinex®

MMC BNF emc

**RESTRICTED**  
Immunology Consultants only

###### Grass pollen extract

(DNP)

Grazax® oral lyophilisates

NICE MMC BNF emc

**RESTRICTED**  
Immunology Consultants only

###### House dust mite extract

RED

Acarizax 12-SQ HDM oral lyophilisates®

NICE MMC BNF emc

**RESTRICTED**  
Immunology Consultants only

###### Peanut protein powder

GREY RED

Palforza® oral powder in capsules; sachet

NICE MMC BNF emc

**RESTRICTED**  
Immunology Consultants only

###### Wasp venom extract

RED

injection

NICE MMC BNF emc

**RESTRICTED**  
Immunology Consultants only

###### White birch (*Betula verrucosa*) tree pollen extract

RED

Itulazax 12-SQ Bet oral lyophilisates®

NICE MMC BNF emc

**RESTRICTED**  
Immunology Consultants only

<b>Omalizumab</b>		
<b>Omalizumab</b> RED (DNP) ££		<b>RESTRICTED</b> as per NICE / GMMMG
injection	PbR X NICE MMC BNF blueiteq emc	
<b>Anti-interleukin-5 (IL-5) antibody</b>		
<b>Benralizumab</b> RED ££		<b>RESTRICTED</b> as per NICE TA565 / TA1096
Fasenra® injection	PbR X NICE MMC BNF blueiteq emc	
<b>Dupilumab</b> RED (DNP) ££		<b>RESTRICTED</b> as per NICE / NHSE
Dupilumab® injection (see also section 13.5.3)	PbR X NICE MMC BNF blueiteq emc	
MHRA Drug Safety Update (Nov-22): Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management		
<b>Mepolizumab</b> RED ££		<b>RESTRICTED</b> as per NICE
Nucala® injection	PbR X NICE MMC BNF blueiteq emc	
<b>Reslizumab</b> RED ££		<b>RESTRICTED</b> as per NICE TA479
Cinqaero® infusion	PbR X NICE MMC BNF blueiteq emc	
<b>Tezepelumab</b> RED ££		<b>RESTRICTED</b> as per NICE TA880
Tezspire® injection	PbR X NICE MMC BNF blueiteq emc	
<b>3.4.3 Allergic Emergencies</b>		
<b>Adrenaline / epinephrine</b> GREEN		<b>PRESCRIBE BY BRAND NAME</b>
injection	BNF emc	
MHRA Drug Safety Update (Jun-23): Adrenaline auto-injectors (AAIs): new guidance and resources for safe use MHRA Drug Safety Update (Nov-21): Adrenaline auto-injectors: reminder for prescribers to support safe and effective use MHRA Drug Safety Update (Aug-17): Adrenaline auto-injectors: updated advice after European review		
<b>Adrenaline / epinephrine (nasal)</b> RED		<b>RESTRICTED</b> service evaluation use only type I allergic reactions
EURneffy® 2mg nasal spray, solution in single-dose container	MMC BNF emc	
<b>Bertralstat</b> RED ££		<b>RESTRICTED</b> specialist use only as per NICE TA738
Orladeyo® capsules	PbR X NICE MMC BNF emc	
<b>C1 esterase inhibitor</b> RED ££		<b>RESTRICTED</b> specialist use only
Beriner®; Cinryze® injection	PbR X MMC BNF blueiteq emc NHS England	
<b>Conestat alfa</b> RED ££		<b>RESTRICTED</b> acute attacks of HAE
Ruconest® injection	PbR X MMC BNF blueiteq emc NHS England	
<b>Garadacimab</b> RED ££		<b>RESTRICTED</b> acute attacks of HAE as per NICE TA1101
Andembry® injection	PbR X NICE MMC BNF emc	
<b>Icatibant</b> RED ££		<b>RESTRICTED</b> adults acute attacks of HAE
Firazyr® injection	PbR X MMC BNF blueiteq emc NHS England	
<b>Lanadelumab</b> RED ££		<b>RESTRICTED</b> in line with NICE TA606
Takhzyro® injection	PbR X NICE MMC BNF blueiteq emc	
<b>Oxandrolone</b> Ⓢ		<b>RESTRICTED</b> adults acute attacks of HAE
tablets	MMC emc	
<b>Sebetralstat</b> Ⓢ RED		<b>RESTRICTED</b> specialist use only in line with EAMS
300mg; 600mg tablets	MMC	

### 3.5 Respiratory stimulants & pulmonary surfactants



#### 3.5.1 Respiratory Stimulants

**Doxapram hydrochloride**

RED

injection (see also section 15.1.7)

BNF emc

**Caffeine citrate**

RED

injection

MMC BNF emc

**RESTRICTED**  
apnoea in premature babies

#### 3.5.2 Pulmonary Surfactants

**Poractant alfa**

RED



Curosurf® liquid

PbR X

BNF emc

## 3.6 Oxygen ([refer to oxygen guidelines](#))



# 3.7 Mucolytics



## Mucolytics

### Acetylcysteine

GREEN

effervescent tablets; injection; sachets

MMC BNF emc

### Carbocisteine

GREEN

capsules; oral solution; sachets

MMC BNF emc

**RESTRICTED**  
COPD Consultant / referral only

### Deutivacaftor with tezacaftor and vanzacaftor

RED ££

Alyftrek® tablets

PbR X NICE MMC BNF emc

**RESTRICTED**  
Specialist use only NICE TA1085



### Ivacaftor

RED ££

Kalydeco® tablets; granules

PbR X NICE MMC BNF emc

**RESTRICTED**  
Paediatric Consultants only



MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio ▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

### Ivacaftor with tezacaftor and elexacaftor

RED ££

Kaftrio® tablets

PbR X NICE MMC BNF emc

**RESTRICTED**  
Specialist use only



MHRA Drug Safety Update (May-25): Kaftrio ▼ (Ivacaftor, tezacaftor, elexacaftor): risk of psychological side effects

MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio ▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

### Lumacaftor with ivacaftor

RED ££

Orkambi® tablets; granules

PbR X NICE MMC BNF emc

**RESTRICTED**  
Specialist use only



MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio ▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

### Tezacaftor with ivacaftor

RED ££

Symkevi® tablets

PbR X NICE MMC BNF emc

**RESTRICTED**  
Specialist use only



MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elexacaftor (Kaftrio ▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT

## Dornase alfa

### Dornase alfa

RED ££

Pulmozyme® nebulas

PbR X MMC BNF emc MedTeq

**RESTRICTED**  
Respiratory only

## Hypertonic sodium chloride

### Sodium chloride (hypertonic)

SA

Nebusal® 7% nebulas

BNF emc

## Mannitol

### Mannitol inhalation powder

RED

Bronchitol® capsules

PbR X NICE MMC BNF emc

**RESTRICTED**  
Respiratory only in line with NICE

### Mannitol diagnostic kit

RED

Osmohale® capsules

PbR X MMC BNF emc

**RESTRICTED**  
Respiratory only

## 3.8 Aromatic inhalations



### Aromatic Inhalations

#### Benzoin Tincture, Compound, BP

*Friars' Balsam liquid*



#### Menthol and Eucalyptus Inhalation, BP 1980

inhalation vapour



## 3.9 Cough preparations



### 3.9.1 Cough Suppressants

#### Codeine phosphate

oral solution



MHRA Drug Safety Update (Feb-24): Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine

MHRA Drug Safety Update (Jul-23): Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine

#### Dextromethorphan hydrobromide

oral solution



**RESTRICTED**  
non-ketotic hyperglycinaemia

### Cough Suppressants (*Palliative Care ONLY*)

#### Methadone hydrochloride

liquid



#### Morphine hydrochloride

oral solution



### 3.9.2 Demulcent & expectorant cough preparations

#### Simple Linctus

liquid



## 3.10 Systemic nasal decongestants



### Systemic Nasal Decongestants

**NO DRUGS ARE RECOMMENDED FROM THIS GROUP**



**NHSE: OTC prescribing reduction**

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)

### 3.11 Antifibrotics



**Antifibrotics**

**Nintedanib esilate**



Ofev® capsules



**RESTRICTED** Respiratory  
Consultants only in line with NICE

**Pirfenidone**
















capsules; tablets



**RESTRICTED**  
Respiratory Consultants only  
**NOT STOCKED**

MHRA Drug Safety Update (Nov-20): Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing

Non-Formulary Items		GMMMG
<b>Adrenaline / epinephrine</b>  <i>Emerade</i> ® 150microgram; 300microgram & 500microgram injection  	<b>REMOVED from formulary Jan-25</b>	
<b>Cyprohepatadine hydrochloride</b>   2mg/5mL liquid   	<b>REMOVED from formulary Jan-25</b>	
<b>Insect bites and stings</b> 	<b>in line with GMMMG / NHSE</b>	
<b>Mild to moderate hay fever / seasonal rhinitis</b> 	<b>in line with GMMMG / NHSE</b>	
<b>Levocetirizine hydrochloride</b>   <i>Xyzal</i> ® tablets  	<b>in line with GMMMG Criterion 2</b>	
<b>Pholcodine</b>  oral solution  	<b>Withdrawn from UK market as per MHRA alert March 2023</b>	
MHRA Drug Safety Update (Mar-23): Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure		

# Chapter 4: Central nervous system

Supported by the  
formulary ([click here](#))



## 4.1 Hypnotics & anxiolytics

- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates
- 4.1.4 Other hypnotics and anxiolytics

## 4.2 Drugs used in psychoses & related disorders

- 4.2.1 Antipsychotic Drugs
- 4.2.2 Antipsychotic Depot Injections
- 4.2.3 Drugs used for mania and hypomania

## 4.3 Antidepressant drugs

- 4.3.1 Tricyclic & Related Antidepressant Drugs
- 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
- 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
- 4.3.4 Other Antidepressant Drugs

## 4.4 CNS stimulants & drugs used for ADHD

## 4.5 Drugs used in the treatment of obesity

## 4.6 Drugs used in nausea & vertigo

## 4.7 Analgesics

- 4.7.1 Non-Opioid Analgesics
- 4.7.2 Opioid Analgesics
- 4.7.3 Neuropathic Pain
- 4.7.4 Antimigraine Drugs

## 4.8 Antiepileptic drugs

- 4.8.1 Control of the Epilepsies
- 4.8.2 Drugs Used in Status Epilepticus

## 4.9 Drugs used in Parkinsonism & related disorders

- 4.9.1 Dopaminergic Drugs Used in Parkinsonism
- 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
- 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders

## 4.10 Drugs used in substance dependence

## 4.11 Drugs for dementia

## Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Obsessive compulsive disorder (OCD) & body dysmorphic disorder (BDD) (CG31)  
 Management of Obesity (CG43) (replaces TA22, TA31 & TA46)  
 Drug misuse: opioid detoxification (CG52)  
 Depression with a chronic physical health problem (CG91)  
 Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)  
 Anxiety (CG113) (replaces CG22)  
 Neuropathic pain - pharmacological management (CG173)  
 Psychosis and schizophrenia in adults (CG178)  
 Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)  
 Narcolepsy with or without cataplexy in adults: pitolisant (ES8)  
 Eating Disorders: recognition and treatment (NG69)  
 Parkinson's disease in adults (NG71)  
 Attention deficit hyperactivity disorder: diagnosis and management (NG87)  
 Stop smoking interventions and services (NG92)  
 Dementia: supporting people with dementia and their carers in health and social care (NG97)  
 Post-traumatic stress disorder (NG116)  
 Depression in children and young people: identification and management (NG134)  
 Epilepsies in children, young people and adults (NG217)  
 Depression in adults: treatment and management (NG222)  
 Motor Neurone Disease: Riluzole (TA20)  
 Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)  
 Drug Misuse: Methadone & Buprenorphine (TA114)  
 Drug Misuse: Naltrexone (TA115)  
 Smoking Cessation: Varenicline (TA123)  
 Schizophrenia - aripiprazole (TA213)  
 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)  
 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)  
 Bipolar disorder (children) - aripiprazole (TA292)  
 Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)  
 Vortioxetine for treating major depressive episodes (TA367)  
 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)  
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)  
 Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)  
 Galcanezumab for preventing migraine (TA659)  
 Cenobamate for treating focal onset seizures in epilepsy (TA753)  
 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)  
 Fremanezumab for preventing migraine (replacing TA631) (TA764)  
 Fenfluramine for treating seizures associated with Dravet syndrome (TA808)  
 Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)  
 Eptinezumab for preventing migraine (TA871)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Rimegepant for preventing migraine (TA906)  
 Rimegepant for treating migraine (TA919)  
 Daridorexant for treating long-term insomnia (TA922)  
 Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)  
 Atogepant for preventing migraine (TA973)  
 Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)  
 Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)  
 Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)  
 Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (TA1115)  
 Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)

## GMMMG Formulary

Formulary Homepage  
 Chapter 4: Central nervous system  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

# 4.1 Hypnotics & anxiolytics



## 4.1.1 Hypnotics

NICE CG112

### Benzodiazepines

MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

#### Temazepam

GREEN

tablets; oral solution (see also section 15.1.4.1)



#### Nitrazepam

tablets; oral suspension



### Zaleplon, Zolpidem & Zopiclone

#### Zopiclone

GREEN

tablets



MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

### Chloral & Derivatives

#### Chloral hydrate

RED

oral solution; suppositories



MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication

#### Chloral hydrate

RED

500mg/5mL oral solution



**RESTRICTED**  
paediatric patients on ketogenic diets

MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication

#### Clomethiazole

192mg capsules



### Sodium oxybate

#### Sodium oxybate

GREY RED

oral solution



**RESTRICTED**  
2<sup>nd</sup> line narcolepsy with cataplexy

### Melatonin

#### Melatonin

capsules; tablets; oral solution



**RESTRICTED**



#### Melatonin (adults)

Tablets: 1mg, 2mg, 3mg, 4mg, 5mg (Adaflex®)  
Prolonged-release tablets: 2mg (prescribe generically)  
For REM sleep behaviour disorder in Parkinson's disease  
Do not prescribe for management of jet lag.

SA

(DNP)

#### Melatonin (children)

Tablets: 1mg, 2mg, 3mg, 4mg, 5mg (Adaflex®)  
Modified-release tablets: 1mg, 5mg (Slenyto®)  
Prolonged-release tablets: 2mg (prescribe generically)

AMBER

Doses greater than 6mg

1 mg/mL oral solution (Colonis brand licensed product). Should not be prescribed due to the propylene glycol content

RED

(DNP)

## 4.1.2 Anxiolytics

NICE CG113

### Benzodiazepines

#### Chlordiazepoxide hydrochloride

GREEN

capsules



**Symptomatic relief of acute alcohol withdrawal**

MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

#### Diazepam

GREEN

tablets; liquid; injection; rectal tube (see also sections 4.8.2; 10.2.2 & 15.1.4.1)



MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

#### Lorazepam

tablets; injection (see also section 4.8.2 & 15.1.4.1)



MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

#### Oxazepam

tablets



MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

**Buspirone****Buspirone hydrochloride**

tablets

BNF emc

**Others****Pregabalin**GREEN 

capsules; oral solution

MMC BNF emc

**RESTRICTED** generalised anxiety disorder after standard treatment following NICE has failed.

MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

**4.1.3 Barbiturates****NO DRUGS ARE RECOMMENDED FROM THIS GROUP****4.1.4 Other hypnotics and anxiolytics****Daridorexant hydrochloride**

GREEN

Quviviq® tablets

NICE MMC BNF emc

**RESTRICTED**  
in line with NICE TA922  
**NOT for initiation in 2<sup>nd</sup> care**

## 4.2 Drugs used in psychoses & related disorders



4.2.1 Antipsychotic Drugs		NICE CG178
MHRA Drug Safety Update (May-12): Antipsychotics: initiative to reduce prescribing to older people with dementia		
<b>Chlorpromazine hydrochloride</b> GREEN	tablets; oral solution; injection MMC BNF emc	
<b>Haloperidol</b> GREEN (DNP)	tablets; capsules; oral solution (500microgram tablets see DNP) BNF emc	
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
<b>Levomepromazine</b> GREEN (DNP)	6.25mg, 25mg tablets; oral solution; injection (6mg tablets see DNP) MMC BNF emc	
<b>Promazine hydrochloride</b>	tablets; oral solution BNF emc	
<b>Sulpiride</b>	tablets; oral solution BNF emc	
<b>Trifluoperazine</b>	tablets; oral solution BNF emc	
<b>Zuclopenthixol</b>	tablets BNF emc	
Atypical Antipsychotic Drugs		
<b>Amisulpride</b> AMBER RED	tablets; oral solution MMC BNF emc	<b>RESTRICTED</b> adults. Consultant Psychiatrist only
<b>Aripiprazole</b> AMBER RED	tablets; oral solution NICE MMC BNF emc	<b>RESTRICTED</b> paediatrics. Consultant Psychiatrist only
MHRA Drug Safety Update (Dec-23): Aripiprazole (Ablify and generic brands): risk of pathological gambling		
<b>Clozapine</b> RED	tablets BNF emc	
MHRA Drug Safety Update (Aug-20): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity		
MHRA Drug Safety Update (Oct-17): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus		
<b>Olanzapine</b> AMBER RED	tablets; orodispersible tablets; oral solution (see also section 18.1.2) MMC BNF emc	CCLG <b>RESTRICTED</b> - Consultant initiation - schizophrenia patients
AMBER RED	tablets; M/R tablets MMC BNF emc	
<b>Risperidone</b> AMBER RED	tablets; orodispersible tablets; oral solution BNF emc	
4.2.2 Antipsychotic Depot Injections		
<b>Flupentixol decanoate</b> AMBER	injection BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
<b>Fluphenazine decanoate</b>	injection BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
<b>Haloperidol decanoate</b> AMBER	injection BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
<b>Risperidone</b> AMBER RED	injection BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
<b>Zuclopenthixol decanoate</b> RED	injection BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only

**4.2.3 Drugs used for mania and hypomania****Lithium carbonate**

AMBER RED

tablets; M/R tablets

**PRESCRIBE BY BRAND NAME****Lithium citrate**

AMBER RED

oral solution

**PRESCRIBE BY BRAND NAME****Valproic acid**

SI

Gastro-resistant tablets



MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance




















MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended

## 4.3 Antidepressant drugs



		NICE CG31
		NICE CG91
4.3.1 Tricyclic & Related Antidepressant Drugs		NICE NG134
Tricyclic antidepressants		NICE NG222
<b>Amitriptyline hydrochloride</b> (standard release preparations only) <b>GREEN</b>		
tablets; oral solution (see also section 7.4.2)		
<b>Clomipramine hydrochloride</b> (standard release preparations only) <b>GREEN</b>		
capsules		
<b>Doxepin hydrochloride</b>		
capsules		
<b>Imipramine hydrochloride</b>		
tablets		
<b>Lofepramine</b> <b>GREEN</b>		1 <sup>st</sup> line use
tablets; oral suspension		
<b>Nortriptyline</b> <b>GREEN</b>		
tablets  neuropathic pain		
<b>Tricyclic-related antidepressants</b>		
<b>Mianserin hydrochloride</b>		<b>RESTRICTED</b> initiation by Psychiatrist
tablets		
<b>Trazodone hydrochloride</b> <b>GREEN</b>		<b>RESTRICTED</b> initiation by Psychiatrist
capsules; tablets; oral solution		
<b>4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)</b>		
<b>Isocarboxazid</b> <b>RED</b>		<b>RESTRICTED</b> initiation by Psychiatrist
tablets		
<b>Phenelzine</b> <b>RED</b>		<b>RESTRICTED</b> initiation by Psychiatrist
15mg tablets		
<b>Tranlycypromine</b> <b>RED</b>		<b>RESTRICTED</b> initiation by Psychiatrist
10mg tablets		
<b>Reversible Monoamine-Oxidase Inhibitors (MAOIs)</b>		
<b>Moclobemide</b> <b>SI</b>		<b>RESTRICTED 2<sup>nd</sup> line</b> initiation by Psychiatrist
150mg; 300mg tablets		
<b>4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)</b>		
MHRA Drug Safety Update (Jan-21): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery		
<b>Fluoxetine</b> <b>GREEN</b>		
capsules; tablets; dispersible tablets; oral solution		
<b>Citalopram</b> <b>GREEN</b>		
tablets; oral drops		
MHRA Drug Safety Update (Jul-16): Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use		
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
<b>Sertraline</b> <b>GREEN</b>		
tablets; oral suspension		
<b>Fluvoxamine maleate</b>		
tablets		
<b>Paroxetine</b>		
tablets; oral suspension		
<b>Escitalopram</b>		<b>RESTRICTED</b> Mental Health Trust initiation only
tablets		
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		

**4.3.4 Other Antidepressant Drugs**

<b>Venlafaxine</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> <span style="background-color: green; color: white; padding: 2px;">SI</span> M/R capsules; tablets; M/R tablets   	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Mirtazapine</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> tablets; orodisperible tablets; oral solution   	
<b>Duloxetine</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> gastro-resistant tablets  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Flupentixol</b> tablets  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Reboxetine</b> tablets   	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Tryptophan</b> capsules  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Vortioxetine</b> <span style="background-color: grey; color: white; padding: 2px;">GREY</span> <span style="background-color: green; color: white; padding: 2px;">SA</span> tablets    	<b>RESTRICTED</b> initiation by Psychiatrist

## 4.4 CNS stimulants & drugs used for ADHD



4.4 CNS stimulants & drugs used for ADHD		NICE NG87
<b>Atomoxetine</b> <p>capsules</p> <p>NICE MMC BNF  </p> <p>MHRA Drug Safety Update (Jan-12): Atomoxetine (Strattera ▼): increases in blood pressure and heart rate                      MHRA Drug Safety Update (Mar-09): Atomoxetine: risk of psychotic or manic symptoms in children and adolescents</p>		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
<b>Dexamfetamine</b> <p>tablets</p> <p>NICE MMC BNF  </p>		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
<b>Guanfacine</b> <p>Prolonged release tablets</p> <p>NICE MMC BNF  </p>		<b>RESTRICTED</b> 2 <sup>nd</sup> line use for ADHD
<b>Lisdexamfetamine</b> <p>capsules</p> <p>NICE MMC BNF   </p>		<b>RESTRICTED</b> 2 <sup>nd</sup> line use for ADHD
<b>Methylphenidate</b> <p>tablets; M/R tablets; capsules; M/R capsules</p> <p>NICE MMC BNF  </p> <p>MHRA Drug Safety Update (Sep-22): Methylphenidate long-acting (MR) preparations: caution if switching between products due to differences in formulations                      MHRA Drug Safety Update (Mar-09): Methylphenidate: safe and effective use to treat ADHD</p>		<b>RESTRICTED</b> on Paediatric / Psychiatric advice <b>PRESCRIBE BY BRAND NAME</b>
<b>Modafinil</b> <p>tablets</p> <p> </p> <p>MHRA Drug Safety Update (Nov-20): Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy                      MHRA Drug Safety Update (Mar-11): Modafinil (Provigil): now restricted to narcolepsy</p>		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
<b>Pitolisant hydrochloride</b> <p>Wakix® tablets</p> <p>NICE MMC BNF   </p>		<b>RESTRICTED</b> Sleep Centre only in line with NICE
<b>Solriamfetol hydrochloride</b> <p>Sunosi® tablets</p> <p>NICE MMC BNF  </p>		<b>RESTRICTED</b> Sleep Centre only in line with NICE

## 4.5 Drugs used in the treatment of obesity



### 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract

**NICE CG43**

**Orlistat**

**GREEN**

**RESTRICTED**

**Consultant initiation - Paeds. only**

capsules



MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines

## 4.6 Drugs used in nausea &amp; vertigo

**Antihistamines****Cyclizine**

GREEN

tablets; injection  children


**1<sup>st</sup> line use****Promethazine hydrochloride**

tablets; oral solution (see also section 3.4.1)



**Promethazine teoclate**

tablets



**Phenothiazines & Related Drugs****Prochlorperazine**

GREEN

tablets; buccal tablet; injection



**Droperidol**

injection




**RESTRICTED**  
Consultant initiation only for PONV**Domperidone & Metoclopramide****Domperidone**

GREEN

tablets; oral suspension (see also section 1.2)




MHRA Drug Safety Update (Dec-19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects

MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects

**Metoclopramide hydrochloride**

GREEN

tablets; oral suspension; injection (see also section 1.2)




MHRA Drug Safety Update (Aug-13): Metoclopramide: risk of neurological adverse effects

**5HT<sub>3</sub>-receptor antagonists****Ondansetron**

RED

SA

tablets; orodispersible tablets; injection; oral solution; orodispersible film



**RESTRICTED** - Chemotherapy induced & post-op vomiting**Palonosetron hydrochloride**

RED

250 microgram solution for injection




**RESTRICTED** - Chemotherapy induced & post-op vomiting

MHRA Drug Safety Update (Jul-13): Ondansetron for intravenous use: dose-dependent QT interval prolongation

MHRA Drug Safety Update (Aug-12): Ondansetron (Zofran): important new intravenous dose restriction

**Neurokinin 1-receptor antagonist****Aprepitant**

RED

80mg; 125mg capsules; 25mg/mL oral suspension




**RESTRICTED**  
highly / moderately emetogenic CINV**Fosaprepitant**

RED

150mg infusion




**RESTRICTED**  
highly / moderately emetogenic CINV**Cannabinoids****Nabilone**

GREY

RED

(DNP)

250micrograms; 1mg capsules




**RESTRICTED**  
highly emetogenic CINV**Hyoscine****Hyoscine hydrobromide**

SI

patches; tablets (for Hyoscine butylbromide see section 1.2)





MHRA Drug Safety Update (Jul-23): Hyoscine hydrobromide patches: risk of anticholinergic side effects, including hyperthermia

**Other Drugs for Ménière's Disease****Betahistine dihydrochloride**

GREEN

tablets




## 4.7 Analgesics



### 4.7.1 Non-Opioid Analgesics

(see also Chapter 10 for NSAIDs)

#### Paracetamol

GREEN

tablets; soluble tablets; infusion; injection; oral suspension; suppositories

MMC BNF emc

1<sup>st</sup> line use

MHRA Drug Safety Update (Sep-25): Paracetamol &amp; pregnancy - reminder that taking paracetamol during pregnancy remains safe

#### Sucrose 24% solution

Sweet-Ease® oral solution

MMC emc

RESTRICTED  
Pain relief in neonates

### Compound Analgesic Preparations

#### Paracetamol and codeine (Co-codamol)

GREEN

Co-codamol® tablets; effervescent tablets

BNF emc

#### Paracetamol and dihydrocodeine (Co-dydramol)

tablets

BNF emc

### 4.7.2 Opioid Analgesics

MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction

#### Buprenorphine

SA

NOT patch

#### Codeine phosphate

GREEN

tablets; syrup; injection

BNF emc

RESTRICTED

MHRA Drug Safety Update (Jul-13): Codeine for analgesia: restricted use in children because of reports of morphine toxicity

MHRA Drug Safety Update (Jun-13): Codeine: restricted use as analgesic in children and adolescents after European safety review

SPS (Mar-26): Using codeine, dihydrocodeine or tramadol during breastfeeding

#### Diamorphine hydrochloride

injection

BNF emc

#### Difelikefalin

RED

Kapruvia® injection

PbR X NICE MMC BNF blueiq emc

RESTRICTED  
Renal Consultants in line with NICE  
NHSE M4C

#### Dihydrocodeine tartrate standard release preparations only

GREEN

tablets

BNF emc

SPS (Mar-26): Using codeine, dihydrocodeine or tramadol during breastfeeding

#### Fentanyl

GREEN

NOT lozenge (see also section 15.1.4.3)

MHRA Drug Safety Update (Oct-18): Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children

MHRA Drug Safety Update (Sep-08): Serious and fatal overdose of fentanyl patches

MMC BNF emc

Spray RESTRICTED palliative care &  
haematology initiation (Wd44)

#### Metadone hydrochloride

oral solution

NICE BNF emc

RESTRICTED  
palliative care & substance misuse

#### Morphine sulfate

GREY GREEN

tablets; M/R tablets; capsules; M/R capsules; oral solution; injection

BNF emc

#### Morphine sulfate

GREY GREEN

Actimorph® orodispersible tablets

MMC BNF emc

RESTRICTED  
palliative care / GMMMG

#### Oxycodone hydrochloride

SA

capsules; liquid; tablets; M/R tablets; injection

MMC BNF emc

RESTRICTED  
2<sup>nd</sup> line for morphine intolerance

#### Pethidine hydrochloride

injection; tablets

BNF emc

#### Tapentadol hydrochloride M/R

GREY SA

tablets

MMC BNF emc

RESTRICTED  
3<sup>rd</sup> line - Pain Team Consultants only

MHRA Drug Safety Update (Jan-19): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines

#### Tramadol hydrochloride

GREEN

capsules; M/R capsules; tablets; M/R tablets; soluble tablets; injection

BNF emc

SPS (Mar-26): Using codeine, dihydrocodeine or tramadol during breastfeeding

**4.7.3 Neuropathic Pain**

**Amitriptyline**

GREEN

tablets; oral solution



**Carbamazepine**

SI

tablets; M/R tablets; oral solution; suppositories



MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

**Gabapentin**

GREEN



capsules; oral suspension



**Gabapentin**

(DNP)



cream



**RESTRICTED**  
Gynaecology / 5<sup>th</sup> line paediatrics neuropathic pain

MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression

Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin

**Lidocaine**

GREY

GREEN

Versatis® 700mg medicated plaster



**RESTRICTED**  
Specialist pain team only  
for in-patient use - not for discharge

**Pregabalin**

GREEN



capsules; oral solution



3<sup>rd</sup> / 4<sup>th</sup> line use if gabapentin contraindicated or not tolerated

MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression

MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin

**4.7.4 Antimigraine Drugs**

**4.7.4.1 Treatment Of Acute Migraine**

**Analgesics**

**Aspirin**

GREEN

OTC

tablets; dispersible tablets; E/C tablets; suppositories



**Paracetamol**

GREEN

OTC

tablets; soluble tablets; oral suspension; infusion; suppositories



MHRA Drug Safety Update (Sep-25): Paracetamol & pregnancy - reminder that taking paracetamol during pregnancy remains safe

**Ibuprofen**

GREEN

OTC

tablets; M/R tablets; oral suspension; sachets



**5HT<sub>1</sub> receptor agonists**

**Sumatriptan**

GREEN

OTC

tablets; nasal spray; injection



**Zolmitriptan**

GREEN

nasal spray



**Calcitonin gene-related peptide (CGRP) receptor antagonist**

**Rimegepant (acute treatment of migraine)**

GREEN



75mg oral lyophilisate (see also prophylaxis below)



**RESTRICTED**  
Specialist use for treatment in line  
with NICE / GMMMG

**4.7.4.2 Prophylaxis of Migraine**

**Atogepant (migraine prophylaxis)**

SA



Aquipta® tablets



**RESTRICTED**  
Neurology initiation only in line  
with NICE / GMMMG

**Botulinum toxin type A**

RED

Botox® injection



**RESTRICTED**  
Specialist use only  
in line with NICE

**Clonidine hydrochloride**

tablets



**Rimegepant (migraine prophylaxis)**

SA



Vydura® 75mg oral lyophilisate



**RESTRICTED**  
Neurology initiation only in line  
with NICE / GMMMG

# 4.8 Antiepileptic drugs



## 4.8.1 Control of the Epilepsies

NICE NG217

### Carbamazepine

SA

tablets; M/R tablets; oral solution; suppositories



MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

### Phenobarbital

SA



tablets; oral solution; injection



### Phenytoin sodium

SA

capsules; oral suspension; injection



### Sodium valproate

SA

tablets; M/R tablets; oral solution; M/R granules; injection



MHRA Drug Safety Update (Jun-25): Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono / Chronosphere, Episenta, Epival, & Syonell ▼): updated safety & educational materials

MHRA Drug Safety Update (Feb-25): Valproate: review by two specialists is required for initiating valproate but not for male patients already taking valproate

MHRA Drug Safety Update (Sep-24): Valproate use in men: as a precaution, men and their partners should use effective contraception

MHRA Drug Safety Update (Jan-24): Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age

MHRA Drug Safety Update (Oct-23): Valproate: dispense full packs of valproate-containing medicines

MHRA Drug Safety Update (Aug-23): Valproate: re-analysis of study on risks in children of men taking valproate

MHRA Drug Safety Update (Dec-22): Valproate: reminder of current Pregnancy Prevention Programme requirements...

MHRA Drug Safety Update (Jan-20): Valproate (Epilim ▼, Depakote ▼) pregnancy prevention programme: updated educational materials

MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance...

MHRA Drug Safety Update (Apr-18): Valproate medicines (Epilim ▼, Depakote ▼): contraindicated in women & girls of childbearing potential unless conditions of PPP met

MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended

### Brivaracetam

SI

tablets; oral solution; injection



**RESTRICTED**  
Specialist use only

### Cenobamate

SI

Ontozry® tablets



**RESTRICTED**  
Specialist use only in line with NICE

### Clobazam

SA

tablets; oral suspension



**RESTRICTED**  
Specialist use only

### Clonazepam

SA

tablets; oral solution; injection



**RESTRICTED**  
Specialist use only

### Eslicarbazepine acetate

SA

tablets; oral suspension



**RESTRICTED**  
Specialist use only in line with NICE

MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

### Ethosuximide

SA

capsules; oral solution



**RESTRICTED**  
Paediatrics only

### Fenfluramine hydrochloride

RED



Fintepla® oral solution



**RESTRICTED**  
Specialist use only in line with NICE  
TA808 / TA1050

### Gabapentin

SA



capsules; oral suspension



**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs

MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression

Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin

### Lacosamide

GREY

SA

tablets; oral solution; infusion



**RESTRICTED**  
Specialist use only

### Lamotrigine

SA

tablets; dispersible tablets



**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review

### Levetiracetam

SA

tablets; oral solution; infusion; granules



**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review

### Oxcarbazepine


















SA

tablets; oral suspension



**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions







<b>Perampanel</b> GREY SA tablets; oral suspension 	<b>RESTRICTED</b> Specialist use only
<b>Potassium bromide</b> Ⓢ RED Ⓢ 850mg tablets 	<b>RESTRICTED</b> Specialist use only Dravet syndrome
<b>Pregabalin</b> GREEN ⚠️ capsules; oral solution 	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Jan-26): Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin	
<b>Primidone</b> SA tablets 	<b>RESTRICTED</b> Specialist use only
<b>Rufinamide</b> GREY SI tablets 	<b>RESTRICTED</b> Specialist use only Lennox-Gastaut Syndrome
<b>Stiripentol</b> GREY RED capsules; sachets 	<b>RESTRICTED</b> Specialist use only
<b>Tiagabine</b> SA tablets 	<b>RESTRICTED</b> Specialist use only
<b>Topiramate</b> GREY GREEN tablets; capsules GREY 	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Jun-24): Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme	
<b>Vigabatrin</b> RED tablets; sachets 	<b>RESTRICTED</b> Specialist use only
<b>Zonisamide</b> SA capsules 	<b>RESTRICTED</b> Specialist use only
<b>Cannabidiol (CBD)</b> GREY RED Ⓢ ⚠️ Epidyolex® <b>4.8.2 Drugs Used in Status Epilepticus</b>	<b>RESTRICTED</b> Specialist use only in line with NICE TA614 / TA615
<b>Lorazepam</b> SI tablets; injection (see also section 4.1.2 & 15.1.4.1) 	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Diazepam</b> SI tablets; liquid; injection; rectal tube (see also sections 4.1.2; 10.2.2 & 15.1.4.1) 	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Clonazepam</b> SI tablets; oral solution; injection 	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Midazolam</b> SI ⚠️ oromucosal solution; injection; infusion (see also section 15.1.4.1) 	
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression	
<b>Paraldehyde</b> injection; rectal solution 	
<b>Phenytoin sodium</b> SA capsules; oral suspension; injection 	
<b>Sulthiame</b> Ⓢ Ospolot® 50mg tablets 	<b>RESTRICTED</b> Consultant Neurologist use only

## 4.9 Drugs used in Parkinsonism &amp; related disorders



4.9.1 Dopaminergic Drugs Used in Parkinsonism	NICE NG71
<b>Amantadine hydrochloride</b> SA capsules; oral solution NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Apomorphine hydrochloride</b> AMBER injection; infusion NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects	
<b>Cabergoline</b> SA tablets NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Co-beneldopa</b> SA capsules; M/R capsules; dispersible tablets NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Co-careldopa</b> SA tablets; M/R tablets (DNP) intestinal gel PbR X NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Entacapone</b> SA tablets NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Foslevodopa with foscarnidopa</b> RED <i>Produodopa</i> ® 240mg/mL / 12mg/mL infusion NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Opicapone</b> GREY SA capsules MMC BNF emc	<b>RESTRICTED 2<sup>nd</sup> line</b> Specialist use only
<b>Pramipexole</b> SA tablets; M/R tablets MMC BNF emc	<b>RESTRICTED 3<sup>rd</sup> line add-on use</b> Specialist use only
<b>Rasagiline</b> SA tablets MMC BNF emc	<b>RESTRICTED</b> patients with end of dose fluctuations
<b>Ropinirole</b> SA tablets; M/R tablets BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Rotigotine</b> SA transdermal patches NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only. NBM patients
<b>Safinamide</b> SA tablets MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Selegiline</b> SA tablets BNF emc	<b>RESTRICTED</b> Specialist use only
<b>4.9.2 Antimuscarinic Drugs Used in Parkinsonism</b>	
<b>Orphenadrine hydrochloride</b> SI oral solution BNF emc	
<b>Procyclidine (oral &amp; IM)</b> GREEN tablets; oral solution; injection (see also section 18.1.1) BNF emc	
<b>Trihexyphenidyl hydrochloride</b> tablet; syrup MMC BNF emc	

**4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders**

<p><b>Idebenone</b>  <span style="background-color: red; color: white; padding: 2px;">RED</span>                      Raxone® 150mg tablets</p>		<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Haloperidol</b>  <span style="background-color: green; color: white; padding: 2px;">GREEN</span> (DNP)                      tablets; capsules; oral solution (500microgram tablets see DNP)</p>		<p><b>RESTRICTED</b>                      Specialist use only</p>
<p>MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium</p>		
<p><b>Piracetam</b>                      tablets; oral solution</p>		<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Propranolol hydrochloride</b>  <span style="background-color: green; color: white; padding: 2px;">GREEN</span>                      tablets; M/R capsules; oral solution; injection</p>		
<p><b>Tetrabenazine</b>                      tablets</p>		<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Torsion Dystonias &amp; Other Involuntary Movements</b></p>		
<p>The dose of botulinum toxin is specific to each individual preparation and is <b>NOT</b> interchangeable.                      The doses for different indications vary - consult product literature &amp; specialist guidance</p>		
<p><b>Botulinum toxin type A</b>  <span style="background-color: red; color: white; padding: 2px;">RED</span>                      Botox® injection</p>		<p><b>RESTRICTED</b>                      Specialist use only  <b>see decision tables</b></p>
<p><b>Botulinum toxin type A</b>  <span style="background-color: red; color: white; padding: 2px;">RED</span>                      Dysport® injection</p>		<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Botulinum toxin type A</b>  <span style="background-color: red; color: white; padding: 2px;">RED</span>                      Xeomin® injection</p>		<p><b>RESTRICTED</b>                      Specialist use only  <b>see decision tables</b></p>

## 4.10 Drugs used in substance dependence



### 4.10.1 Alcohol dependence

**Nalmefene**

GREEN

NICE MMC BNF emc

**RESTRICTED** - Specialist use only in line with NICE TA325

**NOT STOCKED**

### 4.10.2 Nicotine dependence

**Nicotine Replacement Therapy**

GREEN

patches, lozenges, inhalator, microtabs

NICE BNF emc

**NICE NG92**

**1<sup>st</sup> line use**

**Cytisinicline**

GREEN

Cytisine 1.5mg tablets

NICE MMC BNF emc

**1<sup>st</sup> line use**

**Bupropion hydrochloride**

GREEN

150mg modified-release tablets

NICE BNF emc

MHRA Drug Safety Update (Nov-20): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs

**Varenicline**

GREEN

tablets

NICE MMC BNF emc

**NICE CG52**

### 4.10.3 Opioid Dependence

MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction

**Buprenorphine**

GREEN



sublingual tablets

NICE BNF emc

**RESTRICTED** Initiation by substance misuse specialist

**Buprenorphine (Buvidal®)**

GREEN



8mg;16mg;24mg;32mg;64mg;96mg;128mg;160mg prolonged-release solution for injection

NICE MMC BNF emc

**RESTRICTED** Initiation by substance misuse specialist

**Methadone hydrochloride**



oral solution

NICE BNF emc

**RESTRICTED** Initiation by substance misuse specialist

**Naltrexone hydrochloride**

RED

tablets

NICE MMC BNF emc

**RESTRICTED**  
Gastro Consultant - cholestatic itch

## 4.11 Drugs for dementia



### 4.11 Drugs for Dementia

**NICE NG97**
**Donepezil hydrochloride**
**RESTRICTED**  
 Specialist use only

SA

tablets; orodispersible tablets

**Galantamine**
**RESTRICTED**  
 Specialist use only

SA

M/R capsules

MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals

**Memantine hydrochloride**
**RESTRICTED**  
 Specialist use only

SA





















tablets; oral solution

**Rivastigmine**
**RESTRICTED**  
 Specialist use only

GREEN

capsules; oral solution; transdermal patches

Non-Formulary Items		GMMMG
<b>Acoramidis hydrochloride</b> <b>RED</b> <i>Beyontra</i> ® 356mg tablets NICE MMC BNF emc		MFT not a commissioned centre patients referred to NAC - Royal Free
<b>Asenapine maleate</b> <b>RED</b> <i>Sycrest</i> ® sublingual tablets MMC BNF emc		Discontinued January 2026
<b>Aspirin and codeine</b> (DNP) <i>Co-codaprin</i> ® tablets; dispersible tablets BNF emc		in line with GMMMG Criterion 2
<b>Buprenorphine with naloxone</b> Ⓢ <b>RED</b> ⚠️ sublingual tablets BNF emc		Discontinued January 2026 - Removed from HIVE
<b>Cannabis-derived, cannabis-based and hemp products</b> (DNP) with the exception of nabilone and Epidyolex®		in line with GMMMG Criterion 1
<b>Dextropropoxyphene with paracetamol</b> (DNP) <i>Co-proxamol</i> ® NICE BNF emc		in line with GMMMG
<b>Dosulepin hydrochloride</b> (DNP) tablets; capsules BNF emc		in line with GMMMG Criterion 1
<b>Electromagnetic pulse therapy</b> (DNP) <i>ActiPatch</i> ®		in line with GMMMG Criterion 1
<b>Eplontersen sodium</b> <b>RED</b> <i>Wainzua</i> ® 45mg/0.8mL injection MMC BNF emc		MFT not a commissioned centre patients referred to NAC - Royal Free
<b>Eptinezumab</b> <b>RED</b> Ⓢ injection MMC BNF emc		NOT STOCKED
<b>Erenumab</b> <b>RED</b> Ⓢ injection NICE MMC BNF emc		NOT STOCKED
<b>Ergotamine-containing products</b> (DNP) e.g. <i>Migril</i> ®		in line with GMMMG Criterion 1
<b>Esketamine</b> (DNP) <i>Spravato</i> ® nasal spray NICE MMC BNF emc		in line with GMMMG Criterion 1
<b>Fremanezumab</b> <b>RED</b> Ⓢ injection NICE MMC BNF emc bluefeq		NOT STOCKED
<b>Galantamine</b> 4mg; 8mg & 12mg tablets NICE BNF emc		RESTRICTED Specialist use only
<b>Galcanezumab</b> <b>RED</b> Ⓢ injection MMC BNF emc		NOT STOCKED
<b>Ganaxolone</b> <i>Ztalmy</i> ® 50mg/mL oral suspension NICE MMC emc		in line with NICE
<b>Haloperidol</b> (DNP) 500microgram tablets NICE MMC BNF emc		in line with GMMMG Criterion 2
<b>Infrequent migraine</b> (DNP)		in line with GMMMG / NHSE
<b>Levomepromazine</b> (DNP) 6mg tablets BNF emc		in line with GMMMG
<b>Loxapine</b> (DNP) inhalation powder BNF		in line with GMMMG Criterion 1

<b>Meprobamate</b> (DNP) tablets		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Meprobamate</b> (DNP) tablets		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Mild toothache / teething</b> (DNP) e.g. paracetamol, ibuprofen, teething gels.		<b>in line with GMMMG / NHSE</b>
<b>Minor conditions associated with pain, discomfort and/or fever</b> (DNP) e.g. aches and sprains, headache, period pain, back pain		<b>in line with GMMMG / NHSE</b>
<b>Nicotine</b> (DNP) e-Voke®, Voke® (Nicotine inhaler)		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Oxycodone with naloxone</b> (DNP)  Targinact® M/R tablets	  	<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Paracetamol and tramadol</b> (DNP) tablets; effervescent tablets	 	<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Paracetamol mixture / mucilage</b> (DNP) 500mg / 5mL for topical use in patients with sore mouth or throat resulting from cancer treatment		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Paracetamol with buclizine and codeine</b> (DNP) Migrave® (all presentations)		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Paracetamol with isometheptene</b> (DNP) Midrid® 325mg / 65mg capsules		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Pregabalin</b> (DNP) Misabri® 82.5mg; 165mg 330mg prolonged-release tablets	 	<b>in line with GMMMG</b>
<b>Sufentanil citrate</b> (DNP) Zalviso® 30microgram sublingual tablets	 	<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Tafamidis</b> RED Vyndaqel® capsules	   	<b>MFT not a commissioned centre</b> <b>patients referred to NAC - Royal Free</b>
<b>Travel sickness</b> (DNP)		<b>in line with GMMMG / NHSE</b>
<b>Trimipramine</b> (DNP) tablets; capsules	 	<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Vutrisiran</b> RED Ammvutra® injection	   	<b>MFT not a commissioned centre</b> <b>patients referred to NAC - Royal Free</b>

## Section 5: Infections

Supported by the  
formulary ([click here](#))



### 5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulfonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antileprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

### 5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

### 5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

### 5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

### 5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, *Enterobius vermicularis*)
- 5.5.2 Ascariocides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

### 5.6 Miscellaneous

#### Non-Formulary Items

## Trust Guidelines

MFT Adult Antimicrobial guidelines  
 MFT Paediatric Antimicrobial guidelines  
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Prophylaxis against infective endocarditis (CG64)  
 Bacterial meningitis and meningococcal septicaemia (CG102)  
 Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)  
 Hepatitis B (Chronic) (CG165)  
 Tuberculosis (NG33)  
 Sinusitis (acute): antimicrobial prescribing (NG79)  
 Sore throat (acute): antimicrobial prescribing (NG84)  
 Otitis media (acute): antimicrobial prescribing (NG91)  
 Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)  
 Cough (acute): antimicrobial prescribing (NG120)  
 Surgical site infections: prevention and treatment (NG125)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Hepatitis B: Entecavir (TA153)  
 Hepatitis B: Telbivudine (TA154)  
 Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)  
 Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)  
 Hepatitis B: Tenofovir disoproxil (TA173)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Sofosbuvir for treating chronic hepatitis C (TA330)  
 Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)  
 Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)  
 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)  
 Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)  
 Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)  
 Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)  
 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)  
 Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)  
 Cabotegravir with rilpivirine for treating HIV-1 (TA757)  
 Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)  
 Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)  
 Bulevirtide for treating chronic hepatitis D (TA896)  
 Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)  
 Molnupiravir for treating COVID-19 (TA1056)  
 Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

## GMMM Formulary

Formulary Homepage  
 Chapter 5: Infections  
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

**RESTRICTED USE ANTIBIOTICS**  
 1. Must be recommended / approved for use by consultant medical microbiologist  
 2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.  
 3. Only available from Pharmacy

**RESERVED USE ANTIBIOTICS**  
 1. Can be used only in accordance with the restrictions outlined below.  
 2. Indication must be clearly documented on the prescription chart.  
 3. If being used outside of guidelines Microbiology approval must be sought as above.

**UNRESTRICTED USE ANTIBIOTICS**  
 1. Can be used according to MFT Trust guidelines, (those drugs not marked Restricted or Reserved)

**5.1 Antibacterial drugs** 

**5.1.1 Penicillins**

**5.1.1.1 Benzylpenicillin & Phenoxyethylpenicillin**

<b>Benzylpenicillin sodium (Penicillin G)</b>  600mg injection	 	
--	--	--

<b>Phenoxyethylpenicillin (Penicillin V)</b>  tablets	 	
---	--	--

<b>Benzathine benzylpenicillin</b> <span style="color: red;">Ⓢ</span>  injection	  	<b>RESTRICTED</b> unlicensed treatment for syphilis
--	--	--

**5.1.1.2 Penicillinase-Resistant Penicillins**

<b>Flucloxacillin</b>  capsules; injection; oral solution	  	
---	--	--

<b>Temocillin</b>  1g injection	  	<b>RESTRICTED</b> infection caused by multi-resistant coliforms. <b>Micro only</b>
---------------------------------------	--	--

**5.1.1.3 Broad Spectrum Penicillins**

<b>Amoxicillin</b>  capsules; oral suspension; injection	 	
--	--	--

<b>Co-amoxiclav</b>  tablets; oral suspension; injection	 	
--	--	--

**5.1.1.4 Antipseudomonal Penicillins**

<b>Piperacillin with tazobactam</b>  injection	  	<b>RESERVED</b> serious / resistant infections
--	--	---

<b>Ticarcillin with clavulanic acid</b>  <i>Timentin</i> ® 3.2g injection	  	<b>RESERVED</b> serious / resistant infections
---	--	---

**5.1.1.5 Mecillinams**

<b>Pivmecillinam hydrochloride</b>  200mg tablets	  	<b>RESTRICTED</b> UTIs caused by resistant coliforms
---	--	---

**5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams** 




**5.1.2.1 Cephalosporins**

































































<b>Cefalexin</b>  capsules; tablets; oral suspension	 	
--	--	--

<b>Cefazolin</b>  injection	  	<b>RESTRICTED</b> on Micro. advice only
-----------------------------------	--	--

<b>Cefotaxime</b>  injection	 	<b>RESERVED</b> as per guidelines for children
------------------------------------	--	---















<b>Ceftriaxone</b>  injection	 	<b>RESERVED</b> as per guidelines for children
-------------------------------------	--	---

<b>Cefuroxime</b>  injection	 	<b>RESERVED</b> as per guidelines for children
------------------------------------	--	---








<b>Cefixime</b> tablets	  	<b>RESERVED</b> GU infections only
<b>Ceftazidime</b> injection	  	<b>RESERVED</b> pseudomonas infection in CF
<b>Cetazidime with avibactam</b> Zavicefta® infusion	  	<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
<b>Ceftolozane sulfate with tazobactam sodium</b> Zerbaxa® infusion	  	<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
<b>Ceftaroline fosamil</b> Zinforo® infusion	  	<b>RESERVED</b> CAP & cSSTI treatment. <b>Micro. Consultant only</b>
<b>Cefoxitin</b> injection	  	<b>RESERVED for treatment of</b> mycobacterium abscessus in CF. <b>Micro. Consultant only</b>
<b>Cefiderocol</b> Fetcroja® infusion	  	<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
<b>5.1.2.2 Carbapenems</b>		
<b>Ertapenem</b> infusion	  	<b>RESTRICTED</b> Outpatient therapy only
<b>Imipenem with cilastatin</b> infusion	  	<b>RESTRICTED</b> Non-Tuberculous Mycobacteria in CF
<b>Imipenem with cilastatin &amp; relebactam</b>  Recarbrio® infusion	  	<b>RESTRICTED</b> <b>Micro. Consultant only</b>
<b>Meropenem</b> injection	  	<b>RESERVED</b> as per guidelines
<b>Meropenem with vaboractam</b> Vaborem® infusion	  	<b>RESTRICTED</b> <b>Micro. Consultant only</b>
<b>5.1.2.3 Other Beta-Lactam antibiotics</b>		
<b>Aztreonam</b> injection	 	<b>RESTRICTED</b> gram negative organisms
<b>Aztreonam lysine</b>   Cayston® nebuliser solution	  	<b>RESTRICTED 3<sup>rd</sup> line CF patients with</b> chronic pulmonary infection
<b>Aztreonam with avibactam sodium</b> Emblaveo® infusion	  	
<b>5.1.3 Tetracyclines</b>		
<b>Doxycycline</b> capsules; tablets; dispersible tablets	  	
<b>Oxytetracycline</b> tablets	 	
<b>Demeclocycline hydrochloride</b> capsules (see also section 6.5.2)	  	<b>RESTRICTED</b> SIADH only
<b>Lymecycline</b> 408mg capsules (see also section 13.6.2)	  	<b>RESTRICTED</b> Non-Formulary <b>MMC approved for GP referral</b>
<b>Minocycline</b> capsules; tablets	  	<b>RESERVED</b> as per guidelines
<b>Tigecycline</b> infusion	  	<b>RESERVED</b> as per guidelines

**5.1.4 Aminoglycosides**

MHRA Drug Safety Update (Jan-21): Aminoglycosides (gentamicin, amikacin, tobramycin &amp; neomycin): increased risk of deafness in patients with mitochondrial mutations

<b>Amikacin</b>		<b>RESERVED</b> as per guidelines
injection	   	
<b>Gentamicin</b>		
injection	 	
<b>Tobramycin</b>		<b>RESERVED</b> as per guidelines
 		
injection; inhalation powder; nebuliser liquid	   	
<b>Neomycin sulfate</b>		<b>RESTRICTED</b> Gastro team only - op prep
oral solution	 	

**5.1.5 Macrolides**

<b>Clarithromycin</b>		
tablets; oral suspension; infusion	 	
<b>Azithromycin</b>		<b>RESERVED</b> GU only or specialist use
		
tablets; oral suspension	 	
<b>Erythromycin</b>		<b>RESERVED</b> in pregnancy or neonates
tablets; oral suspension; injection	 	

MHRA Drug Safety Update (Dec-20): Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban

MHRA Drug Safety Update (Dec-20): Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis

**5.1.6 Clindamycin**

<b>Clindamycin</b>		<b>RESERVED</b> as per guidelines
capsules; oral suspension; injection; 2% vaginal cream	 	

**5.1.7 Some other Antibacterials**

<b>Chloramphenicol</b>		<b>RESERVED</b> as per guidelines
capsules; injection	 	

MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years

**Dalbavancin**

<b>Dalbavancin</b>		<b>RESTRICTED Consultant only</b>
500mg infusion	  	<b>Micro. approval required</b>

**Fidaxomicin**















<b>Fidaxomicin</b>		<b>RESTRICTED</b> <i>clostridium difficile</i> associated diarrhoea <b>Micro. only</b>
 		
200mg tablets; 40mg/mL granules for oral suspension	  	

**Fusidic Acid**




























































<b>Fusidic acid (sodium fusidate)</b>		<b>RESERVED</b> as per guidelines
		
tablets; oral suspension; 2% cream	 	

MHRA Drug Safety Update (Sep-11): Systemic fusidic acid and interaction with statins

**Glycopeptides**

<b>Vancomycin</b>		
		
injection; capsules; oral suspension	  	
<b>Teicoplanin</b>		<b>RESERVED</b> as per guidelines
injection	 	
<b>Daptomycin</b>		
<b>Daptomycin</b>		<b>RESTRICTED</b> as per guidelines
		
infusion	  	
<b>Linezolid</b>		
<b>Linezolid</b>		<b>RESTRICTED</b> as per guidelines
		
tablets; infusion	  	

Polymyxins		
<b>Colistimethate sodium</b> AMBER RED E£ injection BNF emc		<b>RESTRICTED</b> as per guidelines
<b>Colistimethate sodium (nebulised)</b> AMBER RED E£ Colomycin® injection NICE MMC BNF emc British Thoracic Society		<b>RESTRICTED specialist</b> for CF and non-CF bronchiectasis
<b>Colistimethate sodium (DPI)</b> RED E£ Colobreathe® inhalation powder NICE MMC BNF emc		<b>RESTRICTED</b> as per guidelines
MHRA Drug Safety Update (Nov-14): Colobreathe (colistimethate sodium dry powder for inhalation): risk of capsule breakage - new instructions for use		
Pristinamycin		
<b>Pristinamycin</b> U RED 500mg tablets MMC emc		<b>RESTRICTED</b> as per BASHH guidelines for <i>Mycoplasma genitalium</i>
Rifaximin		
<b>Rifaximin</b> SI 550mg tablets (see also Ch1: Non-formulary items) NICE MMC BNF emc		<b>RESTRICTED</b> as per guidelines / NICE
Spectinomycin		
<b>Spectinomycin</b> U Kirin® injection MMC BNF emc		<b>RESTRICTED</b> cephalosporin resistant gonorrhoea
Taurolidine		
<b>Taurolidine citrate 4%</b> TauroLock® 4% ampoules MMC emc		<b>RESTRICTED</b> as per CVC guidelines
5.1.8 Sulfonamides & Trimethoprim		
<b>Trimethoprim</b> tablets; oral suspension BNF emc		
<b>Co-trimoxazole</b> SA tablets; oral suspension; infusion BNF emc		<b>RESERVED</b> as per guidelines
<b>Sulfadiazine</b> tablets BNF emc		<b>RESTRICTED</b>
5.1.9 Antituberculosis Drugs		
<b>Bedaquiline</b> E£ tablets PbR X MMC BNF emc blueiq		<b>NICE NG33</b> <b>RESTRICTED</b> MDR TB only NHS England
<b>Ethambutol hydrochloride</b> SI tablets NICE MMC BNF emc		
<b>Isoniazid</b> SI tablets; oral solution; injection NICE MMC BNF emc		
<b>Pretomanid</b> E£ Dovprela® 200mg tablets MMC emc blueiq		<b>Restricted RR TB, MDR TB</b> and pre-XDR TB NHS England
<b>Prothionamide</b> U tablets MMC emc		<b>RESTRICTED</b> MDR TB only
<b>Pyrazinamide</b> SI tablets NICE BNF emc		
<b>Rifampicin</b> SI capsules; oral solution; infusion NICE BNF emc		
<b>Rifabutin</b> SI caspules BNF emc		<b>2<sup>nd</sup> line</b> where rifampicin not suitable
<b>Rifater®</b> SI (Rifampicin with isoniazid & pyrazinamide) tablets NICE BNF emc		

<b>Rifinah®</b>  (Rifampicin with isoniazid) tablets	  	
<b>Voractiv®</b>  (Rifampicin with ethambutol hydrochloride, isoniazid and pyrazinamide) tablets	  	
<b>Capreomycin sulfate</b> injection	 	<b>RESTRICTED</b> MDR TB only Not stocked
<b>Cycloserine</b> capsules	 	<b>RESTRICTED</b> MDR TB only Not stocked
<b>Delamanid</b>  tablets	  	<b>RESTRICTED</b> MDR TB only
<b>Streptomycin</b>  injection	  	<b>RESTRICTED</b> MDR TB only Not stocked
<b>Moxifloxacin</b> tablets; injection	   	<b>RESTRICTED</b>
<b>Para aminosalicylic acid (PAS)</b> granules	   	<b>RESTRICTED</b> MDR TB only Not stocked
<b>5.1.10 Antileprotic Drugs</b>		
<b>Clofazimine</b>  capsules	  	<b>RESTRICTED</b> MDR TB only
<b>Dapsone</b>  tablets	  	<b>RESERVED</b>
<b>5.1.11 Metronidazole &amp; Tinidazole</b>		
<b>Metronidazole</b>  tablets; oral suspension; infusion; suppositories; vaginal gel	  	
<b>Tinidazole</b>  tablets	 	<b>RESTRICTED</b>
<b>5.1.12 Quinolones</b>		
<b>Ciprofloxacin</b> tablets; oral suspension; infusion (see also sections 11.3.1 & 12.1.1)	 	<b>RESERVED</b> as per guidelines
<b>Delafloxacin</b>  Quofenix® tablets; infusion	  	<b>RESTRICTED Micro / Infectious diseases recommendation only</b>
<b>Levofloxacin</b> tablets; infusion (see also section 11.3.1)	  	<b>RESTRICTED</b> MDR TB only Not stocked
<b>Moxifloxacin</b> tablets; infusion	  	<b>RESTRICTED</b> MDR TB only
<b>Nalidixic acid</b> tablets	 	<b>RESTRICTED</b> Urology use in children only
<b>Ofloxacin</b> tablets (see also section 11.3.1)	 	<b>RESTRICTED</b> GU infections only
MHRA Drug Safety Update (Jan-24): Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Nov-18): Systemic & inhaled fluoroquinolones: small increased risk of aortic aneurysm & dissection; advice for prescribing in high-risk patients		

**5.1.13 Urinary-tract Infections****Nitrofurantoin**

M/R capsules; capsules; tablets



MHRA Drug Safety Update (Apr-23): Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions

MHRA Drug Safety Update (Sep-14): Nitrofurantoin now contraindicated in most patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m<sup>2</sup>**Fosfomycin**

GREEN

sachets; infusion

**RESTRICTED**  
Micro recommendation only**Methenamine hippurate**

Hiprex® tablets

**RESTRICTED** Urology Consultants**Non-drug treatment****D-Mannose**

Waterfall D-Mannose® tablets / powder (food supplement)

**RESTRICTED** 5<sup>th</sup> line recurrent UTI  
after antibiotic options**Urease inhibitor****Acetohydroxamic acid** Ⓢ

RED

Lithostat® tablets

**RESTRICTED** Urology Consultants

## 5.2 Antifungal drugs



## 5.2.1 Triazole Antifungals

## Fluconazole

GREEN

capsules; infusion; oral suspension.

## Isavuconazole

capsules; infusion

PbR X

**RESTRICTED**  
micro / specialist use only

## Itraconazole

GREEN

capsules; oral solution; infusion

## Posaconazole

RED

££

G/R tablets; oral suspension; infusion

PbR X

**RESTRICTED**  
micro / specialist use only

MHRA Drug Safety Update (Sep-16): Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable

## Voriconazole

RED

££

tablets; oral suspension; infusion (see also section 11.3.2)

PbR X

**RESTRICTED**  
micro / specialist use only

## 5.2.3 Polyene Antifungals

## Nystatin

100,000 units/mL oral suspension

## Amphotericin (liposomal)

RED

££

infusion

PbR X

**RESTRICTED**  
micro / specialist use only

## 5.2.4 Echinocandin Antifungals

## Anidulafungin

RED

££

Ecalta® infusion

PbR X

**1<sup>st</sup> line RESTRICTED**  
micro / specialist use only

## Micafungin

RED

££

Mycamine® infusion

PbR X

**RESTRICTED**  
micro / specialist use only

## Rezafungin

RED

££

Rezzayo® infusion

PbR X

**RESTRICTED**  
micro / specialist use only

## 5.2.5 Other Antifungals

## Griseofulvin

tablets

**2<sup>nd</sup> line**  
following topical therapy

## Terbinafine

RED

tablets

**2<sup>nd</sup> line**  
following topical therapy

## Flucytosine

infusion























































































































**RESTRICTED**  
micro / Neonates only

MHRA Drug Safety Update (Oct-20): Flucytosine (Ancotil): new contraindication in patients with DPD deficiency









































### 5.3 Antiviral drugs



<p><b>Molnupiravir</b>  </p> <p>Lagevrio® 200mg capsules</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED CMDU</b>                  see COVID-19 guidance</p> <p></p>
<p><b>Nirmatrelvir with ritonavir</b>  </p> <p>Paxlovid® 150mg/100mg tablets</p> <p>PbR X NICE MMC BNF </p>	<p><b>RESTRICTED</b>                  see COVID-19 guidance</p> <p></p>
<p>MHRA Drug Safety Update (Nov-23): Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir</p>	
<p><b>Remdesivir</b>  </p> <p>Veklury® infusion</p> <p>MMC  </p>	<p><b>RESTRICTED</b>                  see COVID-19 guidance</p> <p></p>
<p><b>Tecovirimat monohydrate</b>  </p> <p>Tecovirimat SIGA® 200mg capsules</p> <p>PbR X  </p>	<p><b>RESTRICTED patients hospitalised due to monkeypox</b></p> <p></p>
<p><b>5.3.1 HIV Infection</b> </p>	<p><b>BHIVA treatment guidelines</b></p>
<p><b>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</b></p>	<p><b>CHIVA PEP 2023</b> </p>
<p><b>Abacavir</b>  </p> <p>tablets; oral solution</p> <p>PbR X MMC  </p>	
<p><b>Bictegravir with emtricitabine &amp; tenofovir alafenamide</b>  </p> <p>Biktarvy® tablets</p> <p>PbR X MMC  </p>	<p></p>
<p><b>Emtricitabine</b>  </p> <p>capsules</p> <p>PbR X MMC  </p>	
<p><b>Lamivudine</b>  </p> <p>tablets; oral solution</p> <p>PbR X  </p>	
<p><b>Tenofovir disoproxil</b>  </p> <p>tablets; granules</p> <p>PbR X NICE MMC  </p>	
<p><b>Tenofovir alafenamide</b>  </p> <p>Descovy® / Odefsey® / Genvoya® tablets</p> <p>PbR X MMC  </p>	<p><b>RESTRICTED</b>                  patients requiring new formulation</p> <p></p>
<p><b>Tenofovir disoproxil with efavirenz &amp; emtricitabine</b>  </p> <p>Atripla® tablets</p> <p>PbR X MMC  </p>	
<p><b>Tenofovir with cobicistat, elvitegravir &amp; emtricitabine</b>  </p> <p>Stribild® tablets</p> <p>PbR X MMC  </p>	<p></p>
<p><b>Tenofovir with emtricitabine</b>  </p> <p>Truvada® tablets</p> <p>PbR X MMC  </p>	
<p><b>Emtricitabine with rilpivirine &amp; tenofovir</b>  </p> <p>Eviplera® tablets</p> <p>PbR X MMC  </p>	
<p><b>Zidovudine with lamivudine</b>  </p> <p>Combivir® tablets</p> <p>PbR X  </p>	

Protease Inhibitors		BHIVA treatment guidelines
<b>Atazanavir</b>   capsules    		
<b>Atazanavir with cobicistat</b>   Evotaz® tablets    		
<b>Baloxavir marboxil</b>   Xofluza® tablets    		<b>post-exposure prophylaxis of influenza</b>
<b>Darunavir</b>   tablets; oral suspension    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Darunavir with cobicistat</b>   RezoIsta® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Darunavir with cobicistat, emtricitabine &amp; tenofovir alafenamide</b>   Symtuza® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Fosamprenavir</b>   Telzir® tablets    		
<b>Fostemsavir tromethamine</b>   Rukobia® tablets    		
<b>Lopinavir with ritonavir</b>   Kaletra® tablets; oral solution   		<b>Kaletra® 100mg/25mg &amp; 200mg/50mg tablets are being discontinued in Apr-26</b>
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
<b>Ritonavir</b>   tablets; powder for oral suspension   		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
<b>Saquinavir</b>   tablets   		
Non-Nucleoside Reverse Transcriptase Inhibitors (Non-NRTIs)		BHIVA treatment guidelines
<b>Doravirine</b>   Pifeltro® tablets    		
<b>Doravirine with lamivudine &amp; tenofovir disoproxil fumarate</b>   Delstrigo® tablets    		
<b>Efavirenz</b>   tablets; capsules   		
<b>Etravirine</b>   Intelence® tablets    		
<b>Nevirapine</b>   tablets; oral suspension; M/R tablets    		
<b>Rilpivirine</b>   Edurant® tablets / Rekambys® injection     		
Other Antiretrovirals (Integrase inhibitors; Fusion inhibitors; CCR5 antagonists)		BHIVA treatment guidelines
<b>Cabotegravir</b>   Vocabria® injection and Aprelude® tablets; injection     		
<b>Dolutegravir</b>   Tivicay® tablets    		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
MHRA Drug Safety Update (Jun-18): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): increased risk of neural tube defects; DNP to women seeking to become pregnant...		

<b>Dolutegravir with abacavir &amp; lamivudine</b> 		
Triumeq® tablets <span style="float: right;">PbR X   </span>		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
<b>Dolutegravir with lamivudine</b> 		
Dovato® tablets <span style="float: right;">PbR X   </span>		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
<b>Dolutegravir with rilpivirine</b> 		
Juluca® tablets <span style="float: right;">PbR X   </span>		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
<b>Enfuvirtide</b> 		
Fuzeon® injection <span style="float: right;">PbR X   </span>		
<b>Maraviroc</b> 		
Celsentri® tablets <span style="float: right;">PbR X   </span>		
<b>Raltegravir</b> 		
Isentress® tablets; chewable tablets; granules <span style="float: right;"> </span>		
<b>Pharmacokinetic enhancers of antiretrovirals</b>		
<b>Cobicistat</b> 		
Tybost® tablets <span style="float: right;">PbR X   </span>		
<b>5.3.2 Herpesvirus Infection</b>		
<b>5.3.2.1 Herpes Simplex &amp; Varicella-Zoster Infection</b>		
<b>Aciclovir</b> 		
tablets; oral suspension; infusion (see also section 13.10.3) <span style="float: right;"> </span>		
<b>Valaciclovir</b> 		
tablets <span style="float: right;"> </span>		<b>RESTRICTED</b> Specialist use only
<b>Amenamivir</b> 		
Amenalief® 200mg tablets <span style="float: right;"> </span>		<b>RESTRICTED</b> Specialist use only
<b>5.3.2.2 Cytomegalovirus (CMV) Infection</b>		
<b>Cidofovir</b> 		<b>RESERVED</b> Specialist use only
infusion <span style="float: right;">PbR X  </span>		
<b>Foscarnet sodium</b> 		<b>RESERVED</b> Specialist use only; also for aggressive CMV retinitis
infusion <span style="float: right;">PbR X   </span>		
<b>Ganciclovir</b> 		<b>RESERVED</b> Specialist use only
infusion (see also eye gel section 11.3.3) <span style="float: right;">PbR X  </span>		
<b>Letemovir</b> 		<b>RESERVED</b> Specialist use only
Prevymis® tablets <span style="float: right;">PbR X     </span>		
<b>Maribavir</b> 		<b>RESERVED</b> Specialist use only in line with NICE
Livtency® tablets <span style="float: right;">PbR X     </span>		
<b>Valganciclovir</b> 		<b>RESERVED</b> Specialist use only
tablets; oral solution <span style="float: right;">PbR X  </span>		
<b>5.3.3 Viral Hepatitis</b>		
<b>5.3.3.1 Chronic hepatitis B</b>		
		<b>NICE CG165</b>
<b>Adefovir dipivoxil</b> 		
Hepsera® tablets <span style="float: right;">PbR X    </span>		
<b>Entecavir</b> 		
Baraclude® tablets <span style="float: right;">PbR X    </span>		

5.3.3.2 Chronic hepatitis C		NHSE Hepatitis C	NHS England
MHRA Drug Safety Update (Jan-17): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation			
MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR			
<b>Dasabuvir</b> RED ££ Exviera® tablets PbR X	    	<b>RESTRICTED Specialist use only</b> in line with NHSE Commissioning	
<b>Elbasvir with grazoprevir</b> RED ££ Zepatier® tablets PbR X NICE	    	<b>RESTRICTED Specialist use only</b> in line with NICE TA413	
<b>Glecaprevir with pibrentasvir</b> RED ££ Maviret® tablets PbR X NICE	    	<b>RESTRICTED Specialist use only</b> in line with NHSE and NICE TA499	
<b>Ombitasvir with paritaprevir &amp; ritonavir</b> RED ££ Viekirax® tablets PbR X NICE	   	<b>RESTRICTED Specialist use only</b> in line NICE / NHSE Commissioning	
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels			
<b>Sofosbuvir</b> RED ££ Sovaldi® tablets PbR X NICE	    	<b>RESTRICTED Specialist use only</b> in line with NICE TA330	
MHRA Drug Safety Update (Aug-15): Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone			
<b>Sofosbuvir with ledipasvir</b> RED ££ Harvoni® tablets PbR X NICE	    	<b>RESTRICTED Specialist use only</b> in line NHSE Commissioning	
MHRA Drug Safety Update (May-15): Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone			
<b>Sofosbuvir with velpatasvir</b> RED ££ Epclusa® tablets PbR X NICE	    	<b>RESTRICTED Specialist use only</b> in line with NICE TA430	
<b>Sofosbuvir with velpatasvir &amp; voxilaprevir</b> RED ££ Vosevi® tablets PbR X NICE	    	<b>RESTRICTED Specialist use only</b> in line with NICE TA507	
5.3.3.3 Hepatitis D			
<b>Bulevirtide</b> RED ££ Hepcludex® injection PbR X NICE	    	<b>RESTRICTED Specialist use only</b> in line with NICE TA896	
5.3.4 Influenza			
<b>Oseltamivir</b> GREEN Tamiflu® capsules; oral suspension NICE	    		
MHRA Drug Safety Update (Sep-12): Oseltamivir (Tamiflu): changed concentration and dosing dispenser of oral suspension			
<b>Zanamivir</b> GREEN Relenza® inhalation powder NICE	    		
<b>Zanamivir</b> RED Dectova® 10mg/mL infusion NICE	    	<b>RESTRICTED</b> Virology approval only	
5.3.5 Respiratory Syncytial Virus (RSV)			
MHRA Drug Safety Update (Jul-25): Abrysvo (Pfizer) and Arexvy (GSK): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults			
<b>Nirsevimab</b> RED ££ Beyfortus® 50mg/mL; 100mg/mL injection PbR X	   	<b>RESTRICTED Specialist use only</b>	
<b>Palivizumab</b> RED ££ Synagis® 100mg/mL injection PbR X	    	<b>RESTRICTED Specialist use only</b>	
<b>Ribavirin</b> RED ££ capsules; tablets PbR X NICE	    	<b>RESTRICTED Specialist use only</b>	

## 5.4 Antiprotozoal drugs



## Nitazoxanide

RED

500mg tablets; 100mg/5mL oral suspension

PbR X

MMC

emc

**RESTRICTED**  
Specialist use only

## 5.4.1 Antimalarials

treatment

BNF

prophylaxis

BNF

## Artesunate

injection

BNF emc

**RESTRICTED**  
Specialist use only

## Artemether with lumefantrine

SI

tablets

MMC BNF emc

**RESTRICTED**  
Specialist use only

## Chloroquine

RED

tablets

BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions  
 MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment

## Mefloquine

RED

tablets

BNF emc

**RESTRICTED**  
Specialist use only

## Primaquine

RED

tablets

BNF emc

**RESTRICTED**  
Specialist use only

## Proguanil hydrochloride

RED

tablets

BNF emc

**RESTRICTED**  
Specialist use only

## Proguanil hydrochloride with atovaquone

RED

Malarone® tablets

BNF emc

**RESTRICTED**  
Specialist use only

## Pyrimethamine

RED

tablets

MMC BNF emc

**RESTRICTED**  
Specialist use only

## Pyrimethamine with sulfadoxine

RED

tablets

BNF emc

**RESTRICTED**  
Specialist use only

## Quinine dihydrochloride

RED

injection

BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions

## Quinine sulfate

tablets (see also section 10.2.2)

BNF emc

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions

## 5.4.2 Amoebicides

## Metronidazole

GREEN

(see also section 5.1.11)

BNF emc

## Tinidazole

GREEN

Fasigyn® tablets

BNF emc

**RESERVED**  
Specialist use only

## Diloxanide furoate

tablets

BNF emc

**RESTRICTED**  
Non-formulary  
micro. recommendation only

## 5.4.3 Trichomonacides

## Metronidazole

GREEN

(see also section 5.1.11)

BNF emc



























## 5.4.4 Antigiardial drugs

## Metronidazole

GREEN

(see also section 5.1.11)

BNF emc

<b>5.4.5 Leishmaniacides</b>		
<b>Meglumine antimoniate</b>   injection	  	<b>RESTRICTED</b> treatment of Leishmaniacides
<b>Paromomycin</b>   tablets	  	<b>RESTRICTED</b> treatment of Cryptosporidiosis
<b>Sodium stibogluconate</b>  injection	  	<b>RESTRICTED</b> treatment of Leishmaniacides
<b>5.4.7 Drugs for toxoplasmosis</b>		
<b>Sulfadiazine</b>   tablets	 	<b>RESTRICTED</b> treatment of toxoplasmosis <b>micro. recommendation only</b>
<b>5.4.8 Drugs for pneumocystis pneumonia</b>		
<b>Atovaquone</b>   oral suspension	 	<b>RESTRICTED</b> Specialist use only
<b>Pentamidine isethionate</b>   injection	 	<b>RESTRICTED</b> Specialist use only

## 5.5 Anthelmintic



### 5.5.1 Drugs for Threadworms (pinworms, *Enterobius vermicularis*)

#### Albendazole

RED

tablets

MMC

**RESTRICTED**  
Specialist use only

#### Mebendazole

(DNP)

chewable tablets; oral suspension ( threadworms)

### 5.5.2 Ascaricides

#### Levamisole

tablets

MMC

**RESTRICTED**  
Specialist use only

### 5.5.5 Schistosomicides (bilharziasis)

#### Praziquantel

tablets

MMC

**RESTRICTED**  
Schistosomicides / tapeworm

### 5.5.6 Filaricides

#### Diethylcarbamazine

tablets

MMC

**RESTRICTED**  
Specialist use only

## 5.6 Miscellaneous



### 5.6 Miscellaneous antimicrobial treatments

#### Calcium sulphate

RED

Stimulan® antibiotic carrier beads

MMC



**RESTRICTED**  
Specialist use Diabetic Foot Clinic  
only

#### Tauroidine



























RED

TauroPace™ 2% solution

MMC



**RESTRICTED**  
Aspergilloma surgery only

Non-Formulary Items		GMMMG
<b>Bezlotoxumab</b> (DNP)  <i>Zinplava</i> ® injection <span style="float: right;"></span>		<b>In line with GMMMG (Discontinued Jan-25)</b>
<b>Casirivimab with imdevimab</b> RED  <i>Ronapreve</i> ® infusion <span style="float: right;">PbR X    </span>		<b>No longer part of MFT COVID19 Management pathway</b> 
<b>Edetate tetrasodium</b> <i>KiteLock</i> ™ 4% sterile catheter lock solution <span style="float: right;"> </span>		<b>Not MMC approved</b>
<b>Fungal nail infections</b> (DNP) Nail lacquers, paints and softening products		<b>In line with GMMMG / NHSE Criterion 3</b>
<b>Infrequent cold sores of the lip</b> (DNP) Aciclovir cream, Zovirax cold sore cream		<b>In line with GMMMG / NHSE</b>
<b>Ketoconazole (oral administration)</b> (DNP) 200mg tablets <span style="float: right;">  </span>		<b>In line with GMMMG Criterion 1</b>
MHRA Drug Safety Update (Dec-14): Oral ketoconazole: do not prescribe or use for fungal infections—risk of liver injury outweighs benefits		
<b>Sotrovimab</b> RED  <i>Xevudy</i> ® infusion <span style="float: right;">PbR X    </span>		<b>Discontinued February 2026</b> 
<b>Threadworms</b> (DNP) e.g. Mebendazole		<b>In line with GMMMG / NHSE</b>
<b>Tipranavir</b> RED  capsules <span style="float: right;">PbR X  </span>		<b>Discontinued December 2021</b>
<b>Tixagevimab with cilgavimab</b> RED  <i>Evusheld</i> ® injection <span style="float: right;">  </span>		<b>REJECTED in line with NICE TA971</b>

## Section 6: Endocrine system

Supported by the  
formulary (click here)



### 6.1 Drugs used in diabetes

#### 6.1.1 Insulins

##### 6.1.1.1 Short-acting insulins

##### 6.1.1.2 Intermediate & long-acting insulins

##### Biphasic insulins

#### 6.1.2 Antidiabetic drugs

##### 6.1.2.1 Sulphonylureas

##### 6.1.2.2 Biguanides

##### 6.1.2.3 Other antidiabetic drugs

##### Alpha glucosidase inhibitors

##### Dipeptidyl peptidase-4 (DPP-4) inhibitors

##### Rapid acting insulin secretagogues (meglitinides)

##### Glucagon-like peptide-1 (GLP-1) receptor agonists

##### Sodium-glucose co-transporter 2 (SGLT2) inhibitors

##### Thiazolidinediones

#### 6.1.4 Treatment of hypoglycaemia

#### 6.1.5 Treatment of diabetic nephropathy and neuropathy

#### 6.1.6 Diagnostic and monitoring agents for diabetes mellitus

### 6.2 Thyroid & antithyroid drugs

#### 6.2.1 Thyroid hormones

#### 6.2.2 Antithyroid drugs

### 6.3 Corticosteroids

#### 6.3.1 Replacement therapy

#### 6.3.2 Glucocorticoid therapy

### 6.4 Sex hormones

#### 6.4.1 Female sex hormones and their modulators

##### 6.4.1.1 Oestrogens & HRT

##### 6.4.1.2 Progestogens and progesterone receptor modulators

#### 6.4.2 Male sex hormones & antagonists

### 6.5 Hypothalamic and pituitary hormones & anti-oestrogens

#### 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

#### 6.5.2 Posterior pituitary hormones & antagonists

### 6.6 Drugs affecting bone metabolism

#### 6.6.1 Calcitonin & parathyroid hormone

#### 6.6.2 Bisphosphonates & other drugs affecting bone metabolism

### 6.7 Other endocrine drugs

#### 6.7.1 Bromocriptine & other dopaminergic drugs

#### 6.7.2 Drugs affecting gonadotrophins

#### 6.7.3 Metyrapone

#### 6.7.4 Somatomedins

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Safer insulin prescribing (KTT20)  
 Diabetes in pregnancy: management from preconception to the postnatal period (NG3)  
 Type 1 diabetes in adults: diagnosis and management (NG17)  
 Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)  
 Diabetic foot problems: prevention and management (NG19)  
 Type 2 diabetes in adults: management (NG28)  
 Heavy menstrual bleeding: assessment and management (NG88)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Human growth hormone - adults (TA64)  
 Diabetes (type 1) - insulin pump therapy (TA151)  
 Osteoporosis - Primary Prevention (TA160)  
 Osteoporosis - Secondary Prevention (TA161)  
 Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)  
 Osteoporotic Fractures - denosumab (TA204)  
 Bone metastases from solid tumours - denosumab (TA265)  
 Type 2 diabetes - Dapagliflozin combination therapy (TA288)  
 Diabetes (type 2) - canagliflozin (TA315)  
 Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)  
 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)  
 Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)  
 Bisphosphonates for treating osteoporosis (TA464)  
 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)  
 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)  
 Sotagliflozin with insulin for treating type 1 diabetes (TA622)  
 Liraglutide for managing overweight and obesity (TA664)  
 Romosozumab for treating severe osteoporosis (TA791)  
 Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)  
 Somatrogen for treating growth disturbance in people 3 years and over (TA863)  
 Tirzepatide for treating type 2 diabetes (TA924)  
 Empagliflozin for treating chronic kidney disease (TA942)  
 Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)  
 Abaloparatide for treating osteoporosis after menopause (TA991)  
 Burosumab for treating X-linked hypophosphataemia in adults (TA993)  
 Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)  
 Tirzepatide for managing overweight and obesity (TA1026)  
 Relugolix-estradiol-norethisterone for treating symptoms of endometriosis (TA1057)  
 Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)  
 Linzagolix for treating symptoms of endometriosis (TA1067)  
 Dapagliflozin for treating chronic kidney disease (updates & replaces TA775) (TA1075)

## GMMMG Formulary

Formulary Homepage  
 Chapter 6: Endocrine system  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

# 6.1 Drugs used in diabetes



## 6.1.1 Insulins

Type 1 diabetes



Type 2 diabetes



**Insulins must ONLY be initiated by practitioners experienced in their use**  
**Insulins must be prescribed by BRAND NAME**

MHRA Drug Safety Update (Apr-15): High strength, fixed combination & biosimilar insulin products: minimising the risk of medication error

- NICE NG3
- NICE NG17
- NICE NG18
- NICE NG19
- NICE NG28

### 6.1.1.1 Short-acting insulins

#### Human

**Actrapid®**

SI

Human insulin (see also section 18.1.1)



**Apidra®**

GREEN

Insulin glulisine



**Fiasp®**

GREY SA

Insulin aspart (NB: Fiasp FlexTouch® 100units/mL discontinued Nov-25)



**Humalog®**

SI

Insulin lispro



**Humulin R®** Ⓢ

Human insulin



**Humulin S®**

SI

Human insulin



**Admelog®**

GREEN

Insulin lispro



**Lyumjev®**

GREY SA

Insulin lispro



**NovoRapid®**

GREEN

Insulin aspart



**Trurapi®**

GREEN

Insulin aspart



#### Animal

- Some long-standing type 1 diabetic patients may be on animal insulin. These are made by Wockhardt and come in 10ml vials or 3ml Cartridges that fit into the Autopen Classic® which is available on prescription.
- Patients need not be transferred to human insulin unless clinical need dictates
- Human insulin and analogues should be used in preference to animal insulin

**Hypurin® Porcine Neutral**

Insulin porcine



### 6.1.1.2 Intermediate & long-acting insulins

#### Human

**Humulin I® Insulin**

SI

Isophane insulin



**Insulatard®**

SI

Isophane insulin


















































#### Animal

- Some long-standing type 1 diabetic patients may be on animal insulin. These are made by Wockhardt and come in 10ml vials or 3ml Cartridges that fit into the Autopen Classic® which is available on prescription.
- Patients need not be transferred to human insulin unless clinical need dictates
- Human insulin and analogues should be used in preference to animal insulin

**Hypurin® Porcine Isophane**

Isophane insulin







Long-acting insulins		
<b>Human</b>		
<b>Levemir®</b>  Insulin detemir	 	
<b>Lantus®</b> Insulin glargine	 	<b>2<sup>nd</sup> line use</b> in patients where normal basal insulins cause nocturnal hypoglycaemia
<b>Abasaglar®</b>  Insulin glargine (biosimilar)	 	
<b>Toujeo®</b>   Insulin glargine (HIGH STRENGTH)	 	
<b>Tresiba®</b>   Insulin degludec ( <b>NB: Tresiba FlexTouch® 100units/mL discontinued Dec-25</b> )	 	<b>RESTRICTED</b> <b>3<sup>rd</sup> line after Levemir &amp; Lantus</b> <b>Diabetes Consultant only</b>
<b>Biphasic insulins</b>		
<b>Human</b>		
<b>Humalog® Mix 25</b>  Biphasic insulin lispro	 	
<b>Humalog® Mix 50</b>  Biphasic insulin lispro	 	
<b>Humulin M3®</b>  Biphasic isophane insulin	 	
<b>NovoMix® 30</b>  Biphasic insulin aspart	 	
<b>Animal</b>		
<ul style="list-style-type: none"> <li>Some long-standing type 1 diabetic patients may be on animal insulin. These are made by Wockhardt and come in 10ml vials or 3ml Cartridges that fit into the Autopen Classic® which is available on prescription.</li> <li>Patients need not be transferred to human insulin unless clinical need dictates</li> <li>Human insulin and analogues should be used in preference to animal insulin</li> </ul>		
<b>Hypurin® Porcine 30/70 Mix Insulin</b> Biphasic isophane insulin	 	
<b>6.1.2 Antidiabetic drugs</b>		
<b>6.1.2.1 Sulfonylureas</b>		
<b>Gliclazide</b>  tablets	 	
<b>Glipizide</b> tablets	 	<b>RESTRICTED</b> <b>Not for initiation</b>
<b>6.1.2.2 Biguanides</b>		
<b>Metformin hydrochloride</b>   oral solution; tablets	 	
MHRA Drug Safety Update (Jun-22): Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk MHRA Drug Safety Update (Mar-22): Metformin in pregnancy: study shows no safety concerns		
<b>6.1.2.3 Other antidiabetic drugs</b>		<b>NICE NG28</b>
<b>Alpha glucosidase inhibitors</b>		
<b>Acarbose</b> tablets	 	
<b>Dipeptidyl peptidase 4 (DPP 4) inhibitors</b>		
MHRA Drug Safety Update (Sep-12): Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis		
<b>Alogliptin</b>  tablets	 	
<b>Linagliptin</b>  tablets	 	

<b>Saxagliptin</b> <b>GREEN</b> tablets MMC <b>BNF</b> <b>emc</b>	<b>2<sup>nd</sup> line</b> to improve glycaemic control in adults with metformin
<b>Sitagliptin</b> <b>GREEN</b> tablets MMC <b>BNF</b> <b>emc</b>	
<b>Rapid acting insulin secretagogues (meglitinides)</b>	
<b>Repaglinide</b> <b>GREEN</b> tablets MMC <b>BNF</b> <b>emc</b>	<b>2<sup>nd</sup> line</b>
<b>Glucagon-like peptide-1 (GLP-1) receptor agonists</b>	
MHRA Drug Safety Update (Jan-26): GLP-1 receptor agonists & dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising & fatal cases MHRA Drug Safety Update (Oct-24): GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse MHRA Drug Safety Update (Jun-19): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued	
<b>Dulaglutide</b> <b>GREEN</b> injection MMC <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>1<sup>st</sup> line weekly preparation</b> <b>Diabetes Consultants only</b>
<b>Exenatide</b> <b>GREEN</b> injection NICE MMC <b>BNF</b> <b>emc</b>	<b>2<sup>nd</sup> line</b> patients with poor glycaemic control
<b>Bydureon®</b> <b>GREEN</b> Exenatide prolonged release (once weekly injection) MMC <b>BNF</b> <b>emc</b>	<b>3<sup>rd</sup> line</b> after failure / inadequate response to oral therapy
<b>Liraglutide (Victoza®)</b> <b>GREEN</b> 6mg/mL pre-filled pen MMC <b>BNF</b> <b>emc</b>	<b>2<sup>nd</sup> line</b> to achieve glycaemic control with metformin or a sulphonylurea <b>PRESCRIBE BY BRAND NAME</b>
MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products	
<b>Semaglutide</b> <b>GREEN</b> Ozempic® injection NICE MMC <b>BNF</b> <b>emc</b>	<b>1<sup>st</sup> line</b> weekly preparation
MHRA Drug Safety Update (Feb-26): Semaglutide (Wegovy, Ozempic & Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products	
<b>Semaglutide</b> <b>GREEN</b> Rybelsus® tablets NICE MMC <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>as per by GMMMG</b>
MHRA Drug Safety Update (Feb-26): Semaglutide (Wegovy, Ozempic & Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) MHRA Drug Safety Update (Dec-25): Rybelsus® (semaglutide tablets): transition to new formulation and risk of medication error MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products	
<b>Tirzepatide</b> <b>GREEN</b> Mounjaro® injection NICE MMC <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>as per NICE / GMMMG T2DM pathway</b> <a href="#">see also Non-formulary section</a>
MHRA Drug Safety Update (Feb-26): Falsified Mounjaro KwikPen 15mg pre-filled pens	
<b>Sodium-glucose co-transporter 2 (SGLT2) inhibitors</b>	
MHRA Drug Safety Update (Mar-20): SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness MHRA Drug Safety Update (Feb-19): SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum) MHRA Drug Safety Update (Mar-17): SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) MHRA Drug Safety Update (Apr-16): SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis	
<b>Canagliflozin</b> <b>GREEN</b> tablets NICE MMC <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>in line with NICE</b> <b>Diabetes Consultants only</b>
MHRA Drug Safety Update (Jun-16): Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations in trial in high CV risk patients	
<b>Dapagliflozin</b> <b>GREEN</b> tablets NICE MMC <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>in line with NICE diabetes / HF</b>
MHRA Drug Safety Update (Apr-16): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus	
<b>Empagliflozin</b> <b>GREEN</b> tablets NICE MMC <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>in line with NICE diabetes / HF</b>
<b>Ertugliflozin</b> <b>GREEN</b> tablets NICE MMC <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>in line with NICE</b> <b>Diabetes Consultants only</b>
<b>Thiazolidinediones</b>	
<b>Pioglitazone</b> <b>GREEN</b> tablets MMC <b>BNF</b> <b>emc</b>	<b>2<sup>nd</sup> line</b> add-on with metformin or a sulphonylurea
MHRA Drug Safety Update (Aug-11): Pioglitazone: risk of bladder cancer	


**6.1.4 Treatment of hypoglycaemia**

<p><b>Glucagon</b>  <span style="background-color: green; color: white; padding: 2px;">GREEN</span>                      1mg injection (see also section 18.1.1)</p>	 	
<p><b>Glucose gel</b>  <span style="background-color: green; color: white; padding: 2px;">GREEN</span>                      40% oral gel</p>	 	
<p><b>Diazoxide</b>  <span style="background-color: green; color: white; padding: 2px;">SI</span>                      tablets</p>	  	<p><b>Hyperinsulinaemic Hypoglycaemia</b></p>

**6.1.5 Treatment of diabetic nephropathy and neuropathy**

<p><b>Diabetic nephropathy</b>  </p>	<p><b>NICE NG3</b></p>
<p><b>Diabetic neuropathy</b>   (see also section 4.7.3 Neuropathic pain)</p>	<p><b>NICE NG17</b></p>
	<p><b>NICE NG18</b></p>
	<p><b>NICE NG19</b></p>
	<p><b>NICE NG28</b></p>

**6.1.6 Diagnostic and monitoring agents for diabetes mellitus**

<p><span style="background-color: green; color: white; padding: 2px;">SA</span> <span style="background-color: red; color: white; padding: 2px;">RED</span> </p>	<p></p>
---	--

MHRA Drug Safety Update (Oct-24): Insulin pumps & CGM equipment: guidance for users on reporting suspected adverse incidents & safety concerns to the MHRA's Yellow Card

## 6.2 Thyroid & antithyroid drugs



### 6.2.1 Thyroid hormones

#### Levothyroxine sodium

GREEN

oral solution; tablets



MHRA Drug Safety Update (May-21): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products

#### Liothyronine sodium (oral)

GREY SI (DNP)

tablets



2<sup>nd</sup> line use

#### Liothyronine sodium (injection)

GREY RED

injection



2<sup>nd</sup> line use (I.V. RESTRICTED to hypothyroid coma)

### 6.2.2 Antithyroid drugs

#### Carbimazole

SA

5mg; 20mg tablets (see also (DNP) below)



MHRA Drug Safety Update (Feb-19): Carbimazole: increased risk of congenital malformations; strengthened advice on contraception

MHRA Drug Safety Update (Feb-19): Carbimazole: risk of acute pancreatitis

#### Iodine (Aqueous Iodine oral solution) Ⓢ

Lugol's Iodine



#### Potassium iodide

tablets



#### Propylthiouracil

SI

tablets



## 6.3 Corticosteroids



MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

### 6.3.1 Replacement therapy

#### Fludrocortisone acetate

GREEN

tablets



### 6.3.2 Glucocorticoid therapy

#### Prednisolone

GREEN

**1<sup>st</sup> line:** standard tablets

**if 1<sup>st</sup> line not tolerated**

**2<sup>nd</sup> line:** dissolve standard tablets

**3<sup>rd</sup> line:** oral liquid

**4<sup>th</sup> line:** soluble tablets (££)



#### Dexamethasone

GREEN



#### Hydrocortisone

GREEN



MHRA Drug Safety Update (Dec-18): Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks

#### Hydrocortisone M/R

SI

5mg tablets



**RESTRICTED**

**2<sup>nd</sup> line use in adrenal insufficiency**

#### Hydrocortisone

GREEN

Alkindi® granules in capsules



**RESTRICTED**

**2<sup>nd</sup> line use in adrenal insufficiency**

MHRA Drug Safety Update (Feb-21): Alkindi (granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules

#### Betamethasone

GREEN RED



**RESTRICTED**  
**Specialist use only**

#### Methylprednisolone

GREEN



MHRA Drug Safety Update (Oct-17): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows' milk allergy

#### Triamcinolone acetonide

RED

(see also section 10.1.2.2)



**RESTRICTED**  
**Specialist use only**

#### Vamorolone

RED ££

Agamree® 40mg/mL oral suspension

NICE



**RESTRICTED Specialist use only in line with NICE TA1031**

## 6.4 Sex hormones



## 6.4.1 Female sex hormones and their modulators

## 6.4.1.1 Oestrogens &amp; HRT

## Conjugated oestrogens with progestogen

Premique® (Conjugated oestrogens with medroxyprogesterone)

GREEN

tablets

BNF emc

2<sup>nd</sup> line use oral  
(continuous combined HRT)

## Estradiol with Progestogen

Bijuve® (Estradiol with progesterone)

GREEN

1mg/100mg capsules

MMC BNF emc

Elleste-Duet® (Estradiol with norethisterone)

GREEN

tablets

BNF emc

1<sup>st</sup> line use oral  
(sequential HRT)

Evorel Conti® (Estradiol with norethisterone)

GREEN

patch

MMC BNF emc

Evorel Sequi® (Estradiol with norethisterone)

GREEN

patch

MMC BNF emc

Femoston® (Estradiol with dydrogesterone)

GREEN

tablets

BNF emc

2<sup>nd</sup> line use oral  
(sequential HRT)

Kliovance® (Estradiol with norethisterone)

GREEN

tablets

MMC BNF emc

1<sup>st</sup> line use oral  
(continuous combined HRT)

## Estradiol only

Elleste Solo®

GREEN

tablets

BNF emc

1<sup>st</sup> line use oral  
(oestrogen only HRT)

Estradot®

GREEN

patch

BNF emc

**RESTRICTED**  
(Oestrogen only HRT)  
when oral contraindicated.

Evorel®

GREEN

patch

MMC BNF emc

**RESTRICTED**  
Paed. Endocrine Consultants

Lenzetto®

GREEN

transdermal spray

MMC BNF emc

Oestroge!®

GREEN

0.06% gel (pump-pack)

MMC BNF emc

Progynova®

RED

1mg tablets

MMC BNF emc

**RESTRICTED 2<sup>nd</sup> line**  
Paed. Endocrine Consultants

Sandrena®

GREEN

500microgram; 1mg gel sachets

MMC BNF emc

## Ethinylestradiol, raloxifene &amp; tibolone

Ethinylestradiol Ⓢ

2 microgram tablets

MMC BNF emc

**RESTRICTED**  
adults: amenorrhoea  
paeds: pubertal induction (3<sup>rd</sup> line)

Raloxifene hydrochloride

SA

tablets

NICE MMC BNF emc

**RESTRICTED**  
Specialist Med. Consultant only  
NICE TA160 / TA161

Tibolone

GREEN

tablets

BNF emc

3<sup>rd</sup> line use oral  
(continuous combined HRT)

## 6.4.1.2 Progestogens and progesterone receptor modulators

Dydrogesterone

tablets
























emc

Medroxyprogesterone acetate

GREEN

Depo-Provera® 150mg/mL injection

BNF emc

<b>Medroxyprogesterone acetate</b> <b>GREEN</b> Sayana Press® 104mg/0.65 mL injection   	
<b>Norethisterone</b> <b>GREEN</b> tablets  	
<b>Progesterone</b> <b>GREEN</b> <b>SI</b> <b>RED</b> 100mg oral capsules; 200mg, 400mg pessaries; 200mg vaginal capsules; injection   	
<b>Ulipristal acetate</b> <b>RED</b> Esmya® 5mg tablets   	<b>RESTRICTED</b> Specialist use only uterine fibroids
MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users	
<b>6.4.2 Male sex hormones &amp; antagonists</b>	
<b>Testosterone &amp; Esters</b>	
<b>Oral</b>	
<b>Testosterone</b> <b>SA</b> <b>AMBER</b> injection & implants only  	<b>RESTRICTED</b> Specialist use only
<b>Transdermal preparations</b>	
<b>Androstanolone (aka Dihydrotestosterone (DHT))</b> Andractim® 2.5% gel   	<b>RESTRICTED</b> Specialist use only - 3 <sup>rd</sup> line
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure	
<b>Testosterone</b> <b>SA</b> Tostran® 2% gel   	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure	
<b>Anti-androgens</b>	
<b>Cyproterone acetate</b> <b>SI</b> <b>AMBER</b> tablets (see also section 8.3.4.2)  	<b>RESTRICTED</b> Specialist use only
<b>Finasteride</b> <b>GREEN</b> <b>AMBER</b> tablets  	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Apr-24): Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation..) MHRA Drug Safety Update (May-17): Finasteride: rare reports of depression and suicidal thoughts	

# 6.5 Hypothalamic & pituitary hormones & anti-oestrogens



## 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

### Anti-oestrogens

**Clomifene citrate**

RED

tablets

BNF emc

### Anterior pituitary hormones (Corticotrophins)

**Tetracosactide**

injection

BNF emc

**RESTRICTED**  
test for adrenocortical insufficiency

**Corticotropin releasing hormone**

RED

injection

emc

**RESTRICTED**  
Specialist use only

### Anterior pituitary hormones (Gonadotrophins)

**Follitropin alfa**

RED

Bemfola® injection

MMC BNF emc

**RESTRICTED**  
Specialist use only

**Follitropin alfa**

RED

GONAL-f® injection

MMC BNF emc

**RESTRICTED**  
Specialist use only

**Follitropin alfa**

RED

Ovaleap® injection

MMC BNF emc

**RESTRICTED**  
Specialist use only

**Follitropin delta**

RED

Rekovele® injection

MMC BNF emc

**RESTRICTED**  
Specialist use only

**Human Chorionic Gonadotrophin (hCG)** U

RED

Gonasi® injection

MMC emc

**RESTRICTED**  
Specialist use only

**Human Chorionic Gonadotrophin (hCG)**

RED

Zivafert® injection

MMC emc

**RESTRICTED**  
Specialist use only

### Anterior pituitary hormones (Growth Hormone)

**Somapacitan**

RED EE

Sogroya® injection

PbR X NICE MMC BNF emc

**RESTRICTED**  
as per NICE TA1066

**Somatropin**

SI RED EE

injection

PbR X NICE MMC BNF emc

**RESTRICTED**  
as per NICE TA64 / TA188

**Somatrogon**

RED EE

Ngenla® injection

PbR X NICE MMC BNF emc

**RESTRICTED**  
as per NICE TA863

Growth hormone for primary and secondary hypopituitarism

Green

Growth hormone for children

Amber

Growth hormone for adults except in proven primary and secondary hypopituitarism

Red

### Anterior pituitary hormones (Growth Hormone receptor antagonists)

**Pegvisomant**

RED EE

injection

PbR X MMC BNF bluefeg emc

**RESTRICTED**  
acromegaly on named patient basis  
**NOT STOCKED**

### Hypothalamic hormones

**Gonadorelin (GnRH; LHRH)**

RED

injection

BNF emc

**RESTRICTED**  
Specialist use only

**Protirelin (TRH)**

RED

injection

BNF emc

**RESTRICTED**  
Specialist use only

### 6.5.2 Posterior pituitary hormones & antagonists

**Desmopressin**

SI

injection; oral lyophilisates; nasal spray; solution; tablets (see also section 7.4.2)

MMC BNF emc

**RESTRICTED**  
Haematology Consultants only


















**Terlipressin acetate**

injection

MMC BNF emc

**RESTRICTED**  
oesophageal varices / HRS-AKI

MHRA Drug Safety Update (Mar-23): Terlipressin: new recommendations to reduce risks of respiratory failure & septic shock in patients with type 1 hepatorenal syndrome

<p><b>Tolvaptan</b>   </p> <p>tablets</p> <p>    </p>	<p><b>RESTRICTED Adult.</b>                  Endocrine / Renal Consultant only</p> <p></p>
<p><b>Vasopressin</b>  </p> <p>injection</p> <p> </p>	<p><b>RESTRICTED</b>                  pituitary diabetes insipidus</p>
<p><b>Antidiuretic hormone antagonists</b></p>	
<p><b>Demeclocycline hydrochloride</b>  </p> <p>capsules (see also section 5.1.3)</p> <p>  </p>	<p><b>RESTRICTED</b>                  SIADH only</p>

## 6.6 Drugs affecting bone metabolism



### 6.6.1 Calcitonin & parathyroid hormone

#### Abaloparatide (Eladynos®)

RED

80 micrograms injection

PbR X NICE MMC BNF emc

**RESTRICTED** postmenopausal osteoporosis in line with NICE TA991

#### Calcitonin (salmon) / Salcatonin (Miacalcic®)

injection

MMC BNF emc

**RESTRICTED** osteoporosis patients with acute fracture pain.

MHRA Drug Safety Update (Aug-12): Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.

#### Parathyroid hormone

RED

injection

PbR X MMC BNF emc

**RESTRICTED** postmenopausal osteoporosis if failure or non-compliance with bisphosphonates

#### Teriparatide (Forsteo®)

RED

250 micrograms / mL injection

PbR X NICE MMC BNF emc

**RESTRICTED** as per NICE/NHSE

#### Teriparatide (Movymia®)

RED

250 micrograms / mL injection

PbR X NICE MMC BNF emc

Paeds. see decision tables

**RESTRICTED** as per forsteo for new patients

NHS  
England

### 6.6.2 Bisphosphonates & other drugs affecting bone metabolism

MHRA Guidance (Dec-14): Bisphosphonates: use and safety

MHRA Drug Safety Update (Dec-15): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update (Jun-11): Bisphosphonates: atypical femoral fractures

MHRA Drug Safety Update (Nov-09): Bisphosphonates: osteonecrosis of the jaw

#### Alendronic acid

GREEN

tablets

NICE MMC BNF emc

**1<sup>st</sup> line use**

#### Risedronate sodium

GREEN

tablets

NICE MMC BNF emc

**2<sup>nd</sup> line**  
Osteoporosis & Paget's disease

#### Strontium ranelate

oral suspension

MMC BNF emc

**3<sup>rd</sup> line** osteoporosis patients unable to take bisphosphonates

MHRA Drug Safety Update (Dec-14): Strontium ranelate: cardiovascular risk

#### Ibandronic acid

AMBER

tablets; injection

NICE MMC BNF emc

**RESTRICTED** monthly treatment when daily/weekly dosing contraindicated; NICE TA464

#### Denosumab

AMBER

Prolia® injection

NICE MMC BNF emc

**RESTRICTED**  
specialist use / NICE TA204

MHRA Drug Safety Update (May-22): Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia

MHRA Drug Safety Update (Aug-20): Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment

MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva▼, Prolia): reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

#### Denosumab

RED

Xgeva® injection

NICE MMC BNF emc

**RESTRICTED**  
specialist use / NICE TA265

MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new 1ry malignancies reported more frequently...

MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva▼, Prolia): reports of osteonecrosis of the external auditory canal

MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

#### Zoledronic acid

RED

infusion

NICE MMC BNF emc

**RESTRICTED**  
see decision tables; also NICE TA464

#### Burosumab

RED

infusion; pre-filled syringe

NICE MMC BNF emc

**RESTRICTED**  
specialist use only XLH / TIO  
NICE HST8 / TA993

#### Romozosumab

RED

Evenity® injection

NICE MMC BNF emc

**RESTRICTED**  
specialist use NICE TA791

## 6.7 Other endocrine drugs



### 6.7.1 Bromocriptine & other dopaminergic drugs

#### Bromocriptine

SA

1mg; 2.5mg tablets

MMC BNF emc

MHRA Drug Safety Update (Oct-24): Bromocriptine: monitor blood pressure when prescribing bromocriptine for prevention or inhibition of post-partum physiological lactation

#### Cabergoline

SA

500 microgram tablets

BNF emc

**RESTRICTED**  
Hyperprolactinaemia

### 6.7.2 Drugs affecting gonadotrophins

#### Danazol

capsules

BNF emc

#### Buserelin acetate

RED

injection (see also section 8.3.4.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**  
IVF

#### Goserelin acetate

AMBER RED

implant (also section 8.3.4.2)

BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

#### Leuprorelin acetate

AMBER RED

injection (also section 8.3.4.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

#### Triptorelin acetate

AMBER RED

injection (also section 8.3.4.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**

#### Cetrorelix acetate

RED

injection

MMC BNF emc

**RESTRICTED**  
IVF

#### Ganirelix

RED

injection

MMC BNF emc

**RESTRICTED**  
IVF

#### Linzagolix

SA

Yseltly® 100mg; 200mg tablets

NICE MMC BNF emc

**RESTRICTED**  
specialist use NICE TA996 / TA1067

#### Relugolix with estradiol & norethisterone acetate

SA

Ryeqo® 40mg/1mg/0.5mg tablets

NICE MMC BNF emc

**RESTRICTED**  
specialist use NICE TA832 / TA1057

### 6.7.3 Metyrapone

#### Metyrapone

RED

250mg capsules

BNF emc

**RESTRICTED**  
Specialist use only

### 6.7.4 Somatomedins

#### Mecasermin

RED

EE

10mg/mL injection

PbR X

BNF emc

bluefeg

**RESTRICTED**  
Specialist use only

MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex ▼): risk of benign and malignant neoplasia

# Non-Formulary Items



<b>Buserelin acetate</b> <b>RED</b> Suprecur® nasal spray	<b>MMC</b> <b>BNF</b> <b>emc</b>	<b>Discontinued</b> <b>March 2025</b>
<b>Carbimazole</b> <b>(DNP)</b> 10mg; 15mg tablets	<b>MMC</b> <b>BNF</b> <b>emc</b>	<b>in line with GMMMG</b>
<b>Chlorpropamide</b> <b>(DNP)</b> tablets	<b>BNF</b>	<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Fezolinetant</b> Veoza® 45mg tablets	<b>BNF</b> <b>emc</b>	
<b>MHRA Drug Safety Update (Apr-25): Fezolinetant (Veoza): risk of liver injury; new recommendations to minimise risk</b>		
<b>Gliclazide</b> <b>(DNP)</b> Modified-release tablets (e.g. Diamicon® MR)	<b>BNF</b> <b>emc</b>	<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Hypurin® Bovine Isophane</b> Isophane insulin	<b>emc</b>	<b>Discontinued</b> <b>July 2017</b>
<b>Hypurin® Bovine Lente</b> Insulin zinc suspension	<b>emc</b>	<b>Discontinued</b> <b>July 2017</b>
<b>Hypurin® Bovine Neutral</b> Insulin bovine	<b>NICE</b> <b>emc</b>	<b>Discontinued</b> <b>July 2017</b>
<b>Liraglutide</b> <b>RED</b> Saxenda® 6mg/mL pre-filled pen	<b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>Greater Manchester Integrated Care Partnership</b>	<b>Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.</b>
<b>Lixisenatide</b> Lyxumia® 10 microgram; 20microgram injection	<b>MMC</b> <b>BNF</b> <b>emc</b>	<b>Discontinued</b> <b>June 2022 / December 2023</b>
<b>Metformin hydrochloride</b> <b>(DNP)</b> 1g immediate-release tablets	<b>BNF</b> <b>emc</b>	<b>in line with GMMMG</b> <b>Criterion 2</b>
<b>Nateglinide</b> tablets	<b>MMC</b> <b>BNF</b> <b>emc</b>	<b>Discontinued</b> <b>August 2020</b>
<b>Pen needles 8mm, 10mm, or 12mm in length</b> <b>(DNP)</b>		<b>in line with GMMMG</b> <b>Criterion 1</b>
<b>Pen needles costing in excess of £5 per 100</b> <b>(DNP)</b>		<b>in line with GMMMG</b> <b>Criterion 3</b>
<b>Semaglutide</b> <b>RED</b> Wegovy® injection	<b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>Greater Manchester Integrated Care Partnership</b>	<b>Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.</b>
<b>MHRA Drug Safety Update (Feb-26): Semaglutide (Wegovy, Ozempic &amp; Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)</b>		
<b>Sotagliflozin</b> Zynquista® 200mg tablets	<b>NICE</b> <b>MMC</b> <b>emc</b>	<b>Withdrawn</b> <b>August 2022</b>
<b>Tirzepatide</b> <b>(DNP)</b> Mounjaro® injection	<b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>Greater Manchester Integrated Care Partnership</b>	<b>Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.</b>
<b>MHRA Drug Safety Update (Feb-26): Falsified Mounjaro KwikPen 15mg pre-filled pens</b>		

## Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the  
formulary ([click here](#))



### 7.1 Drugs used in Obstetrics

- 7.1.1 Prostaglandins & oxytocics
  - 7.1.1.1 Drugs affecting the ductus arteriosus
- 7.1.2 Mifepristone
- 7.1.3 Myometrial relaxants

### 7.2 Treatment of vaginal & vulval conditions

- 7.2.1 Preparations for vaginal & vulval changes
- 7.2.2 Vaginal & vulval infections

### 7.3 Contraceptives

- 7.3.1 Combined hormonal contraceptives
  - Ethinylestradiol with Desogestrel
  - Ethinylestradiol with Gestodene
  - Ethinylestradiol with Levonorgestrel
  - Ethinylestradiol with Norelgestromin
  - Ethinylestradiol with Norethisterone
  - Ethinylestradiol with Norgestimate
  - Mestranol with Norethisterone
- 7.3.2 Progestogen-only contraceptives
  - 7.3.2.1 Oral progestogen-only contraceptives
  - 7.3.2.2 Parenteral progestogen-only contraceptives
  - 7.3.2.3 Intra-uterine progestogen-only device
- 7.3.5 Emergency contraception

### 7.4 Drugs for genito-urinary disorders

- 7.4.1 Drugs for urinary retention
- 7.4.2 Drugs for urinary, enuresis & incontinence
- 7.4.3 Drugs used in urological pain
- 7.4.4 Bladder instillations & urological surgery
- 7.4.5 Drugs for erectile dysfunction
- 7.4.6 Drugs for premature ejaculation

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Long-acting reversible contraception (CG30)  
Lower urinary tract symptoms (CG97)  
Nocturnal enuresis - the management of bedwetting in children and young people (CG111)  
Antenatal and postnatal mental health: clinical management and service guidance (CG192)  
Heavy menstrual bleeding: assessment and management (NG88)  
Urinary incontinence and pelvic organ prolapse in women: management (NG123)  
Caesarean birth (NG192)  
Antenatal care for uncomplicated pregnancies (NG201)  
Inducing labour (NG207)  
Intrapartum care for healthy women and babies (NG235)  
Overactive bladder - mirabegron (TA290)  
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)  
Vibegron for treating symptoms of overactive bladder syndrome (TA999)

## GMMMG Formulary

Formulary Homepage  
Chapter 7: Obstetrics, gynaecology & urinary tract disorders  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## 7.1 Drugs used in Obstetrics



### 7.1.1 Prostaglandins & oxytocics

**NICE NG207**
**Carbetocin**

RED

Pabal® injection

MMC BNF emc

**RESTRICTED**  
 Obs & Gynae Consultants only

**Carboprost**

RED

injection

BNF emc

**Ergometrine maleate**

injection

BNF emc

**Gemeprost**

RED

pessaries

BNF emc

**Oxytocin**

injection

BNF emc

**Dinoprostone**

injection; pessaries; vaginal gel; vaginal tablet

MMC BNF emc

**RESTRICTED**  
 Obs & Gynae Consultants only

### 7.1.1.1 Drugs affecting the ductus arteriosus

#### Maintenance of patency

**Alprostadil**

RED

Prostin VR® infusion

MMC BNF emc

#### Closure of the ductus arteriosus

**Indometacin**

RED

injection

BNF emc

### 7.1.2 Mifepristone

**Mifepristone**

RED

tablets

BNF emc

### 7.1.3 Myometrial relaxants

**Nifedipine**

RED

capsules; tablets

MMC BNF emc

**RESTRICTED (1<sup>st</sup> line)**  
 Obs & Gynae Consultants only

**Atosiban**

RED

infusion; injection

MMC BNF emc

**RESTRICTED (2<sup>nd</sup> line)**  
 Obs & Gynae Consultants only

**Indometacin**

RED

capsules; suppositories

MMC BNF emc

**RESTRICTED (3<sup>rd</sup> line)**  
 Obs & Gynae Consultants only

### Beta<sub>2</sub> agonists

**Salbutamol (injection)**

RED

 500 micrograms/1mL solution for injection ampoules;  
 5mg/5mL solution for intravenous infusion. (see also section 3.1.1.1)

MMC BNF emc

MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma

**Terbutaline sulfate (injection)**

RED

500 micrograms/mL; 2.5mg/5mL solution for injection ampoules. (see also section 3.1.1.1)

BNF emc

MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma

## 7.2 Treatment of vaginal & vulval conditions



### 7.2.1 Preparations for vaginal & vulval changes

#### Oestrogens, topical

<b>Estradiol</b> <b>GREEN</b> Vagifem® 10 microgram pessaries		
<b>Estriol</b> <b>GREEN</b> Ovestin® 0.1% cream; Gynest® 0.01% cream		
<b>Estriol</b> <b>GREEN</b> Imvaggis® 0.03mg pessaries		
<b>Estriol</b> <b>GREEN</b> Vagirux® 10microgram vaginal tablet		
<b>Estradiol (vaginal ring)</b> <b>GREEN</b> Estring® 7.5 microgram / 24 hours ring		<b>RESTRICTED</b> Obs & Gynae Consultants only

### 7.2.2 Vaginal & vulval infections

#### Preparations for vaginal & vulval candidiasis

<b>Clotrimazole</b> <b>GREEN</b> cream; pessaries		
<b>Miconazole</b> vaginal cream		
<b>Preparations for other vaginal infections</b>		
<b>Clindamycin</b> <b>GREEN</b> 2% vaginal cream		
<b>Dequalinium chloride</b> <b>RED</b> Fluomizin® 10mg vaginal tablets		<b>RESTRICTED</b> 2 <sup>nd</sup> line - bacterial vaginosis (BV)
<b>Metronidazole</b> <b>GREEN</b> Zidoval® 0.75% vaginal gel		<b>RESTRICTED</b> Obs & Gynae Consultants only
<b>Nystatin</b> vaginal cream; pessaries		
<b>Boric acid</b> Ⓢ <b>RED</b> vaginal pessary		<b>RESTRICTED</b> specialist use only for vulvovaginal candidiasis

## 7.3 Contraceptives



MHRA Drug Safety Update (Mar-19): Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?

### 7.3.1 Combined hormonal contraceptives

NICE CG30

MHRA Drug Safety Update (Mar-14): Combined hormonal contraceptives: risk of venous thromboembolism

#### Ethinylestradiol with desogestrel

**Munalea**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

**Mercilon**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

#### Ethinylestradiol with gestodene

**Femodene**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

**Aidulan**®

20microgram / 75 microgram tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

#### Ethinylestradiol with levonorgestrel

**TriRegol**®

tablets



NICE NG88

**Microgynon 30**®

GREEN

tablets



**Ovranette**®

GREEN

tablets



#### Ethinylestradiol with norelgestromin

**Evra**®

GREEN

patch



**RESTRICTED**  
in line with GMMMG and SmPC

#### Ethinylestradiol with norethisterone

**Loestrin 20**®

tablets



**Loestrin 30**®

tablets



**Norimin**®

tablets



#### Ethinylestradiol with norgestimate

**Cilest**®

tablets



#### Mestranol with norethisterone

**Norinyl-1**®

tablets



**2<sup>nd</sup> line**  
due to increased risk of VTE

### 7.3.2 Progestogen-only contraceptives

#### 7.3.2.1 Oral progestogen-only contraceptives

**Norethisterone**

GREEN

Noriday® 350 microgram tablets



**1<sup>st</sup> line**

**Levonorgestrel**

GREEN

Norgeston® 35 microgram tablets



**2<sup>nd</sup> line**

**Desogestrel**

GREEN

Cerazette® 75 microgram tablets



**3<sup>rd</sup> line**

**Drospirenone**

GREEN

Slynd® 4mg tablets



**4<sup>th</sup> line**

**7.3.2.2 Parenteral progestogen-only contraceptives****Injectable preparations****Medroxyprogesterone acetate**

GREEN

Depo-Provera® 150mg/mL intramuscular injection

**Medroxyprogesterone acetate**

GREEN

Sayana Press® 160mg/mL subcutaneous injection

**Implants****Etonogestrel**

Nexplanon® 68mg subdermal implant

**2<sup>nd</sup> line as per MMC**

MHRA Drug Safety Update (Feb-20): Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury &amp; implant migration

MHRA Drug Safety Update (Jun-16): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung

**7.3.2.3 Intra-uterine progestogen-only device****Levonorgestrel**

GREEN

Mirena®; Benilexa One-Handed® Uevosert® U0micrograms/24 hours IUD



MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name

**Levonorgestrel**

Jaydess® 13.5mg IUD

**RESTRICTED**  
Specialist use Tertiary Services only

MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name

**Levonorgestrel**

GREEN

Kyleena® 19.5mg IUD

**RESTRICTED**  
Specialist use Tertiary Services only

MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name

**7.3.5 Emergency contraception****Levonorgestrel**

GREEN

Levonelle® 1500 microgram tablets



MHRA Drug Safety Update (Sep-16): Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers...

MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women

**Ulipristal acetate**

GREEN

ellaOne® 30mg tablets

**RESTRICTED**  
emergency contraception (SARC)

MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women























**Assisted Reproductive Technology (ART) cycles****Progesterone**

Utrogestan® 100mg; 200mg vaginal capsules

**RESTRICTED**  
ART cycles  
**2<sup>nd</sup> line**

7.4 Drugs for genito-urinary disorders		GMMG
7.4.1 Drugs for urinary retention		NICE CG97
Alpha blockers		NICE CG111
		NICE NG123
<b>Alfuzosin hydrochloride</b> GREEN tablets	BNF emc	
<b>Tamsulosin hydrochloride</b> GREEN capsules, tablets	MMC BNF emc	1 <sup>st</sup> line
7.4.2 Drugs for urinary, enuresis & incontinence		
Urinary incontinence		NICE NG123
<b>Oxybutynin hydrochloride</b> GREEN oral solution; patch; tablets	NICE MMC BNF emc	1 <sup>st</sup> line in OAB
<b>Darifenacin hydrobromide</b> GREEN tablets	NICE MMC BNF emc	1 <sup>st</sup> line in OAB
<b>Tolterodine tartrate</b> GREEN capsules, tablets	NICE MMC BNF emc	1 <sup>st</sup> line in OAB
<b>Solifenacin succinate</b> tablets	MMC BNF emc	2 <sup>nd</sup> line in OAB
<b>Duloxetine</b> GREY GREEN capsules	MMC BNF emc	
<b>Tropium chloride</b> GREEN capsules; tablets	MMC BNF emc	RESTRICTED 1 <sup>RY</sup> Care referral only
<b>Mirabegron</b> GREEN tablets	NICE MMC BNF emc	RESTRICTED in line with TA290 / Paeds 3 <sup>rd</sup> line
MHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga ▼): risk of severe hypertension and associated cerebrovascular and cardiac events		
<b>Vibegron</b> Obgemsa® 75 mg tablets	NICE MMC BNF emc	RESTRICTED in line with TA999
Nocturnal enuresis		
<b>Amitriptyline hydrochloride</b> GREEN oral solution; tablets (see also section 4.3.1)	BNF emc	
<b>Desmopressin</b> SI injection; nasal spray; tablets (see also section 6.5.2)	MMC BNF emc	RESTRICTED Haematology Consultants only
7.4.3 Drugs used in urological pain		
<b>Methionine</b> Ⓢ tablets	emc	RESTRICTED resistant calcium phosphate lithiasis eau European Association of Urology
<b>Pentosan polysulfate sodium</b> RED capsules	NICE MMC BNF emc	RESTRICTED Urology Cons. in line with NICE
MHRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy		
<b>Potassium citrate</b> GREEN OTC tablets (DNP) mild cystitis (2-3 days)	BNF emc	
<b>Potassium citrate</b> Ⓢ RED Urociit®-K extended release tablets	MMC emc	

**7.4.4 Bladder instillations & urological surgery**

<b>Chlorhexidine</b> <b>RED</b>	 	
0.02% irrigation solution		
<b>Dimethyl sulfoxide</b>  <b>RED</b>		
50% solution		
<b>Glycine</b> <b>RED</b>	 	
1.5% irrigation solution		
<b>Sodium chloride</b> <b>RED</b>	 	
0.9% irrigation solution		
<b>Sodium citrate</b> <b>RED</b>	 	
3% irrigation solution		
<b>Sodium hyaluronate</b> <b>RED</b>	<b>MMC</b> 	<b>RESTRICTED</b> Urology Consultants only
Cystistat® 40mg/50mL bladder instillation		
<b>Sodium hyaluronate with sodium chondroitin sulfate</b> <b>RED</b>	<b>MMC</b> 	<b>RESTRICTED</b> Urology Consultants only
iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation		
<b>7.4.5 Drugs for erectile dysfunction</b>		
<b>Alprostadil</b> <b>GREEN</b>	<b>MMC</b>  	<b>RESTRICTED</b> Urology Consultants only
cream; injection; urethral sticks		
<b>Aviptadil with phentolamine mesilate</b> <b>SI</b>	<b>MMC</b>  	<b>RESTRICTED</b> Urology Consultants only
Invicorp® injection		
<b>Sildenafil</b> <b>GREEN</b> or <b>RED</b> PAH	<b>MMC</b>  	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
injection; oral suspension; tablets (see also section 2.5.1)		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
<b>Tadalafil</b> <b>GREEN</b> or <b>RED</b> PAH	<b>MMC</b>  	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
tablets (see also section 2.5.1)		
<b>Vardenafil</b>	<b>MMC</b>  	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
tablets		
<b>7.4.6 Drugs for premature ejaculation</b> <span style="border: 1px solid black; padding: 2px;">(DNP)</span>		
<b>NOT STOCKED</b>		

Non-Formulary Items		GMMMG
<b>Dapoxetine hydrochloride</b> (DNP) <i>Priligy® 30mg; 60mg tablets</i>	BNF emc	in line with GMMMG Criterion 1
<b>Doxazosin</b> (DNP) <i>4mg M/R tablets; 8mg tablets</i>	BNF emc	in line with GMMMG Criterion 2
<b>Licensed and off-label topical anaesthetics</b> (DNP)		in line with GMMMG Criterion 1
<b>Mild cystitis (2-3 days)</b> (DNP) <i>e.g. Potassium citrate mixture or sachets, cranberry products</i>		in line with GMMMG / NHSE
<b>Tadalafil</b> (DNP) <i>2.5mg tablets</i>	BNF emc	in line with GMMMG Criterion 2
<b>Tamsulosin with dutasteride</b> (DNP) <i>400microgram / 500microgram hard capsules</i>	BNF emc	in line with GMMMG Criterion 1

## Section 8: Malignant disease & immunosuppression

Supported by the  
formulary ([click here](#))



### 8.1 Cytotoxic drugs

Drugs for cytotoxic-induced side-effects

8.1.1 Alkylating drugs

8.1.2 Anthracyclines & other cytotoxic antibiotics

8.1.3 Antimetabolites

8.1.4 Vinca alkaloids & etoposide

8.1.5 Other antineoplastic drugs

### 8.2 Drugs affecting the immune response

8.2.1 Antiproliferative immunosuppressants

8.2.2 Corticosteroids & other immunosuppressants

8.2.3 Anti-lymphocyte monoclonal antibodies

8.2.4 Other immunomodulating drugs

### 8.3 Sex hormones & hormone antagonists in malignant disease

8.3.1 Oestrogens

8.3.2 Progestogens

8.3.3 Androgens

8.3.4 Hormone Antagonists

8.3.4.1 Breast Cancer

8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists

8.3.4.3 Somatostatin analogues

### 8.4 Miscellaneous preparations

#### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

## NICE Guidance

Advanced breast cancer (CG81)  
 Familial breast cancer (CG164)  
 Hepatitis B (chronic) (CG165)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)  
 Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)  
 Early and locally advanced breast cancer: diagnosis and management (NG101)  
 Lung cancer: diagnosis and management (NG122)  
 Prostate cancer: diagnosis and management (NG131)  
 Colorectal cancer (NG151)  
 Temozolomide for malignant glioma (TA23)  
 Leukaemia (lymphocytic) - fludarabine (TA29)  
 Trastuzumab for advanced breast cancer (TA34)  
 Paclitaxel for ovarian cancer (TA55)  
 Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)  
 Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)  
 Docetaxel for prostate cancer (hormone-refractory) (TA101)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Paclitaxel for early breast cancer (TA108)  
 Docetaxel for early breast cancer (TA109)  
 Gemcitabine for Breast Cancer (TA116)  
 Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)  
 Leukaemia (lymphocytic) - fludarabine (TA119)  
 Carmustine implants and temozolomide for glioma (newly diagnosed & high grade) (TA121)  
 Pemetrexed for lung cancer (non small cell) (TA124)  
 Multiple sclerosis - natalizumab (TA127)  
 Bortezomib for relapsed multiple myeloma (TA129)  
 Pemetrexed for mesothelioma (TA135)  
 Rituximab for follicular non-Hodgkin's lymphoma (TA137)  
 Head and neck cancer - cetuximab (TA145)  
 Renal cell carcinoma - sunitinib (TA169)  
 Lenalidomide - multiple myeloma (TA171)  
 Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)  
 Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)  
 Renal Cell Carcinoma (TA178)  
 Sunitinib for gastrointestinal stromal tumours (TA179)  
 Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)  
 Cervical cancer (recurrent) - topotecan (TA183)  
 Lung cancer (small cell) - topotecan (TA184)  
 Soft tissue sarcoma - trabectedin (TA185)  
 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)  
 Gastric cancer (advanced) - capecitabine (TA191)  
 Lung cancer (non-small-cell, first line) - gefitinib (TA192)  
 Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)  
 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)  
 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)  
 Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)  
 Renal cell carcinoma (1<sup>st</sup> line metastatic) - pazopanib (TA215)  
 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)  
 Myelodysplastic syndrome - azacitidine (TA218)  
 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)  
 Multiple myeloma (1<sup>st</sup> line) - bortezomib and thalidomide (TA228)  
 Osteosarcoma - mifamurtide (TA235)  
 Follicular lymphoma - rituximab (review TA110) (TA243)  
 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)  
 Bevacizumab in combination with paclitaxel & carboplatin for 1<sup>st</sup> line treatment of advanced ovarian cancer (TA284)  
 Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Multiple sclerosis (relapsing) - teriflunomide (TA303)  
 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Multiple myeloma - bortezomib (induction therapy) (TA311)

Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)  
 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)  
 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)  
 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)  
 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)  
 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)  
 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)  
 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)  
 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)  
 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)  
 Idelalisib for treating chronic lymphocytic leukaemia (TA359)  
 Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)  
 Bortezomib for previously untreated mantle cell lymphoma (TA370)  
 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)  
 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)  
 Nintedanib for treating idiopathic pulmonary fibrosis (TA379)  
 Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)  
 Olaparib for ovarian, fallopian tube and peritoneal cancer (TA381)  
 Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)  
 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)  
 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)  
 Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)  
 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)  
 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)  
 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)  
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)  
 Bosutinib for previously treated chronic myeloid leukaemia (TA401)  
 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)  
 Degarelix for treating advanced hormone-dependent prostate cancer (TA404)  
 Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)  
 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)  
 Pegaspargase for treating acute lymphoblastic leukaemia (TA408)  
 Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)  
 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)  
 Nivolumab for previously treated advanced renal cell carcinoma (TA417)  
 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)  
 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)  
 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)  
 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)  
 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)  
 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)  
 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)  
 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)  
 Everolimus for advanced renal cell carcinoma after previous treatment (TA432)  
 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)  
 Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)  
 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)  
 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)  
 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)  
 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)  
 Cabozantinib for previously treated advanced renal cell carcinoma (TA463)  
 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)  
 Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)  
 Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)  
 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)  
 Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)  
 Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)  
 Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)  
 Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)  
 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)  
 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)  
 Ibrutinib for treating Waldenström's macroglobulinaemia (TA491)  
 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)  
 Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)  
 Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)  
 Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)  
 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)  
 Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)  
 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)  
 Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)  
 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)  
 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)  
 Tivozanib for treating advanced renal cell carcinoma (TA512)  
 Obinutuzumab for untreated advanced follicular lymphoma (TA513)  
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)  
 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)  
 Cabozantinib for treating medullary thyroid cancer (TA516)  
 Avelumab for treating metastatic Merkel cell carcinoma (TA517)  
 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)  
 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)  
 Midostaurin for untreated acute myeloid leukaemia (TA523)  
 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)  
 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)  
 Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)  
 Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)  
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)  
 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)  
 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)  
 Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)  
 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)  
 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)  
 Dinutuximab beta for treating neuroblastoma (TA538)  
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)  
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)  
 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)  
 Cabozantinib for untreated advanced renal cell carcinoma (TA542)  
 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)  
 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)  
 Padeliporfin for untreated localised prostate cancer (TA546)  
 Vandetanib for treating medullary thyroid cancer (TA550)  
 Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)  
 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)  
 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)  
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)  
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)  
 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)  
 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)  
 Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)  
 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)  
 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)  
 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)  
 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)  
 Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)  
 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)  
 Ocrelizumab for treating primary progressive multiple sclerosis (TA585)  
 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)  
 Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)  
 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)  
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)  
 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)  
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)  
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)  
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)  
 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)  
 Cladribine for treating relapsing–remitting multiple sclerosis (TA616)  
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)  
 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)  
 Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)  
 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)  
 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)  
 Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)  
 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)  
 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)  
 Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)  
 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)  
 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)  
 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)  
 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)  
 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)  
 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)  
 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)  
 Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)  
 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)  
 Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)  
 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)  
 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)  
 Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)  
 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)  
 Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)  
 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)  
 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)  
 Pembrolizumab with pemetrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)  
 Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)  
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)  
 Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)  
 Avelumab for untreated metastatic Merkel cell carcinoma (TA691)  
 Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)  
 Ofatumumab for treating relapsing multiple sclerosis (TA699)  
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)  
 Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)  
 Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)  
 Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)  
 Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)  
 Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)  
 Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)  
 Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)  
 Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)  
 Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)  
 Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)  
 Midostaurin for treating advanced systemic mastocytosis (TA728)  
 Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)  
 Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)  
 Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)  
 Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)  
 Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)  
 Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)  
 Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)  
 Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)  
 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)  
 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)  
 Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)  
 Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)  
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)  
 Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)  
 Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)  
 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)  
 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)  
 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)  
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)  
 Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer.... (TA786)  
 Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)  
 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)  
 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)  
 Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)  
 Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)  
 Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)  
 Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)  
 Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)  
 Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802)  
 Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)  
 Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)  
 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)  
 Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)  
 Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)  
 Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)  
 Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)  
 Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)  
 Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)  
 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)  
 Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)  
 Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)  
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)  
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)  
 Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)  
 Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)  
 Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)  
 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)  
 Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)  
 Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)  
 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)  
 Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)  
 Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)  
 Regorafenib for previously treated metastatic colorectal cancer (TA866)  
 Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)  
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)  
 Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)  
 Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)  
 Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)  
 Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)  
 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)  
 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)  
 Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia... (TA893)  
 Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)  
 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)  
 Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)  
 Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)  
 Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)  
 Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)  
 Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)  
 Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)  
 Ruxolitinib for treating polycythaemia vera (TA921)  
 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)  
 Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)  
 Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)  
 Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)  
 Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)  
 Loncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)  
 Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)  
 Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)  
 Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)  
 Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)  
 Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)  
 Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)  
 Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)  
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA962)  
 Dostarlimab with platinum-based chemo for advanced / recurrent endometrial cancer with MSI-H or MMR deficiency (TA963)  
 Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)  
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)  
 Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)  
 Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)  
 Tisagenlecleucel for treating relapsed or refractory B-cell ALL in people 25 years and under (updates & replaces TA554) (TA975)  
 Dabrafenib for treating BRAF V600E mutation-positive glioma in children & young people aged 1 year & over (TA977)  
 Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)  
 Pembrolizumab for untreated locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma (TA983)  
 Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)  
 Relugolix for treating hormone-sensitive prostate cancer (TA995)  
 Pembrolizumab with platinum- and fluoropyrimidine-based chemo for untreated advanced HER2-negative gastric or GOJA (TA997)  
 Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)  
 Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)  
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)  
 Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)  
 Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)  
 Avapritinib for treating advanced systemic mastocytosis (TA1012)  
 Quizartinib for treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)  
 Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)  
 Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)  
 Pembrolizumab before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable NSCLC (TA1017)  
 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (updates & replaces TA756) (TA1018)  
 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (updates & replaces TA529) (TA1021)  
 Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)  
 Ublituximab for treating relapsing multiple sclerosis (TA1025)  
 Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for resectable NSCLC (TA1030)  
 Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy (TA1034)  
 Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer (TA1036)  
 Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)  
 Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug... (TA1038)  
 Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug... (TA1039)  
 Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (TA1040)  
 Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)  
 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)  
 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)  
 Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)  
 Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma (TA1048)  
 Blinatumomab for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-cell ALL (TA1049)  
 Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)  
 Ruxolitinib for treating acute GvHD that responds inadequately to corticosteroids in people 12 years and over (TA1054)  
 Rucaparib for treatment of advanced ovarian, fallopian tube & peritoneal cancer... (TA1055)  
 Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)  
 Osimertinib for untreated EGFR mutation-positive advanced NSCLC (TA1060)  
 Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)  
 Capivasertib for treating hormone receptor-positive HER2-negative advanced breast cancer (TA1063)  
 Dostarlimab for treating primary advanced or recurrent endometrial cancer with MSI-H or dMMR (TA1064)  
 Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with MSI-H or dMMR (TA1065)  
 Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (updates & replaces TA823) (TA1071)  
 Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)  
 Fruquintinib for previously treated metastatic colorectal cancer (TA1079)  
 Zanubrutinib for treating relapsed or refractory mantle cell lymphoma (TA1081)  
 Ribociclib for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer (TA1086)  
 Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer (terminated) (TA1089)  
 Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)  
 Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)  
 Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (TA1092)  
 Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer... (TA1097)

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)  
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (TA1099)  
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)  
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1108)  
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA1109)  
Abiraterone (originator & generics) for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer (TA1110)  
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)  
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1114)  
Obecabtagene autoleucl for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (TA1116)  
Dostarlimab for treating primary advanced or recurrent endometrial cancer with MSS or MMRp (TA1117)  
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (updates & replaces TA663) (TA1119)  
Avelumab with axitinib for untreated advanced renal cell carcinoma (updates & replaces TA645) (TA1120)  
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)  
Natalizumab (originator & biosimilar) for treating highly active relapsing–remitting MS after disease-modifying therapy (TA1126)  
Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable NSCLC (TA1127)  
Niraparib for treatment of advanced ovarian, fallopian tube & peritoneal cancer... (updates & replaces TA673) (TA1129)  
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)  
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)  
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma (TA1133)  
Bevacizumab with fluoropyrimidine-based chemo for metastatic colorectal cancer (replaces TA212) (TA1136)  
Durvalumab with gemcitabine & cisplatin for treatment of muscle-invasive bladder cancer (TA1138)  
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (TA1139)

## GMMMG Formulary

Formulary Homepage

Chapter 8: Malignant disease & immunosuppression

GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List












































































































GMMMG Paediatric **Red/Amber/Green**; DNP and Grey Drug List




















































































































## 8.1 Cytotoxic drugs





























































































































































































































































































## 8.1 Drugs for cytotoxic-induced side-effects






<b>Dexrazoxane</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only 
<b>Disodium folinate</b>  Sodiofolin® injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Folinic acid (as calcium folinate)</b>  tablets; injection (see also section 18.1.2) 	<b>RESTRICTED</b> Haematology Consultants only
<b>Mesna</b>  tablets; injection (see also section 18.1.2) 	<b>RESTRICTED</b> Haematology Consultants only
<b>Palifermin</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Sodium thiosulfate (anhydrous)</b>  Pedmarqsi® 80 mg/mL solution for infusion 	<b>RESTRICTED</b> Haematology Consultants only
<b>8.1.1 Alkylating drugs</b>	
<b>Busulfan</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only
<b>Bendamustine</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only MHRA Drug Safety Update (Mar-21): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) MHRA Drug Safety Update (Jul-17): Bendamustine: increased mortality in recent clinical studies in off-label use; monitor for opportunistic infections, HBV reactivation
<b>Carmustine</b>  infusion 	<b>RESTRICTED</b> Haematology Consultants only
<b>Chlorambucil</b>  tablets 	<b>RESTRICTED</b> Haematology Consultants only
<b>Cyclophosphamide</b>  injection; tablets; oral suspension 	<b>RESTRICTED</b> Haematology Consultants only
<b>Ifosfamide</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Lomustine</b>  capsules 	<b>RESTRICTED</b> Haematology Consultants only
<b>Melphalan</b>  injection; tablets 	<b>RESTRICTED</b> Haematology Consultants only
<b>Treosulfan</b>  injection 	<b>RESTRICTED Adult Haematology / Paediatric Haematology / Oncology</b>
<b>8.1.2 Anthracyclines &amp; other cytotoxic antibiotics</b>	
<b>Bleomycin</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Daunorubicin</b>  injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Doxorubicin hydrochloride</b>  infusion; injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Idarubicin hydrochloride</b>  capsules; injection 	<b>RESTRICTED</b> Haematology Consultants only
<b>Mitomycin</b>  injection 	<b>RESTRICTED</b> Consultants only

<b>Mitoxantrone</b>  infusion  	<b>RESTRICTED</b> Haematology Consultants only
<b>Pixantrone</b>   infusion     	<b>RESTRICTED</b> Haematology Consultants only
<b>8.1.3 Antimetabolites</b>	
<b>Azacitidine</b>   injection     	<b>RESTRICTED</b> Haematology Consultants only
<b>Capecitabine</b>  tablets    	
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity MHRA Drug Safety Update (Dec-14): Capecitabine: risk of severe skin reactions - discontinue treatment	
<b>Cladribine</b>   infusion; injection      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Mar-22): Cladribine (Mavenclad): new advice to minimise risk of serious liver injury MHRA Drug Safety Update (Dec-17): Cladribine (Litak, Leustat) for leukaemia: reports of PML; stop treatment if PML is suspected	
<b>Clofarabine</b>   infusion    	<b>RESTRICTED</b> Haematology Consultants only
<b>Cytarabine</b>  injection   	<b>RESTRICTED</b> Haematology Consultants only
<b>Daunorubicin with cytarabine</b>   Vyxeos® 100mg/44mg infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Fludarabine phosphate</b>  injection; tablets   	<b>RESTRICTED</b> Haematology Consultants only
<b>Fluorouracil</b>  injection    	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity	
<b>Gemcitabine</b>  infusion    	<b>RESTRICTED</b> Haematology Consultants only 
<b>Mercaptopurine</b>  oral suspension; tablets (see also section 1.5.3)    	
MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy	
<b>Methotrexate</b>  infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3)   	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions	
<b>Pemetrexed</b>   injection      	<b>RESTRICTED</b> Respiratory Consultants only in line with TA402
<b>8.1.4 Vinca alkaloids &amp; etoposide</b>	
<b>Etoposide</b>  capsules; infusion  	<b>RESTRICTED</b> Haematology Consultants only
<b>Vinblastine sulfate</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Vincristine sulfate</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>8.1.5 Other antineoplastic drugs</b>	
<b>Acalabrutinib</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Arsenic trioxide</b>   infusion      	<b>RESTRICTED</b> Haem. Consultants only / in line with NICE TA526 / NHSE
















<b>Asciminib</b>   <i>Scemblix</i> ® 20mg/40mg tablets      	<b>RESTRICTED</b> Haem. Consultants in line with NICE TA813
<b>Asparaginase</b>  infusion   	<b>RESTRICTED</b> Haematology Consultants only
<b>Axicabtagene ciloleucel</b>   <i>Yescarta</i> ® infusion      	<b>RESTRICTED</b> in line with NICE TA872
<b>Bevacizumab</b>   <i>Avastin</i> ® 100mg in 4mL vial      	<b>RESTRICTED</b> Haematology Consultants only
<b>Bortezomib</b>   injection      	<b>RESTRICTED</b> Haematology Consultants only
<b>Brentuximab vedotin</b>   <i>Adcetris</i> infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Brexucabtagene autoleucel</b>   <i>Tecartus</i> ® infusion      	<b>RESTRICTED</b> Haem. Consultants only in line with NICE / CDF
<b>Cabozantinib</b>   tablets; capsules      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Carfilzomib</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ceritinib</b>   capsules      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Cetuximab</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Crisantaspace</b>   injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Dacarbazine</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Durvalumab</b>   infusion      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE
<b>Entrectinib</b>   injection      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE
<b>Eribulin</b>   injection      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>

<b>Erlotinib</b>   tablets     	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Everolimus</b>   tablets       	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Hydroxycarbamide</b>  capsules; tablets (see GMMM below)  	<b>RESTRICTED</b> Haematology Consultants only
<b>Hydroxycarbamide</b>  <i>Xromi</i> ® oral liquid   	<b>RESTRICTED</b> Paediatric patients with swallowing difficulties
<b>Ipilimumab</b>   infusion       	<b>RESTRICTED</b> Dermatology Consultants only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation	
<b>Ivosidenib</b>   <i>Tibsovo</i> ® 250mg tablets       	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ixazomib</b>   capsules       	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Lorlatinib</b>   <i>Lorviqua</i> ® tablets       	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE
<b>Lisocabtagene maraleucel</b>   <i>Breyanzi</i> ® infusion       	<b>RESTRICTED</b> Haem. Consultants only in line with NICE / CDF
<b>Midostaurin</b>   <i>Rydapt</i> ® capsules       	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Nintedanib esilate</b>   <i>Ofev</i> ® capsules       	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE
<b>Nintedanib esilate</b>   <i>Vargatef</i> ® capsules       	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Niraparib</b>   <i>Zejula</i> ® capsules       	<b>RESTRICTED</b> Gynaecology Consultants only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Oct-20): Niraparib (Zejula ▼): reports of severe hypertension & PRES, particularly in early treatment	
<b>Obecabtagene autoleucel</b>   <i>Aucatzyl</i> ® infusion       	<b>RESTRICTED</b> Haem. Consultants only in line with NICE
<b>Panitumumab</b>   infusion       	<b>RESTRICTED</b> Haematology Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Panobinostat</b>   capsules     	<b>RESTRICTED</b> Haematology Consultants only in line with TA380
<b>Pegaspargase</b>   <i>Oncaspar</i> ® injection       	<b>RESTRICTED</b> Haematology Consultants only
<b>Pembrolizumab</b>   infusion       	<b>RESTRICTED</b> Specialist use only in line with NICE / NHSE
MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection	
<b>Pentostatin</b>   infusion  	<b>RESTRICTED</b> Haematology Consultants only
<b>Pertuzumab</b>   infusion       	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Procarbazine</b>   capsules  	<b>RESTRICTED</b> Haematology Consultants only

<b>Sacituzumab govitecan</b>   <i>Trodelvy</i> ® infusion      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Selinexor</b>   <i>Nexpvio</i> ® tablets      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE
<b>Sorafenib</b>   tablets      	<b>RESTRICTED</b> Haematology Consultants only in line NICE / NHSE
<b>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</b>	
<b>Sotorasib</b>   <i>Lumykras</i> ® tablets      	<b>RESTRICTED</b> PulmonaryOnc Consultants only in line with NICE TA781
<b>Talimogene laherparepvec</b>   injection      	<b>RESTRICTED</b> Dermatology Consultants only in line with TA410
<b>Tisagenlecleucel</b>   <i>Kymriah</i> ® infusion      	<b>RESTRICTED</b> in line with CDF criteria and NICE TA975
<b>Trastuzumab</b>   infusion; injection      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Venetoclax</b>   <i>Venclyxto</i> ® tablets       	<b>RESTRICTED</b> Specialist use only in line with NICE / NHSE
<b>MHRA Drug Safety Update (Dec-21): Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)</b>	
Hydroxycarbamide - Essential thrombocythaemia or polycythaemia with high risk of complications	
Hydroxycarbamide - Sickle Cell Disease	
<b>Other agents</b>	
<b>Isotretinoin</b>   capsules; liquid (20mg/mL unlicensed preparation) (see also section 13.6.2)   	<b>RESTRICTED</b> Specialist use only for management of neuroblastoma
<b>Platinum compounds</b>	
<b>Cisplatin</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Protein kinase inhibitors</b>	
<b>Abemaciclib</b>   <i>Verzenio</i> ® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of ILD &amp; pneumonitis, including severe cases</b>	
<b>Alectinib</b>   <i>Alecensa</i> ® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE TA536 / TA1014
<b>Alpelisib</b>   <i>Piqray</i> ® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA816 <b>NOT STOCKED</b>
<b>Amivantamab</b>   <i>Rybrevant</i> ® injection      	<b>RESTRICTED</b> Specialist use only in line with NICE TA1122
<b>Avapritinib</b>   <i>Ayvakyt</i> ® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA1012
<b>Axitinib</b>   <i>Inlyta</i> ® tablets      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Bosutinib</b>   <i>Bosulif</i> ® tablets      	<b>RESTRICTED</b> Haematology Consultants only in line with TA401
<b>MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation</b>	
<b>Brigatinib</b>   <i>Alunbrig</i> ® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Crizotinib</b>   <i>Xalkori</i> ® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE

<b>Dabrafenib</b>   Tafinlar® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Dabrafenib</b>   Finlee® dispersible tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Dacomitinib</b>   Vizimpro® tablets     	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Dasatinib</b>   Sprycel® tablets; powder for oral suspension      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
<b>Encorafenib</b>   Brafitovi® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Fedratinib</b>   Inrebic® capsules      	<b>RESTRICTED</b> Haematology Consultants only
<b>Gefitinib</b>   tablets     	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Gemtuzumab ozogamicin</b>   Mylotarg® injection      	<b>RESTRICTED</b> Haematology Consultants only
<b>Gilteritinib fumarate</b>   Xospata® tablets      	<b>RESTRICTED</b> Haematology Consultants only
<b>Ibrutinib</b>   Imbruvica® capsules; tablets      	<b>RESTRICTED</b> Haem. Consultants only / also in line with NICE
MHRA Drug Safety Update (Nov-22): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations MHRA Drug Safety Update (Aug-17): Ibrutinib (Imbruvica ▼): reports of ventricular tachyarrhythmia; risk of HBV B reactivation & opportunistic infections	
<b>Idelalisib</b>   Zydelig® tablets     	<b>RESTRICTED</b> Specialist use only in line with NICE TA359
MHRA Drug Safety Update (Sep-16): Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection	
<b>Imatinib</b>   tablets      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
<b>Inotuzumab ozogamicin</b>   Besponsa® 1mg solution for infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Larotrectinib sulfate</b>   Vitrakvi® 20mg/mL oral solution      	<b>RESTRICTED</b> Consultants only in line with NICE
<b>Lazertinib</b>   Lazcluze® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA1133
<b>Leniolisib</b>   Joenja® 70mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE HST33 <b>NOT STOCKED</b>
<b>Lenvatinib</b>   Kisplyx® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE TA498 / 858 <b>NOT STOCKED</b>
<b>Lenvatinib</b>   Lenvima® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE TA535 / 551 <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Loncastuximab tesirine</b>   Zynlonta® infusion      	<b>RESTRICTED</b> Specialist use only in line with NICE TA947
<b>Mobocertinib</b>   Exkivity® capsules      	<b>RESTRICTED</b> Specialist use only

<b>Momelotinib</b>   Omjara® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA957
<b>Neratinib</b>   Nerlynx® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA612 <b>NOT STOCKED</b>
<b>Nilotinib</b>   Tasisna® capsules      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
<b>Osimertinib</b>   Tagrisso® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Palbociclib</b>   Ibrance® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
<b>Ponatinib</b>   Iclusig® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA451
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events	
<b>Quizartinib dihydrochloride</b>   Vanflyta® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA1013
<b>Regorafenib</b>   Stivarga® 40mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA488 / TA555 <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Ribociclib</b>   Kisqali® 200mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
<b>Ruxolitinib</b>   Jakavi® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE / NHSE
<b>Selpercatinib</b>   Retsevmo® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Selumetinib</b>   Koselugo® capsules      	<b>RESTRICTED</b> Specialist use only for NF1 in line with NICE HST20
<b>Sunitinib</b>   Sutent® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Tepotinib</b>   Tepmetko® 225mg tablets      	<b>RESTRICTED</b> Specialist use in line with NICE / NHSE
<b>Tivozanib</b>   Fotivda® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Trametinib</b>   Mekinist® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA396 <b>NOT STOCKED</b>
<b>Zanubrutinib</b>   Brukinsa® 80mg hard capsules      	<b>RESTRICTED</b> Specialist use in line with NICE / NHSE TA833 / TA931 / TA1001 / TA1081

<b>Topoisomerase I inhibitors</b>	
<p><b>Tretinoin</b></p> <p><b>RED</b></p> <p>capsules</p> <p> </p>	<p><b>RESTRICTED</b></p> <p>Haematology Consultants only</p>
<b>Taxanes</b>	
<p><b>Paclitaxel</b></p> <p><b>RED</b></p> <p>Infusion</p> <p>     </p>	<p><b>RESTRICTED</b></p> <p>Haematology Consultants only</p>
<p>MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error</p>	
<p><b>Cabazitaxel</b></p> <p><b>RED</b> </p> <p>Jevtana® Infusion</p> <p>     </p>	<p><b>RESTRICTED</b></p> <p>Haematology Consultants only</p>

## 8.2 Drugs affecting the immune response



### 8.2.1 Antiproliferative immunosuppressants

#### Azathioprine

AMBER

tablets; oral solution; injection (see also sections 1.5.3; 10.1.3 & 13.5.3)



MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy

#### Mycophenolate mofetil

AMBER

capsules; tablets; oral suspension; infusion



MHRA Drug Safety Update (Feb-18): Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients

MHRA Drug Safety Update (Dec-15): Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men

MHRA Drug Safety Update (Jan-15): Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

#### Belatacept

RED ££

Nulojix® 25mg/mL injection



**RESTRICTED**  
Renal Transplant Consultants only  
**NOT STOCKED**

### 8.2.2 Corticosteroids & other immunosuppressants

#### Antithymocyte immunoglobulin (Rabbit)

RED ££

injection



#### Basiliximab

RED ££

Simulect® injection



**RESTRICTED**  
Renal Consultants only

#### Ciclosporin (Deximune®) & I.V. (Sandimmun®)

AMBER

capsules; oral solution; injection (see also sections 10.1.3 and 13.5.3)



#### Sirolimus

AMBER

oral solution; tablets (see also section 13.5.3)



**RESTRICTED**

#### Tacrolimus

AMBER

capsules; tablets; ointment; oral suspension; infusion; sachets (see also section 13.5.3)



#### Voclosporin

RED ££

capsules



**RESTRICTED**  
Specialist use only in line with NICE

Immunosuppressants - e.g. ciclosporin, tacrolimus, sirolimus **AMBER** OR **RED** if no SCP

### 8.2.3 Anti-lymphocyte monoclonal antibodies

#### Alemtuzumab

RED ££

Lemtrada® infusion



**RESTRICTED** Renal Consultants only  
under Patient Access Scheme

MHRA Drug Safety Update (Feb-20): Alemtuzumab: updated restrictions & monitoring requirements following review of serious CV & immune-mediated reactions

MHRA Drug Safety Update (May-19): Alemtuzumab and serious CV & immune-mediated adverse reactions: new restrictions to use & strengthened monitoring requirements

#### Atezolizumab

RED ££

Tecentriq® infusion; solution for injection



**RESTRICTED** Specialist Consultants  
in line with NICE / NHSE

MHRA Drug Safety Update (Jun-21): Atezolizumab (Tecentriq ▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)

#### Avacopan

RED ££

Tavneos® capsules



**RESTRICTED** Specialist Consultants  
in line with NICE

#### Avelumab

RED ££

Bavencio® infusion



**RESTRICTED** Specialist Consultants  
in line with NICE

#### Belantamab mafodotin

RED ££

Blenrep® infusion



**RESTRICTED** Haematology  
Consultants only in line with  
NICE / NHSE

#### Blinatumomab

RED ££

Blinicyto® infusion



**RESTRICTED** Haematology  
Consultants only in line with NICE

#### Burosumab

RED ££

Crysvita® injection



**RESTRICTED**  
X-linked hypophosphatemia

#### Daratumumab

RED ££

Darzalex® infusion



**RESTRICTED** Haematology  
Consultants only in line with  
NICE / NHSE

MHRA Drug Safety Update (Aug-19): Daratumumab (Darzalex ▼): risk of reactivation of hepatitis B virus










































































































#### Elranatamab

RED ££
















Elrexfio® injecton



**RESTRICTED** Haematology  
Consultants only in line with  
NICE

<b>Epcoritamab</b>   <i>Elrexfio</i> ® injection      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Glofitamab</b>   <i>Columvi</i> ® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Isatuximab</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Mogamulizumab</b>   <i>Poteligeo</i> ® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Obinutuzumab</b>   <i>Gazyvaro</i> ® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ofatumumab</b>   <i>Kesimpta</i> ® injection      	<b>RESTRICTED</b> Consultants only in line with NICE
<p>MHRA Drug Safety Update (Aug-14): Ofatumumab ▼: reminder of risk of serious and fatal infusion reactions  MHRA Drug Safety Update (Jan-14): Ofatumumab: screen for hepatitis B virus before treatment</p>	
<b>Pertuzumab</b>   <i>Perjeta</i> ® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Polatuzumab vedotin</b>   <i>Polivy</i> ® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Rituximab</b>   injection; infusion (see also section 10.1.3)       	<b>RESTRICTED</b> Consultants only in line with NICE / NHSE
<p>MHRA Drug Safety Update (Dec-13): Rituximab: screen for hepatitis B virus before treatment</p>	
<b>Talquetamab</b>   <i>Talvey</i> ® injection      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Teclistamab</b>   <i>Tecvayli</i> ® injection      	<b>RESTRICTED</b> Haematology Consultants only
<b>8.2.4 Other immunomodulating drugs</b>	
<b>Interferon alfa</b>	
<b>Peginterferon alfa-2a</b>   <i>Pegasys</i> ® injection    	<b>RESTRICTED</b> Gastro Consultants only
<b>Ropeginterferon alfa-2b</b>   <i>Besremi</i> ® injection   	<b>RESTRICTED</b> myeloproliferative neoplasms
<b>Interferon beta</b>	
<p>MHRA Drug Safety Update (Oct-14): Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome</p>	
<b>Interferon beta-1a</b>   injection      	<b>RESTRICTED</b> Specialist use only in line with NICE TA527 <b>NOT STOCKED</b>
<b>Interferon beta-1b</b>   injection      	<b>RESTRICTED</b> Specialist use only in line with NICE TA527 <b>NOT STOCKED</b>
<b>BCG bladder instillation</b>	
<b>Bacillus Calmette–Guérin</b>  <i>OncoTICE</i> ® bladder instillation  	<b>RESTRICTED</b> Specialist use only
<b>Bacillus Calmette–Guérin</b>  <i>BCG-medac</i> ® intravesical suspension   	<b>RESTRICTED</b> Specialist use only

Other Agents		
<b>Belumosudil</b>   Rezurock® 200mg tablets       	<b>RESTRICTED Specialist use in line with NICE</b>	
<b>Canakinumab</b>   Ilaris® 150mg/mL injection       	<b>RESTRICTED Specialist use in line with NHSE</b>	
<b>Cemiplimab</b>   Libtayo® 50mg/mL injection       	<b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>	
<b>Dimethyl fumarate</b>   Tecfidera® capsules       	<b>RESTRICTED Specialist use only in line with NICE TA320</b>	
MHRA Drug Safety Update (Jan-21): Dimethyl fumarate (Tecfidera): updated advice on the risk of PML associated with mild lymphopenia MHRA Drug Safety Update (Apr-16): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy MHRA Drug Safety Update (Mar-15): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia		
<b>Dinutuximab beta</b>   Qarziba® 4.5mg/mL injection       	<b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>	
<b>Diroximel fumarate</b>   Vumerity® 231mg capsules       	<b>RESTRICTED Specialist use in line with NICE TA794</b> <b>NOT STOCKED</b>	
<b>Fingolimod hydrochloride</b>   Gilenya® capsules       	<b>RESTRICTED Specialist use only in line with NICE TA254</b>	
MHRA Drug Safety Update (Jan-21): Fingolimod (Gilenya ▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis		
<b>Glatiramer acetate</b>   injection       	<b>RESTRICTED Specialist use only in line with NICE TA527</b> <b>NOT STOCKED</b>	
<b>Imlifidase</b>   infusion       	<b>RESTRICTED Specialist use only in line with NICE TA809</b>	
<b>Lenalidomide</b>   Revlimid® capsules       	<b>RESTRICTED Haematology Consultants only</b>	
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (Jan-13): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions		
<b>Mifamurtide</b>   Mepact® Intravenous infusion       	<b>RESTRICTED Specialist use only in line with NICE TA235</b> <b>NOT STOCKED</b>	
<b>Natalizumab</b>   Tysabri® infusion       	<b>RESTRICTED Specialist use only in line with NICE</b> <b>NOT STOCKED</b>	
MHRA Drug Safety Update (Apr-16): Natalizumab (Tysabri ▼): progressive multifocal leukoencephalopathy—updated advice to support early detection		
<b>Nivolumab</b>   Opdivo® 10mg/mL infusion; 600mg/5mL solution for injection       	<b>RESTRICTED Specialist use only in line with NICE</b>	
MHRA Drug Safety Update (Oct-19): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection		
<b>Ocrelizumab</b>   Ocrevus® 30mg/mL infusion       	<b>RESTRICTED Specialist use only in line with NICE TA533 / TA585</b>	
<b>Olaparib</b>   Lynparza® tablets       	<b>RESTRICTED Specialist use only in line with NICE</b> <b>NOT STOCKED</b>	
<b>Pomalidomide</b>   capsules       	<b>RESTRICTED Haematology only / also in line with NICE</b>	
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (May-16): Pomalidomide (Imnovid ▼): risk of hepatitis B reactivation MHRA Drug Safety Update (May-15): Pomalidomide (Imnovid ▼): risks of cardiac failure, interstitial lung disease and hepatotoxicity		
<b>Ponesimod</b>   Ponvory® tablets       	<b>RESTRICTED Specialist use only in line with NICE TA767</b> <b>NOT STOCKED</b>	
<b>Rucaparib</b>   tablets       	<b>RESTRICTED Specialist use only in line with NICE TA611</b> <b>NOT STOCKED</b>	
MHRA Drug Safety Update (Sep-22): Rucaparib (Rubraca ▼): withdrawal of third-line treatment indication		

<b>Teriflunomide</b>   tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA303 <b>NOT STOCKED</b>
<b>Thalidomide</b>   capsules     	<b>RESTRICTED</b> Haematology Consultants only
<p>MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)</p> <p>MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years</p> <p>MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies</p>	

## 8.3 Sex hormones & hormone antagonists in malignant disease



### 8.3.1 Oestrogens

#### Diethylstilbestrol

SI

tablets

BNF emc

**RESTRICTED**  
Specialist use only

### 8.3.2 Progestogens

#### Medroxyprogesterone acetate

SI

tablets

BNF emc

**RESTRICTED**  
Specialist use only

#### Megestrol acetate

SI

tablets

BNF emc

**RESTRICTED**  
Specialist use only

### 8.3.3 Androgens

#### Testolactone

tablets

BNF emc

**RESTRICTED**  
Specialist use only

### 8.3.4 Hormone Antagonists

#### 8.3.4.1 Breast Cancer

##### Aminoglutethimide

tablets

BNF emc

NICE NG101

**RESTRICTED**  
Specialist use only

##### Anastrozole

SA

tablets

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only

##### Exemestane

SA

tablets

NICE MMC BNF emc

**RESTRICTED**  
Specialist use only

##### Letrozole

SA

tablets

NICE BNF emc

**RESTRICTED**  
Specialist use only

##### Tamoxifen

SA

tablets; oral solution

NICE BNF emc

**RESTRICTED**  
Specialist use only

#### 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists

##### Gonadorelin analogues

##### Buserelin acetate

injection (see also section 6.7.2)

BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**  
Specialist use only

##### Goserelin acetate

AMBER RED

implant (also section 6.7.2)

BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**  
Specialist use only

##### Leuprorelin acetate

AMBER RED

injection (also section 6.7.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**  
Specialist use only

##### Triptorelin acetate




















































AMBER RED

injection (also section 6.7.2)

MMC BNF emc

NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

**RESTRICTED**  
Specialist use only

<b>Anti-androgens</b>		
<b>Bicalutamide</b> <span style="background-color: green; color: white; padding: 2px;">SI</span> tablets  		<b>RESTRICTED</b> Specialist use only
<b>Cyproterone acetate</b> <span style="background-color: green; color: white; padding: 2px;">SI</span> tablets (see also section 6.4.2) MHRA Drug Safety Update (Jun-20): Cyproterone acetate: new advice to minimise risk of meningioma MHRA Drug Safety Update (Apr-20): Cyproterone acetate: restrictions in use of due to risk of meningioma  		<b>RESTRICTED</b> Specialist use only
<b>Darolutamide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> 300mg tablets      		<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Flutamide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> tablets  		<b>RESTRICTED</b> Specialist use only
<b>Enzalutamide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> tablets      		<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
<b>Abiraterone acetate</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Zytiga® tablets      		<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
<b>Gonadotrophin-releasing hormone antagonists</b>		
<b>Degarelix</b> <span style="background-color: orange; color: white; padding: 2px;">AMBER</span> Firmagon® 80mg; 120mg injection    		<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Relugolix</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> Orgovyx® 120mg tablets    		<b>RESTRICTED</b> Specialist use only in line with NICE Pending SCP
<b>Other</b>		
<b>Radium-223 dichloride</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Xofigo® 1,100 kBq/mL injection     		<b>RESTRICTED</b> Specialist use only in line with NICE
MHRA Drug Safety Update (Sep-18): Xofigo ▼: new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial MHRA Drug Safety Update (Dec-17): ▼Xofigo: Increased risk of death and fractures in RCT with abiraterone acetate & prednisolone/prednisone		
<b>8.3.4.3 Somatostatin analogues</b>		
<b>Lanreotide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection    		<b>RESTRICTED</b> Consultant only - acromegaly
<b>Octreotide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection (see also section 18.1.2)     		<b>RESTRICTED</b> 3 <sup>rd</sup> line use Gastro. Consultant only
<b>Lutetium (<sup>177</sup>Lu) oxodotreotide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Lutathera® injection     		<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>

## 8.4 Miscellaneous preparations



### Glucarpidase

RED 

Voraxaze® 1,000 unit injection (see also sections 1.10, 10.4, 13.14 & 18.1.2)

PbR X

MMC  

**RESTRICTED**

2<sup>nd</sup> line rescue therapy



### Trifluridine / Tipiracil hydrochloride

RED 

tablets

PbR X

NICE   



**RESTRICTED** Specialist use only in line with NICE

**NOT STOCKED**

## Non-Formulary Items



<b>Adagrasib</b>  <i>Krazati</i> ® tablets <b>MMC</b>	<b>Not NICE approved</b>
<b>Belzutifan</b>  tablets <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to Christie Hospital
<b>Capivasertib</b>  <i>Truqap</i> ® 160mg; 200mg tablets <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to Christie Hospital
<b>Dostarlimab</b>  <i>Jemperli</i> ® 500mg solution for infusion <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to Christie Hospital
<b>Disodium levofolinate</b>  injection <b>MMC</b>	<b>Not MMC approved</b>
<b>Elacestrant</b>  <i>Korserdu</i> ® tablets <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to Christie Hospital
<b>Erdafitinib</b>  <i>Balversa</i> ® tablets <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to Christie Hospital
<b>Enfortumab vedotin</b>  <i>Padcev</i> ® solution for infusion <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to Christie Hospital
<b>Fruquintinib</b>  <i>Fruzaqla</i> ® hard capsules <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to Christie Hospital
<b>Interferon alfa-2a</b>  <i>Roferon-A</i> ® injection 	<b>DISCONTINUED</b> Sep-19
<b>Interferon alfa-2b</b>  <i>IntronA</i> ® 	<b>DISCONTINUED</b> Dec-18
<b>Ofatumumab</b>  <i>Arzerra</i> ® injection <b>MMC</b> <b>BNF</b>	<b>DISCONTINUED</b> Feb-19
<b>Peginterferon alfa-2b</b>  <i>ViraferonPeg</i> ® <b>MMC</b>	<b>DISCONTINUED</b> Dec-16
<b>Talazoparib</b>  <i>Talzenna</i> ® capsules <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to NCA
<b>Tarlatamab</b>  <i>Imdyltra</i> ® 1mg; 10mg solution for infusion <b>MMC</b> <b>BNF</b>	<b>Not NICE approved</b>
<b>Tislelizumab</b>  <i>Tevimbra</i> ® 100mg solution for infusion <b>MMC</b> <b>BNF</b>	<b>Not NICE approved</b>
<b>Ublituximab</b>  <i>Briumvi</i> ® infusion <b>MMC</b> <b>BNF</b>	<b>MFT not a commissioned centre</b> Patients referred to NCA
<b>Zolbetuximab</b>  <i>Vyloy</i> ® infusion <b>MMC</b> <b>BNF</b>	<b>Not NICE approved</b>

## Section 9: Nutrition & blood

Supported by the  
formulary ([click here](#))



### 9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.1.8 Haemophilia

### 9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

### 9.3 Intravenous nutrition

### 9.4 Oral nutrition

- 9.4.1 Nutrition in special diets

### 9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

### 9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

### 9.7 Bitters & tonics

### 9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)  
 Nutrition support in adults (CG32)  
 Coeliac disease: recognition, assessment and management (NG20)  
 Chronic kidney disease: assessment and management (NG203)  
 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)  
 Migalastat for treating Fabry disease (HST4)  
 Eliglustat for treating type 1 Gaucher disease (HST5)  
 Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)  
 Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)  
 Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)  
 Lumasiran for treating primary hyperoxaluria type 1 (HST25)  
 Hyperparathyroidsism - cinacalcet (TA117)  
 Thrombocytopenic purpura - romiplostim (TA221)  
 Thrombocytopenic purpura - eltrombopag (TA293)  
 Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)  
 Etelcalcetide for treating secondary hyperparathyroidism (TA448)  
 Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)  
 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)  
 Patromer for treating hyperkalaemia (TA623)  
 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)  
 Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)  
 Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)  
 Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)  
 Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)  
 Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)  
 Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)  
 Avalglucosidase alfa for treating Pompe disease (TA821)  
 Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)  
 Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)  
 Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)  
 Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)  
 Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)  
 Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)  
 Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)  
 Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)  
 Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)

## GMMMG Formulary

Formulary Homepage  
 Chapter 9: Nutrition & Blood  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

# 9.1 Anaemias and some other blood disorders



## 9.1.1 Iron deficiency anaemias

### 9.1.1.1 Oral iron

<b>Ferrous sulfate</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> tablets	 	<b>1<sup>st</sup> line use</b> <b>STANDARD PREPARATIONS ONLY</b>
<b>Ferrous fumarate</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> tablets; oral solution	 	
<b>Ferric maltol</b> <span style="background-color: grey; color: white; padding: 2px;">GREY</span> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> capsules	  	
<b>Sodium feredetate</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> oral solution	 	<b>LIQUID PREPARATIONS ONLY</b>
<b>Iron &amp; folic acid</b>		
<b>Ferrous sulfate</b> <span style="border: 1px solid black; padding: 2px;">(DNP)</span> M/R tablets	 	
<b>Ferrous fumarate</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> capsules; tablets	 	

### 9.1.1.2 Parenteral iron

NICE NG106 NICE NG203

<b>Ferric carboxymaltose</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> Ferinject® injection MHRA Drug Safety Update (Nov-20): Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures	   	<b>RESTRICTED</b>
<b>Ferric derisomaltose</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> Monofer® injection MHRA: Monofer and Diafer name change (Nov-20) MHRA Drug Safety Update (Sep-13): Intravenous iron and serious hypersensitivity reactions	   	<b>RESTRICTED</b>
<b>Iron sucrose</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> Venofer® 100mg/5mL injection	   	<b>RESTRICTED</b>

### 9.1.2 Drugs used in megaloblastic anaemias

MHRA Drug Safety Update (Dec-23): Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions

<b>Hydroxocobalamin</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> Intramuscular injection; sachets	  	<b>1<sup>st</sup> line use</b>
<b>Cyanocobalamin</b> <span style="background-color: grey; color: white; padding: 2px;">GREY</span> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> 50microgram; 1mg tablets	  	<b>See BSH guidance</b> 

### 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias

































































































































#### Erythropoietins






































MHRA Drug Safety Update (Jan-18): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)

<b>Darbepoetin alfa</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection	    	<b>RESTRICTED</b> Renal Consultants only
<b>Epoetin alfa</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection	   	<b>RESTRICTED</b> Renal Consultants only
<b>Epoetin beta</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection MHRA Drug Safety Update (May-15): Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded	   	<b>RESTRICTED</b> Renal Consultants only

#### Sickle cell disease

<b>Hydroxycarbamide</b> <span style="background-color: orange; color: white; padding: 2px;">AMBER</span> oral solution; capsules	   	<b>RESTRICTED</b> Haematology Consultants only
<b>Exagamglogene autotemcel</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Casgevy® infusion (see also "Iron overload" below)	     	<b>RESTRICTED</b> Haematology Consultants only in line with NICE / NHSE

<b>Iron overload</b>		
<b>Deferasirox</b>   tablets    	<b>RESTRICTED</b> Haematology Consultants only	
<b>Deferiprone</b>   tablets    	<b>RESTRICTED</b> Haematology Consultants only	
<b>Desferrioxamine mesilate</b>   injection (see also section 18.1.2)   	<b>RESTRICTED</b> Haematology Consultants only	
<b>Exagamglogene autotemcel</b>   Casgevy® infusion (see also "Sickle cell disease" above)      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE / NHSE	
<b>Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI)</b>		
<b>Roxadustat</b>   Evrenzo® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>Vadadustat</b>   Vafseo® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>Paroxysmal nocturnal haemoglobinuria &amp; atypical haemolytic uraemic syndrome</b>		
<b>Eculizumab</b>   Soliris® 300mg/30mL infusion       	<b>RESTRICTED</b> Haematology Consultants only	
<b>Eculizumab</b>   Bekemv® 300mg/30mL infusion       	<b>RESTRICTED</b> Haem Consultants only - new patients	
<b>Eculizumab</b>   Epysqli® 300mg/30mL infusion       	<b>RESTRICTED</b> Haem Consultants only new patients < 2years old & patients with HFI	
<b>Ravulizumab</b>   infusion      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>9.1.4 Drugs used in autoimmune thrombocytopenic purpura</b>		
<b>Anagrelide</b>  capsules   	<b>RESTRICTED</b> Haematology Consultants only	
<b>Avatrombopag</b>   Doptelet® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>Caplacizumab</b>   Cablivi® injection      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>	
<b>Eltrombopag</b>   Revolade® tablets      	<b>RESTRICTED</b> Haematology Consultants only	
MHRA Drug Safety Update (Jul-18): Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results		
<b>Fostatinib</b>   Tavlesse® tablets      	<b>RESTRICTED</b> Specialist use only	
<b>Lusutrombopag</b>   Mupleo® tablets      	<b>RESTRICTED</b> Specialist use only	
<b>Romiplostim</b>   Nplate® injection      	<b>RESTRICTED</b> Haematology Consultants only	

9.1.6 Drugs used in neutropenia		
<b>Filgrastim</b> 	   	<b>RESTRICTED</b> Haematology Consultants only
injection MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
<b>Lenograstim</b> 	  	<b>RESTRICTED</b> Haematology Consultants only
injection		
<b>Pegfilgrastim</b> 	   	<b>RESTRICTED</b> Haematology Consultants only
injection MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
9.1.7 Drugs used to mobilise stem cells		
<b>Plerixafor</b>  	     	<b>RESTRICTED - initiation on advice of Haematology Consultant only</b>
injection		
9.1.8 Haemophilia		
<b>Efmoroctocog alfa</b>  	     	<b>RESTRICTED</b> Haematology Consultants only in line with NICE / NHSE
Elocta® injection		
<b>Etranacogene dezaparvovec</b>  	    	<b>RESTRICTED</b> Haematology Consultants only in line with NICE / NHSE
Hemgenix® infusion		

## 9.2 Fluids and electrolytes



### 9.2.1 Oral preparations for fluid & electrolyte imbalance

#### 9.2.1.1 Oral potassium

##### Potassium chloride

GREEN SA

Sando-K® effervescent tablets; oral solution



#### Potassium removal

##### Calcium polystyrene sulfonate

GREEN

Calcium Resonium® powder; enema (unlicensed)



##### Sodium zirconium cyclosilicate

AMBER

Lokelma® powder sachets



#### 9.2.1.2 Oral sodium and water

##### Sodium chloride (Slow Sodium®)

GREEN

600mg M/R tablets



#### Oral Rehydration Therapy (ORT)

##### Oral Rehydration Salts (ORS)

GREEN OTC

oral powder



#### 9.2.1.3 Oral bicarbonate

##### Sodium bicarbonate

500mg capsules; 8.4% (1mmol/mL) oral solution



##### Sodium hydrogen carbonate

NR

Nephrotrans® 50mg gastro-resistant capsules



**RESTRICTED**  
2<sup>nd</sup> line patients with severe GI side effects

### 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

#### 9.2.2.1 Electrolytes & water

##### Intravenous sodium

##### Sodium chloride

infusion; injection



##### Sodium chloride with other ingredients

##### Sodium chloride & glucose

infusion



##### Sodium chloride, calcium chloride & potassium chloride (Ringer's solution)

infusion



##### Sodium chloride, calcium chloride, potassium chloride & sodium lactate

infusion



##### Intravenous glucose

##### Glucose

infusion



MHRA Drug Safety Update (May-23): Glucose solutions: recommendations to minimise the risks associated with the accidental use instead of saline solutions in arterial lines

MHRA Drug Safety Update (Jul-12): Glucose solutions: false blood glucose readings when used to flush arterial lines

##### Intravenous potassium

##### Potassium chloride and glucose

infusion



##### Potassium chloride and sodium chloride












infusion



##### Potassium chloride, sodium chloride & glucose

infusion



<b>Bicarbonate and lactate</b>		
<b>Sodium bicarbonate</b>		
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	 	
<b>Sodium lactate compound</b>		
(Hartmann's solution) infusion	 	
<b>Trometamol</b>		
<b>Trometamol (THAM)</b> 		<b>RESTRICTED neonatal metabolic acidosis with hypernatraemia</b>
 7% injection	<b>MMC</b>	
<b>Water</b>		
<b>Water for Injections</b>		
injection		
<b>9.2.2.2 Plasma &amp; plasma substitutes</b>		
<b>Dextran</b>		
Dextran 40 - 10% in sodium chloride 0.9% infusion		
<b>Dextrose Acid Citrate ACDA</b>		
solution		
<b>Gelatin</b>		
Gelofusine® infusion	 	

## 9.3 Intravenous nutrition



**Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)**

**NICE CG32**

## 9.4 Oral nutrition



**Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)**

**NICE CG32**

### 9.4.1 Nutrition in special diets

**Sapropterin dihydrochloride**



Kuvan® 100mg soluble tablets



**RESTRICTED**  
Tetrahydrobiopterin deficiency



**LaBiNIC® probiotic drops**

LaBiNIC® probiotic drops



**RESTRICTED**  
prevention of NEC

# 9.5 Minerals



## 9.5.1 Calcium and magnesium

### 9.5.1.1 Calcium supplements

#### Oral preparations

##### Calcium carbonate

GREEN SA

Cacit® effervescent tablets; Calcichew® chewable tablets (see also section 9.5.2.2)



##### Calcium carbonate & calcium lactate gluconate

GREEN SA

Calvive® 1000 effervescent tablets



#### Parenteral preparations

##### Calcium gluconate

RED

10% injection



MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia

##### Calcium chloride

10% injection



MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia

#### with vitamin D

see section 9.6.4



#### with risedronate sodium & colecalciferol

see section 6.6.2



### 9.5.1.2 Hypercalcaemia & hypercalciuria

##### Cinacalcet

AMBER RED

30mg, 60mg, 90mg tablets



**RESTRICTED**  
as per NICE TA117

##### Cinacalcet

RED

5mg/5mL; 12.5mg/5mL oral suspension



**RESTRICTED**  
Paediatric CKD patients

##### Etelcalcetide hydrochloride

Parsabiv® 2.5mg/0.5mL; 5mg/1mL; 10mg/2mL injection



**RESTRICTED**  
as per NICE TA448

### 9.5.1.3 Magnesium

##### Magnesium aspartate dihydrate

GREEN SA

Magnaspartate® sachets



**NICE ESUOM4**

**1<sup>st</sup> line use**

##### Magnesium glycerophosphate

GREEN SA

chewable tablets; capsules; oral solution; tablets



##### Magnesium sulfate

GREEN SA

injection; infusion



MHRA Drug Safety Update (May-19): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy

### 9.5.2 Phosphorus

#### 9.5.2.1 Phosphate supplements

##### Phosphate supplements (Phosphate-Sandoz®)

GREEN SA

effervescent tablets



**Effervescent tabs**

##### Phosphates (Polyfusor®)

RED

infusion



**I.V. preparation**

#### 9.5.2.2 Phosphate-binding agents

##### Aluminium hydroxide

SI

capsules



##### Calcium carbonate

SI

tablets (see also section 9.5.1.1)


































##### Calcium acetate

SI

tablets



<p><b>Calcium acetate with magnesium carbonate</b>  </p> <p>Osvaren® 435mg/235mg tablets</p> <p>  </p>	<p><b>RESTRICTED</b>                  Renal Consultants only</p>
<p><b>Lanthanum</b>   </p> <p>chewable tablets; oral powder (  dialysis;  non-dialysis)</p> <p>  </p>	<p><b>RESTRICTED</b>                  Renal Consultants only</p>
<p><b>Patiromer calcium</b>  </p> <p>Veltassa® oral powder</p> <p>   </p>	<p><b>RESTRICTED</b> Consultants only                  in line with NICE TA623</p>
<p><b>Sevelamer carbonate</b>  </p> <p>Renvela® 800mg tablets; 2.4g; 0.8g sachets</p> <p>    </p>	<p><b>RESTRICTED</b>                  Renal Consultants only</p>
<p><b>Sucroferric oxyhydroxide</b>   </p> <p>chewable tablets</p> <p>  </p>	<p><b>RESTRICTED</b>                  Renal Consultants only - 3<sup>rd</sup> line</p>
<p><b>9.5.3 Fluoride</b></p>	
<p><b>Sodium fluoride</b></p> <p>tablets, paediatric drops, dental rinse</p> <p> </p>	
<p><b>9.5.4 Zinc</b></p>	
<p><b>Zinc sulfate</b></p> <p>Solvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules</p> <p> </p>	

## 9.6 Vitamins



### 9.6.1 Vitamin A

#### Vitamin A

150,000units/mL drops



#### Vitamin A palmitate

100,000units/2mL injection



#### Vitamins A & D

capsules



### 9.6.2 Vitamin B group

#### Pyridoxine hydrochloride

SA

tablets



#### Thiamine

GREEN

tablets



#### Vitamin B compound



#### Vitamin B compound Strong

GREY SI

tablets



#### Vitamins B & C

*Pabrinex*® Intravenous (IV) injection



### 9.6.3 Vitamin C (ascorbic acid)

#### Ascorbic acid

tablets



### 9.6.4 Vitamin D

#### Alfacalcidol

SI

capsules; injection; oral drops



#### Calcitriol

SI

capsules; oral solution



#### Ergocalciferol

RED

*Sterogyl*® 600,000 IU / 1.5mL ampoule



### Vitamin D and calcium

#### Colecalciferol

*Calcichew D3*® Forte tablets / *Adcal D3*® chewable tablets



1<sup>st</sup> line use

#### Calcium & Ergocalciferol

calcium 97mg/vitamin D 400units



#### Colecalciferol with calcium carbonate

*Cacit*® D3 effervescent granules; 800 IU capsules



### 9.6.5 Vitamin E (tocopherols)

#### Alpha tocopheryl acetate (Vitamin E)

NR













500mg/5mL liquid



#### Alpha tocopheryl acetate (Vitamin E)

75 unit capsules



<b>9.6.6 Vitamin K</b>		
<b>Phytomenadione</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span>		
<i>Konakion® MM &amp; Konakion® MM Paediatric injection (see also section 18.1.2)</i>	  	
<b>Menadiol sodium phosphate</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span>		
oral solution; tablets	  	
<b>9.6.7 Multivitamin preparations</b>		
<b>Vitamins B,C</b>		<b>RESTRICTED</b>
<i>Renavit® tablets</i>	  	
<b>Vitamins A,D,E,K</b> <span style="background-color: grey; color: white; padding: 2px;">GREY</span> <span style="background-color: green; color: white; padding: 2px;">SI</span>		<b>RESTRICTED</b> Paediatric CF patients
<i>Paravit®-CF and Paravit®-Mod capsules; liquid</i>	  	

## 9.7 Bitters & tonics



**Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use**

## 9.8 Metabolic disorders



### 9.8.1 Drugs used in metabolic disorders

#### Serine deficiency

##### L-Serine

(Nutricia L-Serine) powder

MMC

emc

**RESTRICTED**  
Specialist use only

#### Wilson's Disease

##### Penicillamine

AMBER

tablets (see also sections 10.1.3 and 18.1.1)

BNF

emc

##### Trientine dihydrochloride

RED

capsules

PbR X

MMC

BNF

emc

blueiq

3<sup>rd</sup> line use

NHS  
England

#### Carnitine Deficiency

##### Levocarnitine

RED

injection; oral solution (see also section 18.1.2)

PbR X

BNF

emc

**RESTRICTED**  
Specialist use only

#### Fabry's disease

##### Agalsidase alfa

RED

Replagal® infusion

PbR X

MMC

BNF

emc

**RESTRICTED**  
Specialist use only  
**NOT STOCKED**

##### MigALAstat

RED

Galafold® capsules

PbR X

NICE

MMC

BNF

emc

**RESTRICTED**  
Specialist use only (NICE HST4)

#### Mucopolysaccharidosis

##### Elosulfase alfa

RED

Vimizim® infusion

PbR X

NICE

MMC

BNF

emc

blueiq

**RESTRICTED**  
Specialist use only (NICE HST19)

##### Galsulfase

RED

Naglazyme® infusion

PbR X

MMC

BNF

emc

**RESTRICTED**  
Specialist use only  
**NOT STOCKED**

##### Idursulfase

RED

Elaprase® infusion

PbR X

MMC

BNF

emc

**RESTRICTED**  
Specialist use only

##### Laronidase

RED

Aldurazyme® infusion

PbR X

MMC

BNF

emc

**RESTRICTED**  
Specialist use only  
**NOT STOCKED**

##### Vestronidase alfa

RED

Mepsevii® infusion

PbR X

MMC

BNF

emc

blueiq

**RESTRICTED**  
Specialist use only

NHS  
England

#### Nephropathic cystinosis

##### Cystagon® (Mercaptamine)

RED

capsules (NB: prescribe as CYSTAGON®)

PbR X

BNF

emc

**RESTRICTED**  
Specialist use only

#### Pompe disease

##### Avalglucosidase alfa

RED

Nexviadyme® infusion

PbR X

NICE

MMC

BNF

emc

blueiq

**RESTRICTED**  
Specialist use only (NICE TA821)

#### Tyrosinaemia type I

##### Nitisinone

RED

capsules; oral suspension





















PbR X











































































MMC

BNF

emc

**RESTRICTED**  
Specialist use only

<b>Urea cycle disorders</b>		<b>BIMDG</b>
<b>Arginine</b> RED		<b>RESTRICTED</b> Specialist use only
infusion; oral solution	PbR X MMC  emc	
<b>Carglumic acid</b> RED ££		<b>RESTRICTED</b> Specialist use only
dispersible tablets	PbR X MMC  BNF emc	
<b>Citrulline</b> RED		<b>RESTRICTED</b> Specialist use only
powder	PbR X MMC  emc	
<b>Glycerol phenylbutyrate</b> RED		<b>RESTRICTED</b> Specialist use only
Ravicti® 1.1g/mL oral liquid	PbR X MMC  BNF emc	
<b>Sodium phenylbutyrate</b> RED		<b>RESTRICTED</b> Specialist use only
tablets; injection; oral liquid; granules (discontinued)	PbR X MMC  BNF emc	
<b>Homocystinuria</b>		<b>BIMDG</b>
<b>Betaine</b> RED ££		<b>RESTRICTED</b> Specialist use only
tablets; oral powder	PbR X  BNF emc	
<b>Sodium benzoate</b> RED ££		<b>RESTRICTED</b> Specialist use only
injection; oral solution; tablets; powder	PbR X  BNF emc	
<b>Uridine</b> RED ££		<b>RESTRICTED</b> Specialist use only
	MMC emc	
<b>Other metabolic disorders</b>		
<b>Asfotase alfa</b> RED ££		<b>RESTRICTED</b> Specialist use only (NICE HST23)
Strensiq® injection	PbR X NICE MMC  BNF  emc	
<b>Cerliponase alfa</b> RED ££		<b>RESTRICTED</b> Specialist use only (NICE HST12)
Brineura® 150mg solution for infusion	PbR X NICE MMC  emc	
<b>Eliglustat</b> RED ££		<b>RESTRICTED</b> Specialist use only (NICE HST5)
Cerdelga® 84mg capsules	PbR X NICE MMC  BNF  emc	
<b>Lumasiran</b> RED ££		<b>RESTRICTED</b> Specialist use only (NICE HST25)
Oxlumo® injection	PbR X NICE MMC  BNF  emc	
<b>MigLustat</b> RED ££		<b>RESTRICTED</b> Specialist use only
100mg capsules	PbR X MMC  BNF emc	
<b>Sebelipase alfa</b> RED ££		<b>RESTRICTED</b> Specialist use only (NICE HST30)
Kanuma® 2mg/mL solution for infusion	PbR X NICE MMC  BNF  emc	
<b>Sodium dichloroacetate</b> Ⓢ RED ££		<b>RESTRICTED</b> Specialist use only Primary lactic acidosis / PDHC deficiency
50 mg/mL powder for reconstitution for oral solution (200 mL)	PbR X NICE MMC  BNF emc	
<b>Sodium D,L-3-hydroxybutyrate</b> Ⓢ RED		<b>RESTRICTED</b> Specialist use only (MADD) Multiple acyl-CoA dehydrogenase deficiency
powder	PbR X NICE MMC BNF	
<b>Triheptanoin</b> Ⓢ RED		<b>RESTRICTED (EAMS)</b> Specialist use only (LC-FAOD)
Dojolvi® oral liquid	PbR X MMC emc	
<b>Velaglucerase alfa</b> RED ££		<b>RESTRICTED</b> Specialist use only
VPRIV® 400 units vial	PbR X MMC  BNF emc	
<b>9.8.2 Acute porphyrias</b>		
<b>Haem Arginate</b> RED ££		
infusion	PbR X  BNF emc	

Non-Formulary Items		GMMMG
<b>Artificial saliva</b> (DNP) BioXtra® oral gel; mouthspray	  	in line with GMMMG Criterion 1
<b>Calcium 500mg / colecalciferol 400 units</b> (DNP)		in line with GMMMG Criterion 1
<b>Cipaglucosidase alfa</b>   Pombiliti® infusion	    	MFT not a commissioned centre Patients referred to NCA
<b>Crizanlizumab</b> Adakveo® 10mg/mL injection	   	MA Withdrawn January 2024
MHRA Class 2 Medicines Recall: Novartis Pharmaceuticals UK Limited, Adakveo 10 mg/ml concentrate for solution for infusion, EL(24)A/06		
<b>Crovalimab</b>   PlaSky® infusion	    	MFT not a commissioned centre Patients referred to Leeds
<b>Danicopan</b>   Voydeya® tablets	    	MFT not a commissioned centre Patients referred to Leeds
<b>Fluoride (mouthwashes and toothpastes) for prevention of dental caries</b> (DNP)	 	in line with GMMMG / NHSE
<b>Fosdenopterin</b>   Nulibry® 9.5mg powder for solution for injection.	   	Not recommended by NICE for molybdenum cofactor deficiency type A
<b>Herbal medicines and other natural products</b> (DNP)		in line with GMMMG Criterion 3
<b>Homeopathic medicines</b> (DNP)		in line with GMMMG Criterion 3
<b>Iptacopan hydrochloride monohydrate</b>   Fabhalta® 200mg hard capsules	    	MFT not a commissioned centre Patients referred to Leeds
<b>Multivitamins and mineral preparations for AMD</b> (DNP)	  	in line with GMMMG Criterion 1
ICaps®, Occuvite®, PreserVision®, Viteyes®, Visionace®, Vitalux-plus®		
<b>Olipudase alfa</b>   Xenpozyme® 20mg solution for infusion	    	Rejected in line with NICE HST32
<b>Oral iron (modified-release preparations)</b> (DNP)		in line with GMMMG Criterion 1
<b>Pegcetacoplan</b>   Aspaveli® 1080mg injection	    	MFT not a commissioned centre Patients referred to Leeds
<b>Potassium chloride</b> Kay-Cee-L® 375mg/5mL syrup	  	Discontinued Nov-24 
<b>Sodium fluoride</b> (DNP) Mouthwashes; toothpastes	   	in line with GMMMG
<b>Spatone</b> (DNP) Iron-rich spa water from the mountains of Snowdonia		in line with GMMMG Criterion 1
<b>Vitamins, minerals and antioxidants</b> (DNP) When used in patients with no clinical indication for use		in line with GMMMG Criterion 3
<b>Voxelotor</b> Oxbryta® 500mg tablets	     	MA Withdrawn September 2024

## Section 10: Musculoskeletal & joint diseases

Supported by the  
formulary ([click here](#))



### 10.1 Drugs used in rheumatic diseases & gout

- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs that suppress the rheumatic disease process
  - Gold
  - Penicillamine
  - Antimalarials
  - Drugs affecting the immune response
  - Cytokine modulators
- 10.1.4 Gout and cytotoxic induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases

### 10.2 Drugs used in neuromuscular disorders

- 10.2.1 Drugs that enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants
  - Nocturnal leg cramps
- 10.2.3 Drugs used in neuromuscular disorders

### 10.3 Drugs for the relief of soft-tissue inflammation

- 10.3.1 Enzymes
- 10.3.2 Rubefacients & other topical antirheumatics

### 10.4 Miscellaneous preparations

#### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Rheumatoid arthritis in adults: management (NG100)  
 Osteoarthritis in over 16s: diagnosis and management (NG226)  
 Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)  
 Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)  
 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)  
 Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)  
 Hyperuricaemia - febuxostat (TA164)  
 Psoriasis - ustekinumab (TA180)  
 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)  
 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)  
 Psoriatic arthritis - golimumab (TA220)  
 Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)  
 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)  
 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)  
 Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)  
 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)  
 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)  
 Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Baricitinib for moderate to severe rheumatoid arthritis (TA466)  
 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)  
 Tofacitinib for moderate to severe rheumatoid arthritis (TA480)  
 Sarilumab for moderate to severe rheumatoid arthritis (TA485)  
 Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)  
 Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)  
 Tocilizumab for treating giant cell arteritis (TA518)  
 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)  
 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)  
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)  
 Nusinersen for treating spinal muscular atrophy (TA588)  
 Upadacitinib for treating severe rheumatoid arthritis (TA665)  
 Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)  
 Anakinra for treating Still's disease (TA685)  
 Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)  
 Ixekizumab for treating axial spondyloarthritis in adults (TA718)  
 Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)  
 Tofacitinib for treating juvenile idiopathic arthritis (TA735)  
 Upadacitinib for treating moderate rheumatoid arthritis (TA744)  
 Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)  
 Risdiplam for treating spinal muscular atrophy (TA755)  
 Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)  
 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)  
 Upadacitinib for treating active ankylosing spondylitis (TA829)  
 Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)  
 Bimekizumab for treating axial spondyloarthritis (TA918)  
 Tofacitinib for treating active ankylosing spondylitis (TA920)  
 Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

## GMMMG Formulary

Formulary Homepage  
 Chapter 10: Musculoskeletal & Joint Diseases  
 GMMMG Adult [Red/Amber/Green](#); DNP and [Grey Drug List](#)  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and [Grey Drug List](#)

## 10.1 Drugs used in rheumatic diseases &amp; gout



10.1 Drugs used in rheumatic diseases & gout		NICE CG177
10.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs)		NICE NG100
<p>MHRA Drug Safety Update (Oct-12): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks            MHRA Drug Safety Update (May-09): Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment            MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks</p>		
<p><b>Ibuprofen (oral)</b>            GREEN OTC</p> <p>200mg; 400mg; 600mg tablets; 5% gel</p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk</p>	  	1 <sup>st</sup> line use
<p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk</p>		
<p><b>Ibuprofen (IV)</b></p> <p>200mg in 50mL solution for infusion</p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk</p>	  	short-term symptomatic treatment of acute moderate pain
<p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk</p>		
<p><b>Naproxen</b>            GREEN</p> <p>250mg; 500mg tablets</p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy</p>	 	
<p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy</p>		
<p><b>Celecoxib</b>            GREY GREEN</p> <p>100mg; 200mg capsules</p> <p>MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks</p>	 	RESTRICTED - osteoarthritis in line with NICE NG226
<p>MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks</p>		
<p><b>Diclofenac sodium</b>            GREEN</p> <p>50mg tablets; suppositories</p> <p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription            MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings</p>	  	
<p>MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy            MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription            MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings</p>		
<p><b>Flurbiprofen</b></p> <p>50mg tablets</p>	 	
<p><b>Indometacin</b></p> <p>capsules; suppositories</p>	  	RESTRICTED 3 <sup>rd</sup> line (off-label) for tocolysis
<p><b>Mefenamic acid</b></p> <p>250mg; 500mg tablets</p>	 	
<p><b>Meloxicam</b></p> <p>7.5mg; 15mg tablets</p>	 	
<p><b>Sulindac</b></p> <p>100mg; 200mg tablets</p>	  	
<p><b>Etodolac</b></p> <p>600mg tablets</p>	  	RESTRICTED Consultant Anaesthetist use only
<p><b>Phenylbutazone</b></p> <p>100mg; 200mg tablets</p>	 	RESTRICTED Specialist use only, ankylosing spondylitis

**10.1.2 Corticosteroids**

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

**10.1.2.1 Systemic corticosteroids****NICE NG100****Prednisolone****10.1.2.2 Local corticosteroid injections****NICE NG100****Hydrocortisone acetate**

GREEN

25mg/mL injection

**Methylprednisolone acetate**

GREEN

40mg/mL injection

**Triamcinolone acetonide**

GREEN

10mg/mL; 40mg/mL injection

**Triamcinolone hexacetonide**

20mg/mL injection

**RESTRICTED Paediatric  
Rheumatology Consultants only****10.1.3 Drugs that suppress the rheumatic disease process****Gold****NICE NG100****Auranofin**

tablets

**RESTRICTED Rheumatology  
Consultants only****Penicillamine****Penicillamine**

AMBER

tablets (see also sections 9.8.1 &amp; 18.1.1)

**RESTRICTED Rheumatology  
Consultants only****Antimalarials****Hydroxychloroquine sulfate**

AMBER

tablets

**RESTRICTED Rheumatology  
Consultants only**

MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions

MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment

**Mepacrine hydrochloride**


RED

100mg tablets

**RESTRICTED Rheumatology /  
Infection Consultants only****Drugs affecting the immune response****NICE NG100****Azathioprine**

AMBER

tablets; injection; oral solution (see also sections 1.5.3, 8.2.1 &amp; 13.5.3)

**RESTRICTED Rheumatology  
Consultants only**

MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy

**Ciclosporin**

AMBER

capsules; oral solution; injection (see also sections 8.2.2 &amp; 13.5.3)

**RESTRICTED Consultants only****Leflunomide**

AMBER

tablets

**RESTRICTED Rheumatology  
Consultants only****Methotrexate**

AMBER

RED






























































































































tablets; injections (see also sections 1.5.3, 8.1.3 &amp; 13.5.3)























































**RESTRICTED Consultants only**

MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions

MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose

## Cytokine modulators

<b>Abatacept</b>   injection; infusion       	<b>RESTRICTED</b> Rheum. Consultants only in line with NICE / NHSE  
<b>Adalimumab</b>   injection (see also sections 1.5.3, 11.4.2 & 13.5.3)      	<b>RESTRICTED</b> Consultants only in line with NICE 
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
<b>Anakinra</b>   injection       	<b>RESTRICTED</b> Consultants only in line with NICE / NHSE  
<b>Apremilast</b>   10mg; 20mg; 30mg tablets (see also section 13.5.3)     	<b>RESTRICTED</b> 3 <sup>rd</sup> / 4 <sup>th</sup> line as per NICE/GMMMG
<b>Baricitinib</b>   2mg; 4mg tablets      	<b>RESTRICTED</b> Rheumatology Consultants only in line with NICE 
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality MHRA Drug Safety Update (Aug-20): Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors MHRA Drug Safety Update (Mar-20): Baricitinib (Olumiant▼): risk of venous thromboembolism	
<b>Belimumab</b>   Benlysta® 120mg; 400mg infusion; 200mg/1mL pre-filled pen      	<b>RESTRICTED</b> Consultants only
MHRA Drug Safety Update (Apr-19): Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials	
<b>Bimekizumab</b>   Bimzelx® injection (see also section 13.5.3)      	<b>RESTRICTED</b> in line with NICE
<b>Certolizumab pegol</b>   Cimzia® 200mg/1mL injection (see also section 13.5.3)     	<b>RESTRICTED</b> Rheumatology Consultants in line with NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
<b>Etanercept</b>   injection (see also section 13.5.3)       	<b>RESTRICTED</b> Consultants only; in line with NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
<b>Filgotinib</b>   Jyseleca® 100mg; 200mg tablets (see also section 1.5.3)      	<b>RESTRICTED</b> Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality	
<b>Golimumab</b>   injection (see also section 1.5.3)     	<b>RESTRICTED</b> Consultants only in line with NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
<b>Guselkumab</b>   100mg/mL injection (see also sections 1.5.3 & 13.5.3)     	<b>RESTRICTED</b> in line with NICE
<b>Infliximab</b>   Remicade® infusion; Remsima® infusion (see also section 13.5.3)       	<b>RESTRICTED</b> Consultants only <b>MMC Remsima</b>
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely	
<b>Ixekizumab</b>   80mg/1mL injection (see also section 13.5.3)     	<b>RESTRICTED</b> Consultants only in line with NICE
<b>Rituximab</b>   injection; infusion (see also section 8.2.3)      	<b>RESTRICTED</b> Consultants only in line with NICE / NHSE
<b>Sarilumab</b>   Kevzara® 150mg/1.14mL injection      	<b>RESTRICTED</b> Rheumatology Consultants only in line with NICE
<b>Secukinumab</b>   Cosentyx® 150mg/1mL injection (see also section 13.5.3)      	<b>RESTRICTED</b> Rheumatology Consultants only in line with NICE
<b>Tocilizumab</b>   infusion      	<b>RESTRICTED</b> Consultants only in line with NICE
MHRA Drug Safety Update (Jul-19): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation	

<p><b>Tofacitinib</b>   </p> <p>Xeljanz® 5mg; 10mg tablets (see also section 1.5.3)</p> <p>     </p> <p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality                      MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz ▼): new measures to minimise risk of major adverse cardiovascular events and malignancies                      MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz ▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections                      MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz ▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing</p>	<p><b>RESTRICTED Consultants only in line with NICE</b></p>
<p><b>Upadacitinib</b>   </p> <p>MR tablet (see also sections 1.5.3 &amp; 13.5.3)</p> <p>     </p> <p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality</p>	<p><b>RESTRICTED Consultants only in line with NICE</b></p>
<p><b>Ustekinumab</b>   </p> <p>Stelara® injection; infusion (see also sections 1.5.3 &amp; 13.5.3)</p> <p>     </p> <p>MHRA Drug Safety Update (Jan-15): Ustekinumab (Stelara): risk of exfoliative dermatitis</p>	<p><b>RESTRICTED Consultants only in line with NICE</b></p>
<p><b>Ustekinumab</b>   </p> <p>Wezenla® injection; infusion (see also sections 1.5.3 &amp; 13.5.3)</p> <p>     </p>	<p><b>RESTRICTED Consultants only in line with NICE</b></p>
<p><b>Sulfasalazine</b></p>	
<p><b>Sulfasalazine</b>  </p> <p>tablets</p> <p> </p>	<p><b>1<sup>st</sup> line use</b></p>
<p><b>10.1.4 Gout and cytotoxic induced hyperuricaemia</b></p>	
<p><b>Acute attacks of gout</b></p>	
<p><b>Colchicine</b>   </p> <p>tablets</p> <p> </p>	
<p><b>Long-term control of gout</b></p>	
<p><b>Allopurinol</b>  </p> <p>tablets</p> <p> </p>	<p><b>1<sup>st</sup> line use</b></p>
<p><b>Febuxostat</b>  </p> <p>tablets</p> <p>   </p> <p>MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease                      MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease                      MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric ▼): stop treatment if signs or symptoms of serious hypersensitivity</p>	<p><b>RESTRICTED Rheumatology Consultants only</b></p>
<p><b>Hyperuricaemia associated with cytotoxic drugs</b></p>	
<p><b>Rasburicase</b>   </p> <p>Fasturtec® infusion</p> <p>    </p>	<p><b>RESTRICTED Haematology Consultants only</b></p>
<p><b>10.1.5 Other drugs for rheumatic diseases</b></p>	
<p><b>NICE CG177</b></p>	
<p><b>NICE TA477</b></p>	
<p><b>NICE TA508</b></p>	

## 10.2 Drugs used in neuromuscular disorders



### 10.2.1 Drugs that enhance neuromuscular transmission

#### Anticholinesterases

##### Pyridostigmine bromide

GREEN

tablets

1<sup>st</sup> line use

##### Neostigmine metisulfate

GREEN

tablets; injection (see also section 15.1.6)



##### Edrophonium chloride



injection



**RESTRICTED**  
diagnosis of myasthenia gravis  
**Licensed product discontinued**

### 10.2.2 Skeletal muscle relaxants

##### Baclofen

GREEN

10mg tablets; 5mg/mL oral solution

1<sup>st</sup> line use

##### Dantrolene sodium

SI

25mg; 100mg capsules; *Ryanodex*® 250mg/20mL vial (see also section 15.1.8)

##### Diazepam

GREEN

tablets; liquid; injection; rectal tube (see also sections 4.1.2, 4.8.2 &amp; 15.1.4.1)



##### Tizanidine

SI

2mg; 4mg tablets



**RESTRICTED**  
Consultant Neurologist only

### Nocturnal leg cramps

##### Quinine sulfate

tablets (see also section 5.4.1)



MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions

MHRA Drug Safety Update (Jun-10): Quinine: not to be used routinely for nocturnal leg cramps

### 10.2.3 Drugs used in neuromuscular disorders

##### Ataluren

RED



oral suspension sachets



**Specialist use only**  
in line with NICE HST22

##### Atidarsagene autotemcel

RED

*Libmeldy*® infusion

**Specialist use only**  
in line with NICE HST18

##### Ginvinostat hydrochloride monohydrate

RED

*Duvystat*® oral suspension

**RESTRICTED** Paediatric Neurology  
Consultants only

##### Nusinersen

RED

*Spinraza*® injection

**Specialist use only**  
in line with NICE TA588 / NHSE  
**Named patient access**

MHRA Drug Safety Update (Sep-18): Nusinersen (*Spinraza* ▼): reports of communicating hydrocephalus; discuss symptoms with patients & carers - investigate urgently

##### Onasemnogene abeparvovec

RED

*Zolgensma*® infusion

**RESTRICTED** Paediatric Neurology  
Consultants only NICE / NHSE

##### Risdiplam

RED



oral solution



**Specialist use only**  
in line with NICE TA755

## 10.3 Drugs for the relief of soft-tissue inflammation



### 10.3.1 Enzymes

#### Hyaluronidase

RED

injection



**RESTRICTED**  
extravasation

### 10.3.2 Rubefacients & other topical antirheumatics

#### Piroxicam

GREEN

0.5% gel



#### Capsaicin

GREEN

cream, patch (restricted to neuropathic pain at TGH)



Patch restricted to peripheral  
neuropathic pain specialists at TGH

## 10.4 Miscellaneous preparations



### Dibotermin alfa <sup>U</sup>

RED <sup>EE</sup>

InductOs®

PbR X

MMC

emc <sup>+</sup>

**RESTRICTED**  
NHSE CCP 16063/P



### Givinostat

RED <sup>EE</sup>

Duvyza® 8.86mg/mL oral suspension

PbR X

MMC

BNF

emc <sup>+</sup>

**RESTRICTED**  
DMD patients aged 6 years & older

### Glucarpidase

RED <sup>EE</sup>

Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4, 13.14 & 18.1.2)

PbR X

MMC

BNF

emc <sup>+</sup>

**RESTRICTED**  
2<sup>nd</sup> line rescue therapy



## Non-Formulary Items



<b>Diclofenac sodium</b> <i>Dyloject</i> ® injection <b>MMC</b> <b>BNF</b> <b>emc</b>	<b>Discontinued July 2016</b>
<b>Diclofenac sodium</b> <i>Voltarol</i> ® injection <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Efgartigimod alfa</b> <b>RED</b> <b>EE</b> <i>Vyvgart</i> ® injection; infusion <b>PbR X</b> <b>NICE</b> <b>MMC</b> <b>BNF</b> <b>emc</b> <b>bluebird bio</b>	<b>MFT not a commissioned centre</b> <b>Patients referred to NCA</b>
<b>Glucosamine</b> <b>(DNP)</b> with or without chondroitin <b>BNF</b>	<b>in line with GMMMG</b>
<b>Hyaluronan injections</b> <b>(DNP)</b> injection including hyaluronan and sodium hyaluronate <b>BNF</b>	<b>in line with GMMMG</b>
<b>Naproxen with esomeprazole</b> <b>(DNP)</b> <b>BNF</b> <b>emc</b>	<b>in line with NICE / GMMMG</b>
<b>Satralizumab</b> <b>(DNP)</b> <i>Enspryng</i> ® injection <b>NICE</b> <b>BNF</b> <b>emc</b>	<b>in line with NICE / GMMMG</b>
<b>Sodium aurothiomalate</b> injection <b>BNF</b> <b>emc</b>	<b>Discontinued June 2019</b>

## Section 11: Eye

Supported by the  
formulary ([click here](#))



### 11.3 Anti-infective eye preparations

- 11.3.1 Antibacterials
- 11.3.2 Antifungals
- 11.3.3 Antivirals

### 11.4 Corticosteroid & other anti-inflammatory preparations

- 11.4.1 Corticosteroids
- 11.4.2 Other anti-inflammatory preparations

### 11.5 Mydriatics & cycloplegics

### 11.6 Treatment of glaucoma

- Beta-blockers
- Prostaglandin analogues and prostamides
- Combination products (prostaglandin analogue with beta-blocker)
- Combination products (prostaglandin analogue with Rho kinase inhibitor)
- Sympathomimetics
- Carbonic anhydrase inhibitors
- Miotics

### 11.7 Local anaesthetics

### 11.8 Miscellaneous ophthalmic preparations

- 11.8.1 Tear deficiency, ocular lubricants & astringents
- 11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment
- 11.8.3 Other preparations

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Glaucoma: diagnosis and management (NG81)  
 Age-related macular degeneration (NG82)  
 Diabetic retinopathy: management and monitoring (NG242)  
 Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)  
 Macular degeneration (age related) ranibizimab & pegaptanib (TA155)  
 Macular oedema (retinal vein occlusion) - dexamethasone (TA229)  
 Macular oedema (diabetic) - ranibizumab (TA274)  
 Macular oedema (retinal vein occlusion) - ranibizumab (TA283)  
 Macular degeneration (wet age-related) - aflibercept (1<sup>st</sup> line) (TA294)  
 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)  
 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)  
 Aflibercept for treating diabetic macular oedema (TA346)  
 Cyclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)  
 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Holoclar for treating limbal stem cell deficiency after eye burns (TA467)  
 Aflibercept for treating choroidal neovascularisation (TA486)  
 Cenegermin for treating neurotrophic keratitis (TA532)  
 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)  
 Brolucizumab for treating wet age-related macular degeneration (TA672)  
 Faricimab for treating diabetic macular oedema (TA799)  
 Faricimab for treating wet age-related macular degeneration (TA800)  
 Brolucizumab for treating diabetic macular oedema (TA820)  
 Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)  
 Fluocinolone acetonide intravitreal implant for treating chronic DMO (updates & replaces TA301 / TA613) (TA953)  
 Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)  
 Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)  
 Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)  
 Tebentafusp for treating advanced uveal melanoma (TA1027)  
 Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over (TA1093)













































## GMMMG Formulary
























Formulary Homepage  
 Chapter 11: Eye  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## 11.3 Anti-infective eye preparations



### 11.3.1 Antibacterials

<b>Chloramphenicol</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span> <span style="background-color: purple; color: white; padding: 2px;">OTC</span> <span style="border: 1px solid black; padding: 2px;">(DNP)</span>	 	
0.5% eye drops, 1% eye ointment ( <span style="border: 1px solid black; padding: 2px;">(DNP)</span> bacterial conjunctivitis)		
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
<b>Fusidic acid (ophthalmic)</b> <span style="background-color: green; color: white; padding: 2px;">GREEN</span>	 	
1% eye drops		
<b>Amikacin (ophthalmic)</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> microbial keratitis. Consultant Ophthalmologist only
2.5% eye drops		<b>NOT STOCKED</b>
<b>Azithromycin (ophthalmic)</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
Azyter® 1.5% eye drops	  	
<b>Ceftazidime (ophthalmic)</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
5% eye drops		<b>NOT STOCKED</b>
<b>Cefuroxime (ophthalmic)</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
5% eye drops		
<b>Cefuroxime (intracameral injection)</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
Ximaract® 50mg in 5mL intracameral injection	  	
<b>Chlorhexidine (ophthalmic)</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> acanthamoeba keratitis. Consultant only
0.02% eye drops		
<b>Ciprofloxacin (ophthalmic)</b> <span style="background-color: green; color: white; padding: 2px;">SA</span>	 	<b>RESTRICTED</b> microbial keratitis. Consultant Ophthalmologist only
0.3% eye drops		
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
<b>Erythromycin (ophthalmic)</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> superficial eye infections
0.5% eye ointment		
<b>Gentamicin (ophthalmic)</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
1.5% eye drops (Use with cefuroxime eye drops)		
<b>Levofloxacin (ophthalmic)</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant only corneal ulcers/ keratitis
0.5% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
<b>Ofloxacin</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
0.3% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
<b>Penicillin (ophthalmic)</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> microbial keratitis. Consultant Ophthalmologist only
2,500 units/mL eye drops		
<b>Polihexanide</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>RESTRICTED</b> Acanthamoeba keratitis Consultant Ophthalmologist only
Akantior® 0.8 mg/mL eye drops		
<b>Polihexanide (Polyhexamethylene biguanide (PHMB))</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>RESTRICTED</b> Acanthamoeba keratitis Consultant Ophthalmologist only
0.02% eye drops		
<b>Propamide isetionate</b> <span style="border: 1px solid red; border-radius: 50%; padding: 2px;">U</span> <span style="background-color: red; color: white; padding: 2px;">RED</span>	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
0.1% eye drops		

<b>Vancomycin (ophthalmic)</b>   5% eye drops  	<b>RESTRICTED</b> gram positives, including MRSA but not VRE <b>NOT STOCKED</b>
<b>11.3.2 Antifungals</b>	
<b>Amphotericin</b>   0.15% eye drops  	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Natamycin</b>   5% eye drops  	<b>RESTRICTED</b> fungal keratitis, conjunctivitis, fungal blepharitis
<b>Voriconazole</b>   1% eye drops (see also section 5.2.1)  	<b>RESTRICTED</b> fungal keratitis
<b>11.3.3 Antivirals</b>	
<b>Ganciclovir</b>  0.15% eye gel  	
<b>Trifluorothymidine</b>   1% eye drops  	

## 11.4 Corticosteroid & other anti-inflammatory preparations



### 11.4.1 Corticosteroids

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

<b>Betamethasone</b> <b>SI</b> 0.1% eye drops & ointment		
<b>Dexamethasone</b> <b>SI</b> 0.1% eye drops & minims		
<b>Dexamethasone (intravitreal implant)</b> <b>RED</b>		<b>RESTRICTED</b> as per NICE TA229; TA460 & TA824
<b>Fluocinolone acetonide</b> <b>RED</b>		<b>RESTRICTED</b> as per NICE TA590 & TA953
<b>Prednisolone</b> <b>SI</b> 0.5% & 1% eye drops; 0.5% minims		
<b>Fluorometholone</b> <b>SI</b> 0.1% eye drops		
<b>Hydrocortisone sodium phosphate</b> <i>Softacort</i> ® 3.35 mg/mL PF single use eye drops		
<b>Triamcinolone acetonide</b> <b>RED</b>		<b>RESTRICTED</b> intralesional injection in skin grafts
<b>Triamcinolone acetonide</b> <b>RED</b>		<b>RESTRICTED</b> uveitis; sympathetic ophthalmia
<b>Triamcinolone acetonide</b> <b>RED</b>		<b>RESTRICTED</b> opacification of the vitreous humour
<b>Corticosteroids preparations with antibiotics</b>		
<b>Betamethasone with neomycin sulphate</b> 0.1% / 0.5% eye drops ( <i>Betnesol-N</i> ®)		
<b>Dexamethasone with hypromellose, neomycin and polymyxin B sulfate</b> 1 mg/mL : 3500 IU/mL : 6000 IU/mL ( <i>Maxitrol</i> ® eye drops & ointment)		
<b>11.4.2 Other anti-inflammatory preparations</b>		
<b>Sodium cromoglicate</b> <b>GREEN</b> <b>OTC</b> 2% eye drops		
<b>Adalimumab</b> <b>RED</b>		<b>RESTRICTED Consultant Ophthalmologist only</b> Non-infectious Uveitis
<b>Antazoline with xylometazoline</b> <b>GREEN</b> <b>OTC</b> 0.5% eye drops		
<b>Azelastine hydrochloride</b> 0.05% eye drops		<b>RESTRICTED</b> allergic conjunctivitis, children only
<b>Ketotifen hydrogen fumarate</b> <i>Ketofall</i> ® 0.25mg/mL PF eye drops		
<b>Lodoxamide</b> 0.1% eye drops		<b>RESTRICTED</b> allergic conjunctivitis
<b>Olopatadine</b> <b>GREEN</b> 1mg/mL eye drops		<b>RESTRICTED</b> Seasonal allergic conjunctivitis
<b>Potassium ascorbate</b> 10% eye drops		<b>RESTRICTED</b> management of chemical burns to the cornea

## 11.5 Mydriatics & cycloplegics



### Antimuscarinics

#### Atropine sulfate

GREEN

1% minims



#### Cyclopentolate hydrochloride

GREEN

1% eye drops, 0.5% & 1% minims



#### Tropicamide

0.5% & 1% eye drops, 0.5% & 1% minims



### Sympathomimetics

#### Phenylephrine hydrochloride

2.5% & 10% minims



**10% contraindicated in children & the elderly**

### Sympathomimetics with tropicamide

#### Phenylephrine hydrochloride with tropicamide

RED

Mydrasert® 5.4mg / 280micrograms ophthalmic insert



**RESTRICTED** Pre-operative mydriasis in cataract patients

## 11.6 Treatment of glaucoma



Beta-blockers		NICE NG81
<b>Timolol maleate</b> SA 0.25% & 0.5% eye drops	 	
<b>Timolol once-daily</b> SA 0.25% eye drops, <i>Tiopex</i> ® 0.1% gel, 0.5% long-acting ophthalmic gel	 	
<b>Betaxolol</b> 0.25% & 0.5% eye drops, 0.25% minims	 	
<b>Levobunolol hydrochloride</b> SA 0.5% eye drops	 	
<b>Prostaglandin analogues and prostamides</b>		
<b>Bimatoprost</b> SA 100 micrograms/mL eye drops	  	
<b>Latanoprost</b> SA 50 micrograms/mL eye drops MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation	 	
<b>Latanoprost (preservative free)</b> SA 50 micrograms/mL preservative free eye drops MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation	  	
<b>Travoprost</b> SA 40 micrograms/mL eye drops	  	
<b>Combination products (prostaglandin analogue with beta-blocker)</b>		
<b>Latanoprost with timolol</b> SA 50micrograms/mL / 5mg/mL eye drops; preservative free eye drops	  	
<b>Combination products (prostaglandin analogue with Rho kinase inhibitor)</b>		
<b>Latanoprost with netarsudil</b> SA <i>Roclanda</i> ® 50micrograms/mL / 5mg/mL + 200micrograms/mL eye drops	   	<b>RESTRICTED use in line with NICE TA1009</b> <b>NOT for 1ry care recommendation at present</b>
<b>Sympathomimetics</b>		
<b>Brimonidine tartrate</b> SA 0.2% eye drops	  	
<b>Apraclonidine</b> SI RED 0.5%; 1% eye drops	 	<b>RESTRICTED to delay laser treatment / surgery in uncontrolled glaucoma</b>
<b>Carbonic anhydrase inhibitors &amp; systemic drugs</b>		
<b>Acetazolamide</b> SI 250mg tablets; <i>Diamox SR</i> ® 250mg capsules	 	
<b>Brinzolamide</b> SA 10mg/mL eye drops	 	
<b>Brinzolamide with brimonidine</b> SA <i>Simbrinza</i> ® 2% eye drops	  	<b>RESTRICTED glaucoma patients in whom monotherapy provides insufficient IOP reduction</b>
<b>Dorzolamide</b> SA 2% eye drops; also preservative free	 	
<b>Dorzolamide with timolol</b> SA <i>Cosopt</i> ® 2% eye drops; also preservative free	 	
<b>Miotics</b>		
<b>Pilocarpine</b> SA 1%, 2% & 4% eye drops, 2% minims	 	
<b>Pilocarpine</b> 4% ophthalmic gel	 	

## 11.7 Local anaesthetics



### Ocular Local anaesthetics

#### Fluorescein with lidocaine (minims)

RED

4% / 0.25% eye drops



#### Oxybuprocaine hydrochloride (minims)

RED

0.4% eye drops



#### Proxymetacaine hydrochloride (minims)

RED

0.5% eye drops



#### Tetracaine (Amethocaine) (minims)

RED

1% & 2% eye drops



# 11.8 Miscellaneous ophthalmic preparations



## Other preparations

<b>Botulinum toxin type A</b> 		<b>RESTRICTED</b> Consultant Ophthalmologist only blepharospasm & strabismus
Xeomin® injection	 	
<b>Ciclosporin (eye)</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only
2% eye drops	 	
<b>Ciclosporin (Cequa®)</b> 		<b>RESTRICTED</b> Consultant Ophthalmologist only
0.9mg/mL eye drops	 	
<b>Ciclosporin (Ikervis®)</b> 		<b>RESTRICTED</b> Consultant Ophthalmologist only in line with NICE TA369
1mg/mL eye drops	  	
<b>Ciclosporin (Verkazia®)</b> 		<b>RESTRICTED Paediatrics</b> for vernal keratoconjunctivitis / severe allergic eye disease
1mg/mL eye drops	 	
<b>Mercaptamine</b> 		<b>RESTRICTED</b> Specialist use only <b>NHSE</b>
Cystadrops® eye drops	   	
<b>Sodium chloride</b>		
5% eye drops	 	
<b>Allogeneic Serum eye drops</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only
eye drops (minims) (from NHS Blood & Transplant Service) (not a medicine)	 	
<b>11.8.1 Tear deficiency, ocular lubricants &amp; astringents</b>		
<b>Acetylcysteine</b>		
Ilube® 5% eye drops	 	
<b>Alteplase</b> 		<b>RESTRICTED</b> Consultant Ophthalmologist only
25micrograms in 0.1mL intravitreal injection	 	
<b>Carbomers</b> 		
Viscotears® 0.2% eye drops	 	
<b>Carmellose sodium</b> 		
Celluvisc® 0.5% eye drops	 	
<b>Glycerol and mineral oils (Cationorm®)</b>		
preservative free eye drops	 	
<b>Hydroxyethylcellulose</b>		
Minims® Artificial Tears preservative free eye drops	 	
<b>Hypromellose</b> 		
0.3% eye drops (  ) Dry eyes / sore tired eyes or viral conjunctivitis)	 	
<b>Liquid Paraffin</b> 		
Lacri-Lube® ointment	 	
<b>Polyvinyl alcohol</b> 		
Liquifilm Tears® 1.4% eye drops	 	
<b>Sodium chloride (minims)</b> 		
5% eye drops	 	
<b>Sodium hyaluronate</b> 		
Hyla-Forte® 0.2% eye drops	 	

**11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment****Ocular diagnostic preparations****Fluorescein sodium**

RED

1% &amp; 2% preservative free eye drops

BNF emc

**Fluorescein sodium**

RED

100mg/mL injection

MMC BNF emc

**RESTRICTED**  
Specialist use only  
fundus fluorescein angiography**Indocyanine green (ICG)**

RED

Verdye® 5mg/mL injection

MMC emc

**RESTRICTED**  
Specialist use only**Ocular peri-operative drugs****Acetylcholine chloride**

1% intraocular irrigation

BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only**Apraclonidine**

SI RED

Iopidine® 0.5% eye drops; 1% preservative free eye drops

BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only**Bromfenac**

Yellox® 0.9 mg/mL eye drops

MMC BNF emc

**RESTRICTED** Consultant only for  
pseudophakic CMO**Ketorolac trometamol**

RED

Acular® 0.5% eye drops

BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only**Nepafenac**

Nevanac® 1 mg/mL eye drops

MMC BNF emc

**RESTRICTED**. 1<sup>st</sup> line post cataract  
surgery in diabetics. 2<sup>nd</sup> line CMO**Povidone-Iodine**

5% eye drops

MMC BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only**Heavy Silicone oil**

Densiron® 68 - 10mL syringe

MMC

**RESTRICTED** intraocular tamponade  
of inferior retinal breaks**Subfoveal choroidal neovascularisation****Aflibercept**

RED ££

Eylea® 40mg/mL; 114.3mg/mL injection

PbR X NICE MMC BNF blueq emc

**RESTRICTED** Consultant  
Ophthalmologist only**Bevacizumab**

RED ££

Avastin® 100mg in 4mL vial

PbR X NICE MMC BNF blueq emc

**RESTRICTED** Consultant  
Ophthalmologist only**Bevacizumab**

RED ££

Alymsys® 25mg/mL infusion

PbR X MMC BNF blueq emc

**RESTRICTED** Consultant Neuro-  
oncologist**Bevacizumab gamma**

RED ££

Lytenava® 25 mg/mL injection

PbR X NICE MMC BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only**Brolucizumab**

RED ££

Beovu® 120mg in 1mL injection

PbR X NICE MMC BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only

MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals

**Faricimab**

RED ££

Vabysmo® 120mg/mL injection

PbR X NICE MMC BNF emc

**RESTRICTED** Consultant  
Ophthalmologist in line with NICE  
TA799 / TA800 / TA1004**Ranibizumab**

RED ££

Lucentis® / Ongavia® 10mg/mL injection

PbR X NICE MMC BNF blueq emc

**RESTRICTED** Consultant  
Ophthalmologist only**Verteporfin**

RED ££

Visudyne® 15mg vial

PbR X MMC BNF emc

**RESTRICTED** Consultant  
Ophthalmologist only**Vitreomacular traction****11.8.3 Other preparations**

PbR X NICE














**Disodium edetate****Disodium edetate**
























RED

0.37% (EDTA) eye drops

MMC

**RESTRICTED**  
Consultant Ophthalmologist  
chelation in band keratopathy

<b>Idebenone</b>		
<b>Idebenone</b>   Raxone® 150mg tablets	    	<b>RESTRICTED</b> Specialist use only
<b>Insulin eye drops</b>		
<b>Insulin (soluble) eye drops</b>   Humulin S® in Systane® lubricant eye drops		<b>RESTRICTED</b> Consultant Ophthalmologist
<b>Voretigene</b>		
<b>Voretigene neparvovec</b>   Luxturna® 2mL vial		<b>RESTRICTED</b> Consultant Ophthalmologist in line with NICE

<b>Non-Formulary Items</b>		
<b>Cenergermin</b>  <i>Oxervate</i> ®  (DNP)		<b>DISCONTINUED</b> <b>January 2020</b>
<b>Commercial eyelid cleansing preparations</b> (DNP)		<b>in line with GMMMG</b>  <b>Criterion 1</b>
<b>Conjunctivitis (bacterial)</b> (DNP)		<b>in line with GMMMG / NHSE</b>
<b>Conjunctivitis (viral)</b> (DNP)		<b>in line with GMMMG / NHSE</b>
<b>Dry eyes / sore tired eyes</b> (DNP)		<b>in line with GMMMG / NHSE</b>
<b>Ocriplasmin</b>  	    	<b>DISCONTINUED</b> <b>May 2020</b>
<b>Polymyxin B sulfate</b>  <i>Polyfax</i> ® eye ointment	 	<b>DISCONTINUED</b> <b>November 2017</b>
<b>Poly (carboxymethylglucose sulfate)</b>  <i>Cacicol</i> ® eye drops (0.33mL)	  	<b>DISCONTINUED</b> <b>December 2019</b>
<b>Simple eye ointment</b> (DNP)	 	<b>in line with GMMMG</b>  <b>Criterion 1</b>
<b>Tebentafusp</b>  	    	<b>NOT STOCKED. Patients treated at</b> <b>commissioned centre in Liverpool</b>

## Section 12: Ear, nose & oropharynx

Supported by the  
formulary ([click here](#))



### 12.1 Drugs acting on the ear

- 12.1.1 Otitis externa
- 12.1.3 Removal of ear wax

### 12.2 Drugs acting on the nose

- 12.2.1 Drugs used in nasal allergy
- 12.2.2 Topical nasal decongestants
- 12.2.3 Nasal preparations for infection

### 12.3 Drugs acting on the oropharynx

- 12.3.1 Drugs for oral ulceration & inflammation
- 12.3.2 Oropharyngeal anti-infective drugs
- 12.3.4 Mouthwashes, gargles & dentifrices
- 12.3.5 Treatment of dry mouth

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79)  
Sore throat (acute): antimicrobial prescribing (NG84)  
Otitis media (acute): antimicrobial prescribing (NG91)  
Tinnitus: assessment and management (NG155)  
Otitis media with effusion in under 12s (NG233)  
Allergic rhinitis (CKS)

## GMMMG Formulary

Formulary Homepage  
Chapter 12: Ear, nose & oropharynx  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## 12.1 Drugs acting on the ear



### 12.1.1 Otitis externa

#### Astringent preparations

##### Aluminium acetate

ear drops



#### Anti-inflammatory preparations

##### Betamethasone sodium phosphate

GREEN

Betnesol® 0.1% ear drops



##### Prednisolone sodium phosphate

Predsol® 0.5% ear drops



#### Anti-inflammatory with antibacterial preparations

##### Dexamethasone with glacial acetic acid and neomycin sulfate

GREEN

Otomize® 0.1% / 3250u per mL ear spray



##### Dexamethasone with framycetin sulfate and gramicidin

Sofradex® 0.05% / 0.5% / 0.005% ear/eye drops



##### Flumetasone pivalate with clioquinol

GREEN

Locorten-Vioform® 0.02% / 1% ear drops



##### Gentamicin with hydrocortisone

GREEN

1% / 0.3% ear drops



##### Hydrocortisone with neomycin and polymyxin B sulfate

Otosporin® 1% : 3400u/mL : 10,000u/mL ear drops



#### Analgesic / Anti-inflammatory / local anaesthetic preparations

##### Phenazone with lidocaine

Otigo® 40mg/g / 10mg/g ear drops



**RESTRICTED**  
paeds in line with NICE NG91

#### Anti-infective preparations

##### Ciprofloxacin

GREY GREEN

Cetraxal® 0.2% ear drops



MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling &amp; potentially long-lasting or irreversible side effects

##### Clotrimazole

GREEN OTC

1% ear drops



### 12.1.3 Removal of ear wax

##### Olive oil ear drops

(DNP) OTC

ear drops



##### Sodium bicarbonate

(DNP) OTC

5% ear drops



## 12.2 Drugs acting on the nose



### 12.2.1 Drugs used in nasal allergy

#### Antihistamines

##### Azelastine hydrochloride

Rhinolast® 40micrograms nasal spray



##### Azelastine hydrochloride

Azelair® 0.15% nasal spray



#### Corticosteroids

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

##### Beclometasone dipropionate

GREEN OTC

50micrograms nasal spray



1<sup>st</sup> line use

##### Betamethasone sodium phosphate

GREEN

0.1% nose drops



##### Mometasone furoate

GREEN

50micrograms nasal spray



1<sup>st</sup> line use nasal polyps

##### Fluticasone furoate

GREEN

Avamys® 27.5micrograms nasal spray



##### Fluticasone propionate with azelastine hydrochloride

GREY GREEN

Dymista® 50micrograms / 137micrograms nasal spray



RESTRICTED 3<sup>rd</sup> line use

#### Cromoglicate

##### Sodium cromoglicate

4% nasal spray



### 12.2.2 Topical nasal decongestants

#### Sympathomimetics

##### Ephedrine hydrochloride

(DNP)

0.5%; 1% nasal drops



1<sup>st</sup> line use

##### Sodium chloride

GREEN OTC

0.9% nasal drops



##### Xylometazoline hydrochloride

GREEN

0.1% nasal drops



#### Antimuscarinics

##### Ipratropium bromide

GREEN

0.03% nasal spray



Rhinorrhoea associated with allergic & non-allergic rhinitis

### 12.2.3 Nasal preparations for infection

##### Chlorhexidine dihydrochloride with neomycin

GREEN

Naseptin® 0.1% / 0.5% nasal cream



1<sup>st</sup> line use staphylococcal infections

##### Mupirocin

Bactroban® 2% nasal ointment



RESTRICTED MRSA / post nasal cautery

## 12.3 Drugs acting on the oropharynx



### 12.3.1 Drugs for oral ulceration & inflammation

#### Local Analgesics

##### Benzydamine hydrochloride

GREEN OTC

0.15% oral rinse; 0.15% spray

BNF emc

##### Carmellose sodium

30g protective paste

BNF emc

#### Corticosteroids

##### Hydrocortisone

(DNP)

muco-adhesive buccal tablets

BNF emc

### 12.3.2 Oropharyngeal anti-infective drugs

#### Oropharyngeal fungal infections

##### Miconazole

GREEN

2% oral gel (DNP) oral thrush)

BNF emc

MHRA Drug Safety Update (Sep-17): Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin

##### Nystatin

GREEN

100,000 units/mL oral suspension (DNP) oral thrush)

BNF emc

### 12.3.4 Mouthwashes, gargles & dentifrices

##### Chlorhexidine gluconate

GREEN OTC

0.2% mouthwash; 1% dental gel

BNF emc

### 12.3.5 Treatment of dry mouth

#### Local treatment

##### AS Saliva Orthana®

GREEN OTC

spray; lozenges

BNF emc

##### BioXtra®

oral gel

BNF emc

#### Systemic treatment

##### Pilocarpine

5mg tablets

BNF emc

**RESTRICTED Consultant use only**  
following irradiation for head & neck cancer

#### Treatment of Dental Caries

##### Silver diamine fluoride (SDF) 38%

liquid

MMC emc

## Non-Formulary Items



<b>Acute sore throat</b> <input type="checkbox"/> (DNP) Sore throat lozenges and sprays, analgesics	in line with GMMMG
<b>Arachis oil / chlorobutanol</b> Cerumol® ear drops all forms	Removed Nov-25
<b>Coughs, colds and nasal congestion</b> <input type="checkbox"/> (DNP) Pseudoephedrine nasal sprays and oral preparations. Xylometazoline and ephedrine nasal sprays and drops	in line with GMMMG
<b>Ear wax removal</b> <input type="checkbox"/> (DNP) Olive oil, sodium bicarbonate ear drops. Includes prior to syringing	in line with GMMMG
<b>Mouth ulcers</b> <input type="checkbox"/> (DNP) Local anaesthetic gels, hydrocortisone buccal tablets	in line with GMMMG
<b>Oral thrush</b> <input type="checkbox"/> (DNP) Miconazole oral gel, nystatin oral suspension	in line with GMMMG

## Section 13: Skin

Supported by the  
formulary ([click here](#))



### 13.2 Emollient & barrier preparations

- 13.2.1 Emollients
- 13.2.2 Barrier preparations

### 13.3 Topical local anaesthetics & antipruritics

### 13.4 Topical corticosteroids

### 13.5 Preparations for eczema & psoriasis

- 13.5.1 Preparations for eczema
- 13.5.2 Preparations for psoriasis
- 13.5.3 Drugs affecting the immune response
  - Cytokine Modulators

### 13.6 Acne & Rosacea

- 13.6.1 Topical preparations for acne
- 13.6.2 Oral preparations for acne

### 13.7 Preparations for warts & calluses

### 13.8 Sunscreens & camouflagers

- 13.8.1 Sunscreen preparations

### 13.9 Shampoos & other preparations for scalp/hair conditions

### 13.10 Anti-infective skin preparations

- 13.10.1 Antibacterial preparations
- 13.10.2 Antifungal preparations
- 13.10.3 Antiviral preparations
- 13.10.4 Parasitocidal preparations
- 13.10.5 Preparations for minor cuts & abrasions

### 13.11 Skin cleansers, antiseptics & desloughing agents

- 13.11.1 Alcohols & saline
- 13.11.2 Chlorhexidine salts
- 13.11.4 Iodine
- 13.11.6 Oxidisers & dyes
- 13.11.7 Desloughing agents

### 13.12 Antiperspirants

### 13.13 Topical circulatory preparations

### 13.14 Miscellaneous preparations

### 13.15 BAD unlicensed specials list

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Atopic eczema in children (CG57)  
 Psoriasis: assessment and management (CG153)  
 Pressure Ulcers (CG179)  
 Pubic lice CKS (2011)  
 Scabies CKS (2011)  
 Acne vulgaris CKS (2014)  
 Head lice CKS (2015)  
 Surgical site infections: prevention and treatment (NG125)  
 Atopic dermatitis (eczema) - topical steroids (TA81)  
 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)  
 Psoriasis - efalizumab and etanercept (TA103) EMA (efalizumab)  
 Psoriasis - infliximab (TA134)  
 Psoriasis - adalimumab (TA146)  
 Alitretinoin for the treatment of severe chronic hand eczema (TA177)  
 Psoriasis - ustekinumab (TA180)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Secukinumab for treating moderate to severe plaque psoriasis (TA350)  
 Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)  
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)  
 Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Ixekizumab for treating moderate to severe plaque psoriasis (TA442)  
 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)  
 Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)  
 Brodalumab for treating moderate to severe plaque psoriasis (TA511)  
 Guselkumab for treating moderate to severe plaque psoriasis (TA521)  
 Dupilumab for treating moderate to severe atopic dermatitis (TA534)  
 Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)  
 Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)  
 Risankizumab for treating moderate to severe plaque psoriasis (TA596)  
 Baricitinib for treating moderate to severe atopic dermatitis (TA681)  
 Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)  
 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)  
 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)  
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)  
 Bimekizumab for treating active psoriatic arthritis (TA916)  
 Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)  
 Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)  
 Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)  
 Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)  
 Spesolimab for treating generalised pustular psoriasis flares (TA1070)  
 Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)  
 Delgocitinib for treating moderate to severe chronic hand eczema (TA1107)

## GMMMG Formulary

Formulary Homepage  
 Chapter 13: Skin  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

# 13.2 Emollient & barrier preparations



## 13.2.1 Emollients

### Non-Proprietary emollient preparations

MHRA Drug Safety Update (Aug-20): Emollients and risk of severe and fatal burns: new resources available  
 MHRA Drug Safety Update (Jul-20): Safe use of emollient skin creams to treat dry skin conditions  
 MHRA Drug Safety Update (Dec-18): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients  
 MHRA Patient Info Leaflet (Jul-20): Skin creams - risk of fire and burns

#### Aqueous cream BP

cream		
-------	--	--

#### Emulsifying ointment BP

ointment		
----------	--	--

#### Liquid & white soft paraffin

ointment		
----------	--	--

#### Paraffin, white soft BP

white petroleum jelly		
-----------------------	--	--

#### Paraffin, yellow soft BP

yellow petroleum jelly		
------------------------	--	--

### Proprietary emollient preparations

MHRA Drug Safety Update (Jul-24): Epimax Ointment and Epimax Paraffin-Free Ointment: reports of ocular surface toxicity & ocular chemical injury

#### Doublebase®

gel		
-----	--	--

#### Hydromol®

Sodium pidolate 2.5% cream		
----------------------------	--	--

#### Hydromol®

YSP 30%, LP 40%, EW 30% ointment		
----------------------------------	--	--

#### Oilatum®

--	--	--

### Preparations containing urea

#### Balneum® Plus

--	--	--

### With antimicrobials

#### Dermol® & Dermol® 500

		<b>RESTRICTED patients unable to tolerate 1<sup>st</sup> / 2<sup>nd</sup> line antimicrobial washes</b>
--	--	---

#### 13.2.1.1 Emollient bath and shower preparations

(DNP)

#### Emollient bath and shower preparations without antimicrobials

When used for the management of eczema in children or adults. This recommendation does not apply to the use of standard emollients when used in the bath or shower as a soap substitute

(DNP)

### With antimicrobials

#### Dermol® 600

bath emollient		
----------------	--	--

#### Oilatum® Plus

bath emollient		<b>2<sup>nd</sup> line MRSA decolonisation therapy</b>
----------------	--	--

### 13.2.2 Barrier preparations

### Proprietary barrier preparations

#### Sudocrem®

cream		<b>2<sup>nd</sup> line only at parental request</b>
-------	--	---

# 13.3 Topical local anaesthetics & antipruritics



## 13.3 Topical local anaesthetics & antipruritics

### Crotamiton

GREEN

cream; lotion



### Levomenthol

GREEN

Menthol in aqueous cream: 0.5%, 1%, 2%



### Mepyramine maleate

2% w/w cream



### Difelikefalin

RED

Kapruvia © injection



**RESTRICTED**  
Renal Consultants in line with NICE  
NHSE M4C

## 13.4 Topical corticosteroids



### Corticosteroid only preparations

**NICE TA81**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration

#### HYDROCORTISONE

**Potency**
**Canesten HC®**

GREEN

hydrocortisone 1% plus clotrimazole 1% cream



Mild

**Daktacort®**

hydrocortisone 1%, miconazole nitrate 2% cream; ointment



Mild

**Eurax-hydrocortisone®**

hydrocortisone 0.25%, crotamiton 10% cream



Mild

**Fucidin H®**

GREEN

hydrocortisone 1%, fusidic acid 1% cream



Mild

**Terra-Cortril®**

hydrocortisone 1%, oxytetracycline 3% ointment



Mild

#### BETAMETHASONE ESTERS

**Potency**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

**Betamethasone valerate**

GREEN

betamethasone valerate 0.025% ointment, cream



Moderate

**Betnovate-RD®**

GREEN

betamethasone valerate 0.025% cream; ointment



Moderate

#### CLOBETASONE BUTYRATE

**Potency**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

**Eumovate®**

GREEN

Clobetasone butyrate 0.05% cream; ointment



Moderate

#### BETAMETHASONE ESTERS

**Potency**

MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions

MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

**Betamethasone valerate**

GREEN

betamethasone valerate 0.1% ointment; cream; lotion; scalp lotion



Potent

**Betnovate®**

GREEN

Betamethasone valerate 0.1% cream; ointment; scalp application; lotion



Potent

**Betamethasone valerate with clioquinol**

betamethasone valerate 0.1% / clioquinol 3% ointment; cream



Potent

**Betamethasone valerate with neomycin sulfate**

betamethasone valerate 0.1% / neomycin sulfate 0.5% cream; ointment



Potent

**Diprosalic®**

GREEN

Betamethasone dipropionate 0.05%, salicylic acid 3% ointment



Potent

**Fucibet®**

GREEN

betamethasone valerate 0.1% plus fusidic acid 2% cream



Potent








**Betnovate®**

betamethasone valerate ointment 25% in coal tar



Potent

**DERMATOLOGY ONLY**

<b>CLOBETASOL PROPIONATE</b>		<b>Potency</b>
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions		
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
<b>Dermovate®</b> <b>GREEN</b> clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	 	Very potent
<b>Dermovate NN®</b> clobetasol propionate 0.05% / neomycin sulfate / nystatin cream	 	Very potent
<b>Etrivex®</b> <b>GREEN</b> clobetasol propionate 500micrograms/g shampoo	<b>MMC</b>  	Very potent <b>RESTRICTED - 1<sup>st</sup> Care referral</b>
<b>DIFLUCORTOLONE VALERATE</b>		<b>Potency</b>
<b>Diflucortolone valerate</b>  diflucortolone valerate 0.3% oily cream	<b>MMC</b> 	Very potent <b>RESTRICTED Consultant Gynaecologist</b>

# 13.5 Preparations for eczema & psoriasis



## 13.5.1 Preparations for eczema

### Alitretinoin

RED

10mg; 30mg capsules

PbR X NICE MMC BNF

**RESTRICTED**  
Dermatology Consultants only

MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic

MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women

### Delgocitinib

RED

Anzupgo® 20 mg/g cream

PbR X NICE MMC BNF

**RESTRICTED**  
Dermatology Consultants only  
in line with NICE

## 13.5.2 Preparations for psoriasis

### Topical preparations for psoriasis

NICE CG153

### Calcipotriol

GREEN

Dovonex® ointment; with Betamethasone (Dovobet® 0.05% ointment)

**RESTRICTED**  
Dermatology Consultants only

### Dithranol

RED

0.1% & 0.25% cream

**RESTRICTED**  
Dermatology Consultants only

### Salicylic acid

Zinc & Salicylic acid paste BP (Lassar's Paste)

**RESTRICTED**  
Dermatology Consultants only

### Tacalcitol

Curatoderm® lotion; ointment

**RESTRICTED**  
Dermatology Consultants only

### Tars

### Coal tar paste BP

paste

**RESTRICTED**  
Dermatology Consultants only

### Coal tar with salicylic acid and precipitated sulfur

Cocois® scalp ointment

**RESTRICTED**  
Dermatology Consultants only

### Oral retinoids for psoriasis

### Acitretin

RED

10mg; 25mg capsules

**RESTRICTED**  
Dermatology Consultants only

### Dimethyl fumarate

### Dimethyl fumarate

RED

30mg; 120mg tablets

PbR X NICE MMC BNF

**RESTRICTED**  
3<sup>rd</sup>/4<sup>th</sup> line as per NICE/GMMMG  
Referral to SRFT

### 13.5.3 Drugs affecting the immune response

### Abrocitinib

RED

Cibingo® 50mg; 100mg; 200mg tablets

PbR X NICE MMC BNF

**RESTRICTED**  
Dermatology Consultants only  
in line with NICE

MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality

### Azathioprine

AMBER

25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3)

PbR X NICE

**RESTRICTED**  
Dermatology Consultants only

MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy

### Ciclosporin

AMBER

25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2)

PbR X MMC

**RESTRICTED**  
Dermatology Consultants only  
**PRESCRIBE BY BRAND**

### Methotrexate

AMBER

2.5mg tablets (see also sections 8.1.3 & 10.1.3)

MMC

**RESTRICTED**  
Dermatology Consultants only

### Pimecrolimus

SA

1% cream

NICE MMC

**RESTRICTED**  
Dermatology Consultants only

### Ruxolitinib

RED

Opzelura® 1.5% cream

NICE MMC

**RESTRICTED**  
Dermatology Consultants only

### Sirolimus

RED

Hyftor® 0.2% gel (see also section 8.2.2)

MMC

**RESTRICTED**  
Dermatology Consultants only

### Tacrolimus (specially made by SRFT)

SA

0.03%; 0.1% ointment (see also section 8.2.2)

PbR X NICE MMC

**RESTRICTED**  
Dermatology Consultants only

**Upadacitinib**





















































































































































Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3)



**RESTRICTED**  
Dermatology Consultants only  
in line with NICE

MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality

<b>Cytokine Modulators</b>		(see also section 10.1.3)
<b>Adalimumab</b>   injection (see also sections 1.5.3, 10.1.3 & 11.4.2)	     	<b>RESTRICTED</b> Dermatology Consultants only
<b>Apremilast</b>   10mg; 20mg; 30mg tablets (see also section 10.1.3)	     	<b>RESTRICTED</b> 3 <sup>rd</sup> /4 <sup>th</sup> line as per NICE/GMMMG
<b>Bimekizumab</b>   <i>Bimzelx</i> ® injection (see also section 10.1.3)	     	<b>RESTRICTED</b> in line with NICE
<b>Brodalumab</b>   <i>Kyntheum</i> ® 140mg/mL injection	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Certolizumab pegol</b>   <i>Cimzia</i> ® 200mg/1mL injection (see also section 10.1.3)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Dupilumab</b>   <i>Dupixent</i> ® 150mg/mL injection (see also section 3.4.2)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Etanercept</b>   injection (see also section 10.1.3)	      	<b>RESTRICTED</b> Dermatology Consultants only
<b>Guselkumab</b>   100mg/mL injection (see also sections 1.5.3 & 10.1.3)	     	<b>RESTRICTED</b> in line with NICE
<b>Infliximab</b>   100mg injection (see section 10.1.3)	      	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Ixekizumab</b>   80mg/1mL injection (see also section 10.1.3)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Lebrikizumab</b>   <i>Ebglyss</i> ® 250mg in 2mL injection	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Risankizumab</b>   <i>Skyrizi</i> ® 75mg; 150mg injection (see also section 1.5.3)	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Ritlecitinib</b>   <i>Litfulo</i> ® 50mg capsules	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Secukinumab</b>   <i>Cosentyx</i> ® 150mg/1mL injection (see also section 10.1.3)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Tildrakizumab</b>   100mg injection	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Tralokinumab</b>   <i>Adtralza</i> ® 150mg; 300mg injection	     	<b>RESTRICTED</b> Dermatology only in line with NICE / NHSE
<b>Ustekinumab</b>   <i>Stelara</i> ® injection (see also sections 1.5.3 & 10.1.3)	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Ustekinumab</b>   <i>Wezenla</i> ® injection (see also sections 1.5.3 & 10.1.3)	     	<b>RESTRICTED</b> Specialist use only in line with NICE

## 13.6 Acne & Rosacea



### 13.6.1 Topical preparations for acne

(DNP)

NICE CKS: Acne

**For mild to moderate acne, use topical benzyl peroxide or a topical retinoid 1<sup>st</sup> line. Topical antibiotic should be reserved for patients who have not responded to other topical preparations.**

#### Benzyl peroxide & azelaic acid

##### Benzoyl peroxide

GREEN OTC

4% cream; 5% gel

1<sup>st</sup> line

##### Azelaic acid

GREEN

Skinoren® 20% cream

2<sup>nd</sup> line

#### Topical antibacterials for acne

##### Clindamycin

Dalacin T® 1% topical lotion

2<sup>nd</sup> / 3<sup>rd</sup> line

##### Erythromycin with zinc acetate

Zineryt® 40mg/mL erythromycin; zinc acetate 12mg/mL lotion

2<sup>nd</sup> / 3<sup>rd</sup> line

#### Topical retinoids & related preparations for acne

##### Adapalene

GREEN

Differin® 0.1% cream; 0.1% gel

1<sup>st</sup> line

#### Topical retinoids with antibacterial

##### Isotretinoin with erythromycin

GREEN

Isotrexin® 500micrograms/1g : 20mg/1g gel



**RESTRICTED**  
Dermatology Consultants only

### 13.6.2 Oral preparations for acne

NICE CKS: Acne

**Oral antibiotics should be reserved for moderate to severe acne or where topical preparations have failed. Please refer to Chapter 5.**

##### Lymecycline

GREEN

408mg capsules (see also section 5.1.3)



**RESTRICTED**  
GP referral only

#### Hormone treatment for acne

##### Co-cyprindiol

GREEN

Cytroterone acetate 2mg / ethinylestradiol 35micrograms tablets



**RESTRICTED**  
GP referral only

#### Oral retinoid for acne

##### Isotretinoin

RED

5mg; 10mg; 20mg; 40mg capsules (see also section 8.1.5)



**RESTRICTED**  
Dermatology Consultants only

MHRA Drug Safety Update (Jan-26): Isotretinoin – changes to prescribing guidance and additional risk minimisation measures

MHRA Drug Safety Update (Oct-25): Isotretinoin – updates to prescribing guidance and survey of services

MHRA Drug Safety Update (Oct-23): Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight on initiation of treatment in under 18s

MHRA Drug Safety Update (Apr-23): Isotretinoin (Roaccutane ▼): new safety measures, including additional oversight on initiation of treatment in under 18s

MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼, and acitretin ▼): temporary monitoring advice during COVID-19 pandemic

MHRA Drug Safety Update (Nov-20): Isotretinoin (Roaccutane ▼): contribute to expert review

MHRA Drug Safety Update (Aug-20): Isotretinoin (Roaccutane ▼): reminder of important risks and precautions

MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women

MHRA Drug Safety Update (Oct-17): Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido

MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders

# 13.7 Preparations for warts & calluses



## 13.7 Preparations for warts & calluses (DNP)













<b>Salicylic acid</b> <span style="border: 1px solid black; padding: 2px;">(DNP)</span>	 	
ointment; liquid		
<b>Silver nitrate</b>	 	<p style="text-align: center;"><b>RESTRICTED</b> Dermatology Consultants only</p>
pencil		
<b>Silver nitrate</b>	  	<p style="text-align: center;"><b>RESTRICTED</b> ENT - nasal cautery</p>
75% applicator		
<b>Silver nitrate</b>	  	<p style="text-align: center;"><b>RESTRICTED</b> Recurrent tracheo-oesophageal fistula (TOF)</p>
75% applicator		
<b>Anogenital warts</b>		
<b>Podophyllotoxin</b>	 	<p style="text-align: center;"><b>1<sup>st</sup> line</b></p>
<span style="background-color: green; color: white; padding: 2px;">SI</span>		
0.15% cream		
<b>Imiquimod</b>	  	<p style="text-align: center;"><b>RESTRICTED</b> GUM Consultant only</p>
5% cream		

## 13.8 Sunscreens & camouflagers



### 13.8.1 Sunscreen preparations

#### Photodamage

<b>Diclofenac sodium</b> Solaraze® 3% gel	 	<b>RESTRICTED</b> Dermatology Consultants
<b>Fluorouracil</b> GREEN Efudix® 5% cream	 	<b>RESTRICTED</b> Dermatology Consultants
<b>Fluorouracil with salicylic acid</b> Actikerall® 5mg/g / 100mg/ 1g cutaneous solution	  	<b>RESTRICTED</b> Dermatology Consultants as per MMC
<b>Imiquimod</b> SA 5% cream	 	<b>RESTRICTED</b> Dermatology Consultants
<b>Methyl-5-aminolevulinate</b> RED 160mg/g cream	  	<b>RESTRICTED</b> Dermatology Consultants & Vulval Intraepithelial Neoplasia (VIN) only

## 13.9 Shampoos & other preparations for scalp / hair conditions



### Shampoos

#### Ketoconazole

GREEN

Nizoral® 2% shampoo



**RESTRICTED** persistent / severe  
seborrhoeic dermatitis / dandruff

#### Capasal®

GREEN

OTC

coal tar 1%, coconut oil 1% &, salicylic acid 0.5% shampoo



**RESTRICTED**  
Dermatology Consultants only

#### Ceanel Concentrate®

cetrimide 10%, undecenoic acid 1% & phenylethyl alcohol 7.5% shampoo



**RESTRICTED**  
Dermatology Consultants only

### Other scalp preparations

#### Polytar®

GREEN

OTC

40mg/mL coal tar scalp shampoo



### Hirsutism

#### Eflornithine hydrochloride monohydrate

GREY

GREEN

Vaniqa® 11.5% cream



**RESTRICTED**  
Dermatology Consultants only

## 13.10 Anti-infective skin preparations



### 13.10.1 Antibacterial preparations

**Topical antibacterials should generally be avoided for the treatment of infections**

#### 13.10.1.1 Antibacterial preparations only used topically

<b>Mupirocin</b> 		
2% cream; ointment	MMC	
<b>Fusidic acid</b> 		<b>RESTRICTED</b> superficial impetigo
2% cream; ointment		
<b>Metronidazole</b> 		<b>RESTRICTED</b> topical treatment of rosacea
0.75% topical gel		
<b>Silver sulfadiazine</b> 		<b>RESTRICTED</b> Treatment/prophylaxis of burns
1% w/w cream		

#### 13.10.2 Antifungal preparations

<b>Amorolfine</b>		<b>1<sup>st</sup> line</b> antifungal for nail infections
5% nail lacquer	MMC	
<b>Benzoic acid with salicylic acid</b>		<b>1<sup>st</sup> line</b> treatment of ringworm
benzoic acid 6% / salicylic acid 3% / in emulsifying ointment		
<b>Clotrimazole</b> 		<b>1<sup>st</sup> line</b> fungal skin infections
1% cream		
<b>Miconazole</b> 		<b>2<sup>nd</sup> line</b> fungal skin infections
2% cream		
<b>Terbinafine</b> 		<b>2<sup>nd</sup> line</b> fungal skin infections
1% cream		

#### 13.10.3 Antiviral preparations

<b>Aciclovir</b> 		<b>1<sup>st</sup> line</b>
5% cream (see also section 5.3.2.1)		

#### 13.10.4 Parasitocidal preparations

		<b>NICE CKS: Head lice</b>
		<b>NICE CKS: Pubic lice</b>
		<b>NICE CKS: Scabies</b>
<b>Ivermectin</b>		
tablets	MMC	
<b>Malathion</b> 		
0.5% aqueous solution		
<b>Permethrin</b> 		
1% crème rinse; 5% dermal cream		

MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition...

#### 13.10.5 Preparations for minor cuts & abrasions

<b>Brulidine</b>		<b>RESTRICTED</b> Theatres only
0.15% w/w cream		
<b>Preparations for boils</b>		
<b>Magnesium sulfate</b>		
paste, BP		
<b>Skin tissue adhesive</b>		
<b>Histoacryl®</b>		<b>RESTRICTED</b> Theatres only
0.5mL skin adhesive		

# 13.11 Skin cleansers, antiseptics & desloughing agents



## 13.11.1 Alcohols & saline

Isopropyl alcohol 70%



Sodium chloride

0.9% irrigation solution



## 13.11.2 Chlorhexidine salts

Chlorhexidine gluconate

GREEN OTC



## 13.11.4 Iodine

Alcoholic Iodine solution BP



Iodine weak solution



Povidone-Iodine



## 13.11.6 Oxidisers & dyes

Hydrogen peroxide solution, BP

3% solution; 6% solution



**RESTRICTED**  
Specialist use only

Potassium permanganate

RED

400mg tablets for cutaneous solution



**RESTRICTED**  
Specialist use only

National Patient Safety Alert (Apr-22): Inadvertent oral administration of potassium permanganate

## 13.11.7 Desloughing agents

**CONTACT THE TISSUE VIABILITY TEAM on x64042**

## 13.12 Antiperspirants



### Aluminium salts

#### Aluminium chloride hexahydrate

20% cutaneous solution



### Glycopyrronium bromide

#### Glycopyrronium bromide (glycopyrrolate)

Robinul® (unlicensed special can be used when the licensed product is not available)



#### Glycopyrronium bromide (glycopyrrolate) Ⓢ

0.5% cream



**RESTRICTED**  
Diabetes Consultants only  
(gustatory sweating)

## 13.13 Topical circulatory preparations



### Topical circulatory preparations


#### Heparinoid

Hirudoid® 0.3% cream; 0.3% gel










## 13.14 Miscellaneous preparations



<b>8-Methoxypsoralen</b> (U) 10mg tablets	<b>MMC</b> <b>emc</b>	<b>RESTRICTED</b> <b>Dermatology Consultants only</b>
<b>Fumaric acid esters</b> (U) <i>Fumaderm</i> ® tablets	<b>MMC</b> <b>emc</b>	<b>RESTRICTED</b> <b>Dermatology Consultants only</b>
<b>Glucarpidase</b> (U) <i>Voraxaze</i> ® 1,000 unit injection (see also sections 1.10, 8.4, 10.4 & 18.1.2)	PbR X <b>MMC</b> <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>2<sup>nd</sup> line rescue therapy</b> 
<b>Hyaluronic acid with lidocaine</b> (U) <i>Juvederm</i> ® / <i>Belotero</i> ® injection	PbR X <b>MMC</b> <b>emc</b>	<b>RESTRICTED</b> <b>vocal cord paralysis</b>
<b>Trichloroacetic acid solution</b> (U) <span style="background-color: red; color: white; padding: 2px;">RED</span> <i>TCA50</i> ® 50% solution	<b>MMC</b>	<b>RESTRICTED</b> <b>ENT Surgery Consultants only</b>

## 13.15 British Association of Dermatologists Specials List

<b>Steroid combinations</b>		
<b>Coal tar solution 5% in betamethasone valerate 0.025%</b> Ⓢ		<b>RESTRICTED Dermatology Consultants only</b>
<i>BP 5% w/w in 0.025% w/w ointment (100g)</i>	<b>MMC</b>	
<b>Tars</b>		
<b>Coal tar BP 5% w/w in YSP</b> Ⓢ		<b>RESTRICTED Dermatology Consultants only</b>
<i>BP 5% w/w in yellow soft paraffin (100g)</i>	<b>MMC</b>	
<b>Keratolytics</b>		
<b>Salicylic acid 5% in emulsifying ointment</b> Ⓢ		<b>RESTRICTED Dermatology Consultants only</b>
<i>5% w/w in emulsifying ointment (100g)</i>	<b>MMC</b>	
<b>Salicylic acid 10% in emulsifying ointment</b> Ⓢ		<b>RESTRICTED Dermatology Consultants only</b>
<i>10% w/w in emulsifying ointment (100g)</i>	<b>MMC</b>	
<b>Salicylic acid 20% in emulsifying ointment</b> Ⓢ		<b>RESTRICTED Dermatology Consultants only</b>
<i>20% w/w in emulsifying ointment (100g)</i>	<b>MMC</b>	
<b>Miscellaneous</b>		
<b>Glycopyrrolate 2% w/w in cetomacrogol cream</b> Ⓢ		<b>RESTRICTED Dermatology Consultants only</b>
<i>2% w/w in cetomacrogol cream (100g)</i>	<b>MMC</b>	
<b>Hydroquinone, hydrocortisone &amp; tretinoin in a non-aqueous gel</b> Ⓢ		<b>RESTRICTED Dermatology Consultants only</b>
<i>5% w/w; 1% w/w &amp; 0.1% w/w in a non-aqueous gel (100g)</i>	<b>MMC</b>	

## Non-Formulary Items



<b>Bio-oil®</b> (DNP) OTC		in line with GMMMG
<b>Cradle cap (self-limiting)</b> (DNP) OTC E.g. almond oil, olive oil, cradle cap shampoos		in line with GMMMG / NHSE
<b>Dandruff</b> (DNP) OTC		in line with GMMMG / NHSE
<b>Deoxycholic acid</b> (DNP) Belkyra® 10 mg/ml solution for injection	emc	in line with GMMMG
<b>Diprobase®</b> cream; ointment	BNF emc	DISCONTINUED September 2021
<b>Dithranol</b> RED Dithocream® 0.1% & 0.25% cream	MMC BNF emc	DISCONTINUED May 2021
<b>Emollient bath and shower preparations without antimicrobials</b> (DNP) OTC		in line with GMMMG
<b>Excessive sweating (hyperhidrosis)</b> (DNP) OTC Aluminium chloride 20% solutions (e.g. Driclor, Anhydrol Forte)		in line with GMMMG / NHSE
<b>Head lice</b> (DNP) OTC Dimeticone, malathion, cyclomethicone, permethrin shampoos and liquids. "Bug buster" kits, nit combs.		in line with GMMMG / NHSE
<b>Hydrocortisone</b> (DNP) 0.5% ointment; 2.5% cream and ointment	BNF emc	in line with GMMMG
<b>Hydrocortisone butyrate</b> 0.1% ointment	BNF emc	WITHDRAWN November 2025 in line with GMMMG
<b>Idoxuridine in dimethyl sulfoxide</b> (DNP) Herpid® topical solution	emc	in line with GMMMG
<b>Infrequent cold sores of the lip</b> (DNP) OTC Aciclovir cream, Zovirax® cold sore cream		in line with GMMMG / NHSE
<b>Ingenol mebutate</b> Picato® 150 micrograms/g gel (face & scalp); 500 micrograms/g gel (trunk & extremities)	MMC	WITHDRAWN February 2020
MHRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy MHRA Drug Safety Update (Oct-19): Ingenol mebutate gel (Picato▼): increased incidence of skin tumours seen in some clinical studies		
<b>Lanolin cream</b> (DNP) OTC e.g. Lansinoh HPA	BNF emc	in line with GMMMG
<b>Metanium®</b> (DNP) ointment	BNF emc	Removed from formulary Nov-25
<b>Mild acne</b> (DNP)		in line with GMMMG / NHSE
<b>Mild dry skin or irritant dermatitis</b> (DNP)		in line with GMMMG / NHSE
<b>Minocycline</b> (DNP) tablets; capsules; M/R capsules	BNF emc	in line with GMMMG
<b>Minor burns and scalds</b> (DNP)		in line with GMMMG / NHSE
<b>Minoxidil</b> (DNP) cutaneous foam	BNF emc	in line with GMMMG / NHSE

<b>Nappy rash</b> (DNP) OTC E.g. barrier preparations ( <i>Sudocrem</i> ®, <i>Metanium</i> ®)		in line with GMMMG / NHSE
<b>Potassium hydroxide</b> (DNP)		in line with GMMMG
<i>MolluDab</i> ® 5% topical solution <b>Proflavine cream, BPC</b> 0.1% cream	emc	DISCONTINUED July 2018
<b>Ringworm / Athlete's foot</b> (DNP) OTC Topical preparations containing miconazole, clotrimazole, etc	PbR X emc	in line with GMMMG / NHSE
<b>Ruxolitinib</b> <i>Opzelura</i> ® 15mg/g cream	PbR X NICE MMC emc	Not NICE approved
<b>Silk garments</b> (DNP)		in line with GMMMG / NHSE
including <i>Dermasilk</i> ®, <i>Dreamskin</i> ®, <i>Skinnies Silk</i> ® <b>Sun protection</b> (DNP) OTC		in line with GMMMG / NHSE
<b>Sunburn due to excessive sun exposure</b> (DNP) OTC E.g. emollients, oral and topical antihistamines, analgesics		in line with GMMMG / NHSE
<b>Warts and verrucae</b> (DNP) OTC Salicylic acid-containing products, glutaraldehyde		in line with GMMMG / NHSE

## Section 14: Immunological products & vaccines

Supported by the  
formulary ([click here](#))



### 14.4 Vaccines & antisera

- Bacillus Calmette-Guérin (BCG) vaccines
- Botulism antitoxin
- COVID-19 vaccine
- Diphtheria vaccines (children under 10yrs old)
- Diphtheria vaccines (children over 10yrs old & adults)
- Haemophilus type B conjugate vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Human papilloma virus vaccine
- Influenza vaccine
- Measles, Mumps & Rubella (MMR) vaccine
- Meningococcal vaccines
- Pneumococcal vaccines
- Poliomyelitis vaccines
- Rabies vaccines
- Respiratory syncytial virus (RSV) vaccine
- Tetanus vaccines
- Typhoid vaccines
- Varicella-zoster vaccines

### 14.5 Immunoglobulins

- 14.5.1 Normal immunoglobulin
- 14.5.2 Disease-specific immunoglobulins
- 14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin  
Immunoglobulin follow up form  
Immunoglobulin Prescribing and Administration Guidelines  
Immunoglobulin Prescribing Flow Chart  
Immunoglobulin request form  
National Demand Programme for Immunoglobulin - Clinical Info  
[Non-formulary Conversion Table](#)

## NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

## GMMMG Formulary

Formulary Homepage  
Chapter 14: Immunological products & vaccines  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## Other Links

National Immunoglobulin Database  
DH: Clinical guidelines for immunoglobulin use (2<sup>nd</sup> edition update)  
Immunoglobulin handbook (HPA)

## 14.4 Vaccines & antisera



MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunosuppressed

### **Bacillus Calmette-Guérin (BCG) vaccines**

**Tuberculosis: the Green Book, ch.32**

#### **Bacillus Calmette-Guérin (BCG) vaccine**

injection



#### **BCG vaccine diagnostic agent (tuberculin purified protein derivative (PPD))**

injection



### **Botulism antitoxin**

#### **Botulism antitoxin**

injection



**RESTRICTED  
Emergencies only**

### **COVID-19 vaccine**

**Covid19: the Green Book, ch.14a**

#### **Pfizer-BioNTech COVID-19 vaccine (tozinameran / famtozinameran)**

Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)



**12 years of age and older  
pending availability of XBB1.5**

#### **Pfizer-BioNTech COVID-19 vaccine (raxtozinameran)**

Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)



**12 years of age and older**

#### **Pfizer-BioNTech COVID-19 vaccine (raxtozinameran)**

Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)



**5 to 11 year olds**

MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023

MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023

MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023

MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022

MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022

MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022

MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022

MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022

MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022

MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022

MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022

MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022

MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022

MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022

MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022

MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021

MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021

MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021

MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021

MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021

MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021

MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021

MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021

MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021

MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice

MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19

### **Diphtheria vaccines (children under 10yrs old)**

**Diphtheria: the Green Book, ch.15**

#### **Infanrix hexa®**

injection



#### **Infanrix-IPV®**

injection



#### **Repevax®**

injection











































### **Diphtheria vaccines (children over 10yrs old & adults)**

**Diphtheria: the Green Book, ch.15**

#### **Revaxis®**

injection



<b>Haemophilus type B conjugate vaccine</b>		<b>Hib: the Green Book, ch.16</b>
<b>Haemophilus Influenzae B &amp; Meningitis C vaccine</b>		
Menitorix® injection	 	
<b>Hepatitis A vaccine</b>		<b>Hepatitis A: the Green Book, ch.17</b>
<b>Hepatitis A vaccine single component</b>		
Havrix Monodose®; Havrix Junior Monodose®; Vaqta® Paediatric injection	 	
<b>Hepatitis B vaccine</b>		<b>Hepatitis B: the Green Book, ch.18</b>
<b>Hepatitis B single component</b>		
Engerix B®; Engerix B® Paediatric injection	 	
<b>Hepatitis B single component</b>		
HBvaxPRO®; HBvaxPRO® Paediatric injection	 	
<b>Human papilloma virus (HPV) vaccine</b>		<b>HPV: the Green Book, ch.18a</b>
<b>Human Papilloma Virus (HPV) quadrivalent vaccine</b>		<b>RESTRICTED</b> <b>Paediatric Immunology Consultant</b>
Gardasil® injection	  	
<b>Influenza vaccine</b>		<b>Influenza: the Green Book, ch.19</b>
<b>Influenza vaccine</b>		
injection, intranasal	 	
<b>Measles, Mumps &amp; Rubella (MMR) vaccine</b>		<b>Measles: the Green Book, ch.21</b> <b>Mumps: the Green Book, ch.23</b> <b>Rubella: the Green Book, ch.28</b>
<b>Measles, Mumps &amp; Rubella vaccine</b>		
injection	 	
<b>Meningococcal vaccines</b>		<b>Meningococcal: the Green Book, ch.22</b>
<b>Meningococcal Polysaccharide A, C, W135 &amp; Y vaccine</b>		
injection	 	
<b>Meningococcal group B vaccine</b>		<b>RESTRICTED</b> <b>childhood immunisation schedule</b> <b>&amp; high risk patients</b>
Bexsero® injection	  	
<b>Meningococcal group C vaccine</b>		
injection	 	
<b>Pneumococcal vaccines</b>		<b>Pneumococcal: the Green Book, ch.25</b>
<b>Pneumococcal Polysaccharide vaccine</b>		
injection	 	
<b>Poliomyelitis vaccines</b>		<b>Polio: the Green Book, ch.26</b>
<b>Poliomyelitis vaccine inactivated</b>		
	 	
<b>Rabies vaccines</b>		<b>Rabies: the Green Book, ch.27</b>
<b>Rabies vaccine inactivated</b>		<b>RESTRICTED</b> <b>Not Stocked</b>
Rabipur® injection	 	
<b>Respiratory syncytial virus (RSV) vaccine</b>		<b>RSV: the Green Book, ch.27a</b>
<b>Respiratory syncytial virus (RSV) vaccine (bivalent, recombinant)</b>		
Abrysvo® injection	   	
<b>Tetanus vaccines</b>		<b>Tetanus: the Green Book, ch.30</b>
<b>Tetanus vaccine adsorbed</b>		
injection	 	
<b>Typhoid vaccines</b>		<b>Typhoid: the Green Book, ch.33</b>
<b>Typhoid polysaccharide vaccine</b>		
Typhim Vi® injection	 	
<b>Varicella-Zoster vaccines</b>		<b>Varicella: the Green Book, ch.34</b>
<b>Varicella-Zoster live attenuated vaccine</b>		
 	 	
Varivax® injection		

# 14.5 Immunoglobulins



- 1.) All Immunoglobulin requests should follow [NHSE Clinical Commissioning Policy for the use of therapeutic immunoglobulin \(Ig\) England \(2024\)](#).
- 2.) MFT have adopted a 'no form, no immunoglobulin' policy. All IVIg requests must have an Immunoglobulin Request Form completed via Hive.
- 3.) All immunoglobulin use **MUST** be recorded on the [National Immunoglobulin Database](#).

## 14.5.1 Normal immunoglobulin RED (for ITP & home treatment programmes)



### For intramuscular use

Normal immunoglobulin injection

RED ££

injection

PbR X



RESTRICTED  
Specialist use only

### For subcutaneous use

Normal immunoglobulin injection

RED ££

injection

PbR X



RESTRICTED  
Specialist use only

### For intravenous use

Human normal immunoglobulin

RED ££

injection

PbR X



RESTRICTED  
Specialist use only

## 14.5.2 Disease-specific immunoglobulins



### Hepatitis B immunoglobulin

Hepatitis B immunoglobulin

injection



RESTRICTED  
Not Stocked

### Rabies immunoglobulin

Rabies immunoglobulin

injection



RESTRICTED  
Virology advice only

### Tetanus immunoglobulin

Tetanus immunoglobulin

injection



### Varicella-Zoster immunoglobulin

Varicella-Zoster immunoglobulin

GREEN

injection



RESTRICTED  
Not Stocked

### Cytomegalovirus (CMV) immunoglobulin

Human normal immunoglobulin (CMV)

injection



RESTRICTED  
Specialist use only

## 14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin



















Anti-D (Rh<sub>0</sub>) immunoglobulin

RED

injection



Non-Formulary Items		
<b>AstraZeneca COVID-19 vaccine</b>		<b>DISCONTINUED</b> <b>May 2024</b>
<i>Vaxzevria</i> ® injection	  	
<b>Chikungunya vaccine</b>		
<i>IXCHIQ</i> ® injection	 	
MHRA Drug Safety Update (Feb-26): IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety review MHRA Drug Safety Update (Jun-25): IXCHIQ Chikungunya vaccine: temporary suspension in people aged 65 years or older		
<b>Moderna Biotech COVID-19 vaccine</b>		<b>DISCONTINUED</b>
<i>Spikevax</i> ® injection	  	
<b>Novavax COVID-19 vaccine</b>		<b>PAUSED by JCVI</b>
<i>Nuvaxovid</i> ® injection	  	
<b>Pediacel</b> ®		<b>REPLACED by</b> <b>Infanrix hexa</b> ®
injection	 	
<b>Infanrix-IPV+Hib</b> ®		<b>REPLACED by</b> <b>Infanrix hexa</b> ®
injection	 	

## Section 15: Anaesthesia

Supported by the  
formulary ([click here](#))



### 15.1 General anaesthesia

- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative & analgesic post-operative drugs
  - 15.1.4.1 Benzodiazepines
  - 15.1.4.2 Non-opioid analgesics
  - 15.1.4.3 Opioid analgesics
  - 15.1.4.4 Other drugs for sedation
- 15.1.5 Neuromuscular blocking drugs
  - Non-depolarising neuromuscular blocking drugs
  - Depolarising neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
  - Anticholinesterases
  - Other drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central & respiratory depression
- 15.1.8 Drugs for malignant hyperthermia

### 15.2 Local anaesthesia

- Lidocaine
- Bupivacaine
- Levobupivacaine
- Prilocaine
- Ropivacaine
- Tetracaine
- Local Anaesthetic Toxicity
- Other agents

### Non-Formulary Items

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
Paediatric Anaesthesia Website  
Children's Pain Management Website  
PICU Emergency Drugs Calculator  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

## GMMMG Formulary

Formulary Homepage  
Chapter 15: Anaesthesia (**ON HOLD**)  
GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List  
GMMMG Paediatric **Red/Amber/Green**; DNP and Grey Drug List

## 15.1 General anaesthesia

### 15.1.1 Intravenous anaesthetics

#### Etomidate

injection



#### Ketamine

RED

injection



#### Propofol

injection; infusion



#### Thiopental sodium

injection



### 15.1.2 Inhalational anaesthetics

#### Volatile liquid anaesthetics

#### Desflurane

anaesthetic agent



**RESTRICTED**  
Theatres only

#### Isoflurane

anaesthetic agent



#### Methoxyflurane

Penthrox® inhalation vapour



**RESTRICTED**  
ED only

#### Sevoflurane

anaesthetic agent



#### Nitrous oxide

#### Nitrous oxide



#### Nitrous oxide 50% & oxygen 50%

Entonox®



### 15.1.3 Antimuscarinic drugs

#### Atropine sulfate

600microgram/1mL injection



**Adults 600microgram/1mL**  
I.M. or I.V.

#### Glycopyrronium bromide

200micrograms/1mL; 600micrograms/3mL injection



**Adults 200-400microgram I.V.**

#### Hyoscine hydrobromide

400microgram/mL injection



### 15.1.4 Sedative & analgesic post-operative drugs

#### 15.1.4.1 Benzodiazepines

**NICE CG112**

#### Diazepam

GREEN

tablets; liquid; injection; rectal tube (see also sections 4.1.2; 4.8.2 &amp; 10.2.2)



#### Lorazepam

tablets; injection (see also sections 4.1.2 &amp; 4.8.2)



#### Midazolam

GREEN

oromucosal solution; injection; infusion (see also section 4.8.2)



#### Midazolam with lidocaine

RED

20mg/0.5mL and 10mg/0.5mL nasal solution



**RESTRICTED Dental**  
conscious sedation in dental surgery  
/ procedures

#### Temazepam

GREEN

tablets; oral solution (see also section 4.1.1)








### 15.1.4.2 Non-opioid analgesics

#### Ketorolac trometamol

injection



<b>Parecoxib</b>		<b>RESTRICTED</b> Theatres only - acute postop. pain
injection	MMC BNF emc	
<b>15.1.4.3 Opioid analgesics</b>		
<b>Alfentanil</b>		
 injection	BNF emc	
<b>Fentanyl</b>		
 injection (see also section 4.7.2)	BNF emc	
<b>Remifentanyl</b>		<b>RESTRICTED</b> Specialist use only
 injection	MMC BNF emc	
<b>15.1.4.4 Other drugs for sedation</b>		
<b>Dexmedetomidine hydrochloride</b>		<b>RESTRICTED</b> Specialist use only
infusion	MMC BNF emc	
<b>15.1.5 Neuromuscular blocking drugs</b>		
<b>Non-depolarising neuromuscular blocking drugs</b>		
<b>Atracurium besilate</b>		
injection	BNF emc	
<b>Cisatracurium</b>		<b>RESTRICTED</b> Consultant only
injection	MMC BNF emc	
<b>Mivacurium</b>		
injection	BNF emc	
<b>Rocuronium bromide</b>		
injection	BNF emc	
<b>Vecuronium bromide</b>		
injection	BNF emc	
<b>Depolarising neuromuscular blocking drugs</b>		
<b>Suxamethonium chloride</b>		
injection	BNF emc	
<b>15.1.6 Drugs for reversal of neuromuscular blockade</b>		
<b>Anticholinesterases</b>		
<b>Neostigmine metilsulfate</b>		
injection (see also section 10.2.1)	BNF emc	
<b>Neostigmine metilsulfate with glycopyrronium bromide</b>		
injection	BNF emc	
<b>Other drugs for reversal of neuromuscular blockade</b>		
<b>Sugammadex</b>		<b>RESTRICTED - Consultant</b> (Emergency) use in Theatres only Complete Trust incident & audit forms
Bridion® injection (see also section 18.1.1)	MMC BNF emc	
<b>15.1.7 Antagonists for central &amp; respiratory depression</b>		
<b>Doxapram hydrochloride</b>		
injection (see also section 3.5.1)	BNF emc	
<b>Flumazenil</b>		
injection (see also section 18.1.1)	BNF emc	
<b>Naloxone hydrochloride</b>		
 injection (see also section 18.1.1)	BNF emc	
<b>Naloxone hydrochloride dihydrate</b>		<b>RESTRICTED</b> suspected opioid overdose
 Nyxoid® 1.8mg nasal spray (see also section 18.1.1)	MMC BNF emc	

**15.1.8 Drugs for malignant hyperthermia****Dantrolene sodium hemiheptahydrate**

Agilus® 120mg injection ([see also section 18.1.2](#))



MHRA Drug Safety Update (Jul-14): Intravenous dantrolene: risk of undissolved crystals

## 15.2 Local anaesthesia

### AAGBI SAFETY GUIDELINE

#### 15.2 Local anaesthesia

##### Lidocaine hydrochloride

###### Lidocaine

0.5%, 1% & 2% injection (see also section 2.3.2)



###### with adrenaline

###### Lidocaine with adrenaline

1%, 2% injection



###### for surface anaesthesia

###### Lidocaine with chlorhexidine

Instillagel® 2% gel



###### Lidocaine

OptiLube Active CHG Free® 2% gel



###### Lidocaine with phenylephrine

Co-phenylcaine® 5% / 0.5% spray



###### Lidocaine with prilocaine

EMLA® 5% cream



###### Lidocaine

4% topical solution



###### Lidocaine

Laryngojet® 4% (160mg/4mL) jet spray



###### Lidocaine

5% ointment



###### Lidocaine

Xylocaine® 10% spray



###### Lidocaine

GREY GREEN

Versatis® 700mg medicated plaster



###### Lidocaine with adrenaline and tetracaine

RED

LAT® (Lidocaine 4%, Adrenaline 0.1% and Tetracaine 0.5%) gel



**RESTRICTED**  
Specialist pain team only  
for in-patient use - not for discharge  
**RESTRICTED**  
suturing of wounds in paediatric A&E

##### Bupivacaine hydrochloride

###### Bupivacaine hydrochloride

0.25% Infusion (500mL)



###### Bupivacaine hydrochloride with glucose

Marcaïn Heavy® 0.5% Injection



###### with adrenaline

###### Bupivacaine and adrenaline

0.25% with 1:200,000 injection



###### Bupivacaine and adrenaline

0.5% with 1:200,000 injection



###### with other ingredients

###### Bupivacaine and fentanyl



0.125% with 1mg/500mL infusion



###### Bupivacaine and sodium chloride



























0.08% in 0.9%



###### Bupivacaine hydrochloride with glucose

20mg with 320mg/4mL spinal injection



<b>Levobupivacaine</b>		
<b>Levobupivacaine</b>		
Chirocaine® 25mg/10mL; 50mg/10mL; 75mg/10mL injection; epidural 250mg/200mL	MMC  	
<b>Levobupivacaine with fentanyl</b>		
 0.1% with 2microgram/mL epidural	 	
<b>Prilocaine hydrochloride</b>		
<b>Prilocaine hydrochloride</b>		
Citanest® 1% injection	 	
<b>Prilocaine hydrochloride</b>		
Prilotekal® 2% injection	MMC  	
<b>Prilocaine with felypressin</b>		
Octapressin® 3% cartridges (30mg/mL Citanest with 0.54micrograms/mL)	 	
<b>Ropivacaine hydrochloride</b>		
<b>Ropivacaine hydrochloride</b>		For Consultant use on CDU (elective CS), Theatre 1 (ortho) & wards 1 & 2 (following surgery in Th. 1)
injection; infusion	MMC  	
<b>Tetracaine (amethocaine)</b>		
<b>Tetracaine</b>		RESTRICTED children under 1yr by specific doctor request or /V team
Ametop® 4% gel	MMC  	
<b>Local Anaesthetic Toxicity</b>		
<b>Intralipid 20%</b>		<b>AAGBI SAFETY GUIDELINE</b>
20% injection (see also section 18.1.1)	 	
<b>Other agents</b>		
<b>Benzocaine 20% oral gel</b>		RESTRICTED Paediatrics Oral surgery
 Orajel® Extra Strength oral gel	MMC 	
<b>Cocaine</b>		
 5% solution	 	
<b>Ethyl chloride</b>		
Cryogesic® spray	MMC 	
<b>Mepivacaine hydrochloride</b>		
3% injection	 	
<b>Neomycin sulfate with fluocinolone acetonide &amp; lidocaine hydrochloride</b>		RESTRICTED Paediatrics. Intra-urethral steroid ointment
Nefluan® 10g gel	MMC 	

# Non-Formulary Items



Cocaine hydrochloride



10% solution w/v

**REMOVED from formulary  
October 2025**



## Section 16: Miscellaneous

Supported by the  
formulary ([click here](#))



### 16.1 Organ Perfusion Fluids

- 16.1.1 Cardiac Perfusion Fluids
- 16.1.2 Kidney / Pancreas / Liver perfusion fluids
- 16.1.3 Contrast Agents
- 16.1.4 Hydrogen / Methane breath tests
- 16.1.5 Catheter Lock Solution

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance









Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

## GMMMG Formulary

Formulary Homepage  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## 16.1 Organ Perfusion fluids






### 16.1.1 Cardiac perfusion fluids

Aspartate / Glutamate solution 		
100mL	<b>MMC</b>	
Bretschneiders Histidine-Tryptophan-Ketoglutarate (HTK) 		
<i>Custodiol Cardioplegia</i> ® solution (1000mL)	<b>MMC</b>	<b>emc</b> 
Cardioplegia in Ringer's solution 		
1000mL	<b>MMC</b>	<b>emc</b> 
Cardioplegic ULTH Formula A 		
500mL	<b>MMC</b>	
Cardioplegic ULTH Formula B 		
500mL	<b>MMC</b>	
Sterile Concentrate for Cardioplegia infusion		
20mL	<b>MMC</b>	<b>emc</b> 

### 16.1.2 Kidney / Pancreas / Liver perfusion fluids

Cold Storage Solution (UW solution)		
<i>Belzer UW</i> ® (1000mL)	<b>MMC</b>	
Kidney Perfusion Fluid		
<i>Soltran</i> ® (1000mL)	<b>MMC</b>	
Lung Perfusion solution		
<i>Perfadex</i> ® (1000mL)	<b>MMC</b>	
Machine Perfusion solution		
<i>Belzer MPS</i> ® UW machine perfusion solution (1000mL)	<b>MMC</b>	


### 16.1.3 Contrast Agents

Gadobutrol		
<i>Gadovist</i> ® (1.0mmol/mL) injection	<b>MMC</b>	<b>emc</b> 
Gadoteric acid		
<i>Dotarem</i> ® (0.5mmol/mL) injection	<b>MMC</b>	<b>emc</b> 
Gadoxetic acid		
<i>Primovist</i> ® (0.25mmol/mL) injection	<b>MMC</b>	<b>emc</b> 
Perflutren		
<i>Luminy</i> ® (150microlitres/mL) lipid microspheres for injection	<b>MMC</b>	<b>emc</b> 
Sulphur hexafluoride		
<i>SonoVue</i> ® (8microlitre/mL) injection	<b>MMC</b>	<b>emc</b> 

### 16.1.4 Hydrogen / Methane breath tests

Fructose, Glucose, Lactose and Lactulose 		<b>RESTRICTED Gastro. only in line with ESPGHAN guidelines</b>
powder	<b>MMC</b>	<b>emc</b> 

### 16.1.5 Catheter Locking Solution

Tetrasodium ethylene diamine tetra acetic acid (EDTA)		
<i>KiteLock</i> ™ 4% sterile catheter lock solution	<b>MMC</b>	<b>emc</b> 
Trisodium citrate 30%		
<i>Citra-Lock</i> ™ 30%	<b>MMC</b>	<b>emc</b> 

## Section 18: Emergency Treatment of Poisoning

Supported by the  
formulary ([click here](#))



### 18.1 Poisoning

18.1.1 Products immediately available in A&E (ED) (Category A)

18.1.2 Products available within 1 hour (Category B)

18.1.3 Products held Supra-regionally (Category C)

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

## GMMMG Formulary

Formulary Homepage  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#); DNP and Grey Drug List

## Other poisons

Consult either the National Poisons Information Service day and night or [TOXBASE](#).

The National Poisons Information Service (Tel: 0344 892 0111) will provide specialist advice on all aspects of poisoning day and night.
















































































## 18.1 Poisoning

### 18.1.1 Products immediately available in A&E (ED) (Category A)




























TOXBASE

NPIS

<b>Acetylcysteine</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Paracetamol overdose</b>
Parvolex® 200mg/mL infusion	 	
<b>Activated charcoal</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Many oral poisons</b>
Carbomix® granules SF	 	
<b>Actrapid®</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>HIET for calcium channel blocker / beta-blocker poisoning</b>
Human insulin 100 international units/mL (see also 6.1.1.1)	 	
<b>Atropine sulfate</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Organophosphorus / carbamate insecticides / nerve agents</b>
injection	 	<b>Management of bradycardia</b>
<b>Benzotropine mesylate</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>acute dystonic reactions caused by antipsychotics and some antiemetics</b>
2mg/2mL injection		
<b>Calcium chloride</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Calcium channel blocker antidote</b>
10% injection	 	
<b>Calcium gluconate</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Hydrofluoric acid poisoning</b>
10% injection	 	<b>Calcium channel blocker antidote</b>
<b>Calcium gluconate</b> (antidote) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Hydrofluoric acid burns</b>
2.5% gel	 	
<b>Digoxin-specific antibody fragments</b> <span style="background-color: red; color: white; padding: 2px;">RED</span> 		<b>Digoxin &amp; related glycosides antidote</b>
Digifab® 40mg infusion (see also section 2.1.1)	 	
<b>Dobutamine</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Calcium channel blocker overdose</b>
infusion (see also section 2.7.1)	 	
<b>Dopamine hydrochloride</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Calcium channel blocker overdose</b>
infusion (see also section 2.7.1)	 	
<b>European adder (<i>Vipera berus</i>) antivenom</b>  <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>European viper venom antivenom</b>
ViperaTab® solution for infusion		
<b>Flumazenil</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Benzodiazepine antidote</b>
injection (see also section 15.1.7)	 	
<b>Glucagon</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Beta-adrenoceptor blocking drugs antidote</b>
GlucaGen® Hypokit 1mg injection (see also section 6.1.4)	 	
<b>Glyceryl trinitrate</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Management of hypertension associated with poisoning or overdose</b>
injection (see also section 2.6.1)	 	
<b>Hydroxocobalamin</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Cyanide poisoning</b>
Cyanokit® 5g solution for infusion	  	
<b>Iloprost</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>severe frostbite; critical limb ischemia; pulmonary hypertension crises</b>
infusion	 	
<b>Intralipid 20%</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Local Anaesthetic Toxicity</b>
20% injection (see also section 15.2)	 	
<b>Isoprenaline hydrochloride</b> <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Emergency treatment of life-threatening bradycardia</b>
infusion (see also section 2.7)	 	
<b>Methylthioninium chloride (methylene blue)</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Methaemoglobinaemia</b>
injection	 	
<b>Naloxone hydrochloride</b> (poisoning) <span style="background-color: red; color: white; padding: 2px;">RED</span>		<b>Opioid overdose</b>
injection (see also section 15.1.7)	 	

<b>Naloxone hydrochloride dihydrate</b> (poisoning)  Nyxoid® 1.8mg nasal spray (see also section 15.1.7)	  	<b>Opioid overdose</b>
<b>Penicillamine</b> (poisoning)  tablets (see also sections 9.8.1 & 10.1.3)	 	<b>Copper antidote</b>
<b>Procyclidine</b> (poisoning)  10mg/2mL injection (see also 4.9.2)	 	<b>Dystonic reactions (DISCONTINUED Sep-25) see benzotropine</b>
<b>Sodium bicarbonate</b> (poisoning)  injection	 	<b>TCAs &amp; classes Ia and Ic antiarrhythmic drugs antidote Urinary alkalinisation</b>
<b>Sodium thiosulfate</b> (poisoning)  25% injection	 	<b>Cyanide antidote</b>
<b>Sugammadex</b>  Bridion® injection (see also section 15.1.6)	  	<b>Reversal of NMB induced by rocuronium or vecuronium Complete incident &amp; audit forms</b>
<b>18.1.2 Products available within 1 hour (Category B)</b>		
<b>Andexanet alfa</b>   Ondexxya® infusion (see also section 2.8.2)	   	<b>Apixaban / rivaroxaban reversal agent</b>
<b>Cyproheptadine hydrochloride</b> (poisoning)  4mg tablets	  	<b>Serotonin syndrome</b>
<b>Dantrolene sodium</b>  Agilus® 120mg injection; Ryanodex® 250mg injection (see also section 15.1.8);	  	<b>neuroleptic malignant syndrome and other drug-related hyperpyrexia</b>
<b>Desferrioxamine mesilate</b>   500mg injection (see also section 9.1.3)	 	<b>Iron poisoning</b>
<b>Folinic acid</b> (as calcium folinate) (poisoning)  tablets; injection (see also section 8.1)	 	<b>Methotrexate, methanol and formic acid antidote</b>
<b>Fomepizole</b> (poisoning)  injection	 	<b>Ethylene glycol &amp; methanol antidote</b>
<b>Idarucizumab</b>   Praxbind® 2.5g/50mL solution for infusion (see also section 2.8.2)	  	<b>Dabigatran reversal agent</b>
<b>Levocarnitine</b> (poisoning)  injection; oral solution (see also section 9.8.1)	  	<b>Severe sodium valproate toxicity</b>
<b>Macrogol 3350</b>  Plenvu® powder for oral solution (see also section 1.6.5)	  	<b>whole bowel irrigation for agents not bound by activated charcoal</b>
<b>Mesna</b> (poisoning)  tablets; injection (see also section 8.1)	 	<b>Cyclophosphamide antidote</b>
<b>Octreotide</b> (poisoning)   injection (see also section 8.3.4.3)	  	<b>Sulphonylurea antidote</b>
<b>Olanzapine</b>  injection (see also section 4.2.1)	  	<b>Serotonin syndrome</b>
<b>Phytomenadione</b>  Konaktion® MM & Konaktion® MM Paediatric injection (see also section 9.6.6)	  	<b>Vitamin K dependent anticoagulant reversal / poisoning</b>
<b>Protamine sulfate</b>  injection (see also section 2.8.3)	 	<b>Heparin overdose / reversal</b>
<b>Pyridoxine hydrochloride</b> (poisoning) (U)  50mg/2mL injection	 	<b>Isoniazid antidote</b>

**18.1.3 Products held Supra-Regionally (Category C)**

<b>Botulinum antitoxin (poisoning)</b>   700mg solution for injection 	<b>Botulism antidote</b> <b>Stocked at NCA</b>
<b>Glucarpidase</b>   Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4, 10.4 & 13.14)    	<b>Methotrexate antidote</b> <b>Stocked at NCA</b>
<b>Potassium ferric hexacyanoferrate (Berlin / Prussian blue) (antidote)</b>  capsules	<b>Thallium antidote</b> <b>Stocked at NCA</b>
<b>Pralidoxime chloride (poisoning)</b>  1g solution for injection  	<b>organophosphorus insecticide antidote</b> <b>Stocked at NCA</b>
<b>Sodium calcium edetate (poisoning)</b>   injection 	<b>Heavy metal poisoning (lead) antidote</b> <b>Stocked at NCA</b>
<b>Succimer (DMSA) (poisoning)</b>   capsules 	<b>Heavy metal poisoning (lead &amp; arsenic) antidote</b> <b>Stocked at NCA</b>
<b>Unithiol (DMPS) (poisoning)</b>   injection; hard capsules 	<b>Heavy metal poisoning (mercury) antidote</b> <b>Stocked at NCA</b>
<b>Uridine triacetate (poisoning)</b>    oral granules  	<b>Fluorouracil (5-FU) or capecitabine toxicity</b> <b>Stocked at NCA</b> 